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ABSTRACT  
BACKGROUND: Radiation exposure to the abdominal region causes intestinal 
toxicity and is also capable of inducing colorectal cancers (CRC).  Genotype-
phenotype studies provide some evidence explaining the variation in familial 
adenomatous polyposis (FAP) patients caused by modifiers of adenomatous 
polyposis coli (APC).  This study aims to extend our understanding of irradiation-
induced modifiers of ApcMin/+ mice and CRC.   
METHODS: By using a pre-existing backcross between recombinant inbred line of 
ApcMin/+ mice to the irradiation sensitive inbred BALB/c mouse, we obtained panels 
of 2Gy-irradiated and sham-irradiated N2 ApcMin/+ mice for genotyping with a 
genome-wide panel of microsatellites markers. Using the number of adenomas in 
different intestinal segments to represent polyp multiplicity, we carried out a 
genome wide quantitative trait loci (QTL) scan followed by statistical epistasis 
modelling and bioinformatics analysis. 
RESULTS: We identified five significant QTLs responsible for radiation induced 
tumour multiplicity in the upper small intestine defined as Mom (Modifier of Min) 
radiation-induced polyposis (Mrip1-5) on chromosome 2 (LOD 2.8, p = 0.0003), two 
regions within chromosome 5 (LOD 5.2, p=0.00001, 6.2, p=0.00001) and two regions 
within chromosome 16 (LOD 4.1, p=4x10-5 and 4.8, p=0.00001).  Suggestive QTLs 
were found for sham-irradiated mice on chromosomes 3, 6 and 13 (LOD 1.7, 1.5 and 
2.0 respectively; p,0.005).  Two significant QTLs were detected in the 2large 
intestine on chromosome 2 and 7 (LOD 2.7, p=1.2x10-3 and 2.2, p=1.2x10-3, 
 12 
respectively). Using statistical epistasis modelling and logical selection of target 
genes though in silico sequence based on BALB/c specific non-synonymous 
polymorphisms which are predicted deleterious we selected target genes and 
further eliminated genes by sequencing and mRNA expression. 
CONCLUSIONS: Our study locates the QTL regions responsible for increased 
radiation-induced intestinal tumorigenesis in ApcMin/+ mice and identifies candidate 
genes with predicted functional polymorphisms that are involved in spindle 
checkpoint and chromosomal stability (Bub1b, Bub1r, and Casc5), Wnt pathway 
(Tiam1, Rac1), DNA repair (Recc1 and Prkdc) and inflammation (Duox2, Itgb2l and 
Cxcl5).  
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1. CHAPTER 1 INTRODUCTION 
1.1 COLORECTAL CANCER 
1.1.1 Incidence of colorectal cancer Worldwide, Europe and in the UK 
Colorectal cancer (CRC), which affects the areas of the colon and rectum, is the third 
most commonly diagnosed cancer worldwide, affecting men and women fairly 
equally with a ratio of 1.2:1 (Parkin et al., 2005).  The incidence rate is just over 1 
million cases per year with a mortality rate of approximately 50% making CRC the 
second leading cause of cancer mortality in the Western world (Parkin et al., 2005; 
Jemal et al., 2009; Herszényi and Tulassay, 2010).  In Europe, the incidence of CRC is 
increasing, particularly in the Southern and Eastern European regions with 334,000 
new CRC cases reported in 2008, accounting for 12.9% of all European cancer cases.  
Cancer Research UK reported just under 40,000 new cases of CRC were diagnosed 
and approximately 16,000 deaths reported in 2008 (Cancerstats Incidence, 2008).   
Parkin et al reported at least a 25-fold variation in global CRC incidence rates, with 
the highest rates observed in North America, Western Europe, Australia, New 
Zealand, and Japan, intermediate in South America, and low in Africa and South and 
Central Asia (Parkin et al., 2005).  Stirbu et al show that immigrants from low risk to 
high risk regions and their descendents reach the cancer incidence rates of their 
host country (Stirbu et al., 2006) underscoring the importance of environmental and 
dietary differences.   
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1.1.2 Cancer survival 
While the prevalence of CRC has steadily increased the mortality rates have declined 
as a result of efficient screening and early detection.  About 60% of all patients with 
cancer will receive radiotherapy during the course of their disease as part of cancer 
treatment and survival (Halperin et al., 2009).  The 5-year relative survival rates 
from the US Surveillance, Epidemiology and End Results (SEER9) database, shows 
an overall increase of 8.3% from patients diagnosed in 1980 to those diagnosed in 
2004 (Howlader et al., 2009).  Recent estimates from Maddams and colleagues show 
that there are approximately 2 million cancer survivors (59% women and 41% 
men) in the UK (recorded to the end of 2008) of which 13% are aged 65 years and 
above (Maddams et al., 2009, Maddams et al., 2012).  'Cancer ‘survivors’ were 
defined as ‘living individuals who were diagnosed with cancer at some point in their 
life’ and distinctions of whether these patients are ‘having active disease’, ‘in 
remission’ or ‘cured of their cancer’ were not possible.  These conservative 
estimates show that the number of long term cancer survivors in the general 
population of the UK is substantial and increasing.   
1.1.3 Cancer burden in the UK following medical radiation exposure  
Radiotherapy targets clonogenic cancer cells however there is an increased risk of 
damage to healthy, non neoplastic tissue and the therapeutic window between 
tumour cure and normal tissue damage is thought to be quite narrow resulting in 
radiotherapy exposed cancer survivors experiencing adverse side effects which 
include secondary malignancies (Hall and Wu., 2003; Suit et al., 2007; Brenner et al., 
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2003; Hall, 2006).  Maddams et al provided the first estimate for the burden of 
secondary cancers caused by radiotherapy.  She calculated an overall estimate of 
1,346 cases (0.45%) of the 298,000 new cancers registered in the UK in 2007, to be 
attributable to radiation therapy for a previous cancer.  The largest numbers of 
radiotherapy-induced secondary cancers were observed in the lung (23.7% of the 
total), oesophageal (13.3%), and then female breast tissue (10.6%).  15% of 
secondary cancers were associated with radiotherapy among survivors of Hodgkin's 
disease and oral and pharyngeal tumours (Maddams et al., 2011).  Further evidence 
for the risk of radiotherapy comes from some 6,000 UK patients a year who are 
affected by toxicity and inflammatory responses in the gut, which are well known 
risk factors for CRC (Andreyev et al., 2005; Andreyev 2007).   
In addition, a sharp increase in the use of computer tomography (CT) scans is 
observed since the 1980s, with a total of three million scans performed in 2008 in 
the UK (Brenner et al., 2010).  It is believed that 35mSv (equivalent to four 
abdominal CT scans) is the lowest dose of irradiation absorbed by human tissue to 
possibly cause cancer (Sountoulides et al., 2010).  The lifetime risk of cancer 
incidence as a result of CT colonography scans performed on individuals between 
55–70 years every 5 years is likely to affect 2.6 males and 1.9 females in 1000 from a 
recent press release by the Health Protection Agency (Public Health England, August 
2011).  Therefore, the collective radiation dose from CT scans and other diagnostic 
tools probably accounts for a large proportion of the total amount of medical 
radiation exposure to the adult population of UK which presents a considerable 
health risk (Frush et al., 2008; Pearce et al., 2012).   
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At present, no account is taken of an individual’s genetic background and 
susceptibility to radiation-induced CRC.  A major uncertainty is the prevalence and 
impact of susceptibility loci involved in heritable cancer disorders which may 
influence or modify radiation exposed damage.  Furthermore, nothing is known 
about IR damage incidence in different ethnic communities or social classes.   
Identifying these genes would allow pre-screening advantage to distinguish risk 
prior to medical or occupational irradiation exposure.  Thus the study of the genes 
involved in the molecular mechanisms of CRC not only has the potential of 
elucidating the pathways and interactions which operate within a CRC framework, 
but also of identifying candidates for irradiation induced intestinal toxicity. 
1.1.5 Intestinal early and late radiation injury 
The first case of radiation induced damage to GI was reported by Walsh in 1897 just 
two years after X-rays were discovered by Wilhelm Roentgen in 1895, when a man 
developed diarrhoea after several weeks of occupational X-ray irradiation exposure.  
Walsh concluded that X-rays caused inflammation of the intestinal mucus 
membrane (Walsh 1897).  Radiation effects on normal intestinal tissues can be 
divided broadly into early or acute, sub-acute and late reactions.  Symptoms of early 
effects and intestinal dysfunction occur between 60–90% patients and can last as 
long as two years in cancer patients receiving abdominal radiotherapy (Yeoh et al., 
1995).  Furthermore, studies show there is a higher (8.2%) occurrence of late 
complications developing from patients who initially experience early complications 
compared to the 3% that develop only late complications (Bourne et al., 1983).  In 
general, early damage occurs within 24 hours and is not dose-dependent but 
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sensitive to the time (dose-rate) of exposure, typically ~0.1Gray (Gy)/hour is 
sufficient to cause radiation damage. 
1.1.6 Radiation induced colitis  
Radiation induced colitis and related proctitis involve the inflammation and damage 
to the lower parts of small intestine, sigmoid colon and rectum.  It is a progressive 
disease and depending on the sensitivity of the gut and the dose of radiation the 
extent of the injury varies, and is therefore difficult to predict in patients (Cho et al., 
1995).  Complications may develop within a few months with late effects 
manifesting up to 5 years after radiation.  A small number of patients will develop 
chronic radiation colitis of which 50% may require surgical intervention, which has 
a high complication rate and death rate of 10.7%, often due to the poor condition of 
the patient (Kennedy and Heise, 2007).  More chronic forms of colitis include the 
development of fibrosis, edema, perforations, intestinal obstructions, and 
precancerous lesions which may manifest as deep ulcers or masses and eventually 
into adenocarcinomas.   
It appears that the sequential loss of epithelial cell mitosis following radiation 
exposure to the intestine ablates the ability to produce enough cells to repopulate 
the villi, this results in the denudation of the mucosal surface and diminution in 
villus height followed by blood vessel damage, depletion in nutrient absorption, loss 
of fluid, electrolytes and oxygen supply and the overall impact is the loss of mucosal 
protective barrier.  The gut is left permeable to xenobiotics, bacteria and other 
antigens leading to an inflammatory response (Figure 1-1).   
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Figure 1-1 The biphasic early and acute late effects of radiation toxicity with 
examples of intestinal radiation injury.  Damage to the stromal tissue affects the 
vasculature and connective cells and reactions mediated by vascular deficiencies 
such as the fibrosis, malabsorption, strictures, obstruction, perforation and 
carcinogenesis.   
1.1.7 Radiation-induced secondary CRCs  
There is significant evidence for the increase in bladder cancer and to a lesser extent 
of CRC, following prostatic radiotherapy probably due to the direct radiation and 
some low scatter emissions (Baxter et al., 2005, Rapiti et al., 2008).  Baxter reported 
that long term prostate survivors who received radiotherapy had an increased risk 
of rectal cancer (RC) (a hazard ratio of 1.7) similar to having a first degree relative 
with CRC (Baxter et al., 2005).  Injury to the rectum is more common possibly owed 
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to its fixed position in the pelvis and is rendered more susceptible to radiation 
injury.  A retrospective study by Yang and colleagues (2008) identified 5 patients 
who had developed CRC following successful treatment for their primary cancers; 
cervix (n=3), bladder (n=1) and one for rectal with radiotherapy (Yang et al., 2008).  
More, recently, a study looked at the age standardised incidence ratios (SIR) of RC in 
patients diagnosed with prostate cancer between 1982–2005 comparing groups 
treated with irradiation or surgery.  A significant increased risk was observed in the 
development of RC with the radiotherapy group (SIR 1.8) compared to those 
managed by surgery (SIR 1.21) (Margel et al., 2011).  On the contrary, Kendal and 
colleagues reported that infrequent incidence of RC was balanced by the incidence of 
spontaneous RC (Kendal and Nicholas, 2007).   
These data suggest early intestinal injury is an almost inevitable consequence 
following abdominal radiation therapy with an additional and significant risk of 
patients showing late effects.  There appears to be sufficient grounds to assume that 
cancer predisposed individuals may be at a higher risk for irradiation induced 
intestinal toxicity and or secondary CRCs.  It is estimated that more than 1 million 
patients in the US have GI related dysfunction related to radiotherapy, similarly, a 
significant proportion of patients in the UK suffer from some form of intestinal 
injury following pelvic radiotherapy.  The incidence is likely to continue and even 
increase and so there is a growing need for research behind CRC and irradiation..   
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1.1.5 Biological effects of irradiation 
Tissue damage caused by irradiation involves direct or indirect absorption of high 
transfer energy within cells.  It has been proposed that the radiation-induced effects 
are caused, in part, by the induction of free radicals and reactive oxygen species 
(ROS) via chronic oxidative stress (Hernandez-Flores et al;, 2005) and inflammation 
(Matsunami et al., 1999).  Though the mechanisms have not been fully elucidated, it 
is generally accepted that an increase in ROS leads to the lipid peroxidation, 
oxidation of DNA and proteins as well as inactivation of pro-inflammatory factors 
(Poli et al., 2008).   
Cells usually show alterations in the genetic processes and favour abnormal cellular 
growth and proliferation via mutational effects.  These processes affect double 
strand breaks (DSBs), activation of intracellular signalling pathways, DNA repair 
mechanisms and genomic instability involving genetic and epigenetic processes 
between the initiated cells and the microenvironment (Rothkamm et al., 2001; 
Vilenchik and Knudson 2003; Harper and Elledge, 2007).  DNA repair activities are 
monitored and processed by five different pathways: homologous repair (HR); non-
homologous end joining (NHEJ); nucleotide excision repair (NER); base excision 
repair (BER); and mismatch repair (MMR) (Hoeijmakers 2001).  Defects in DNA 
repair pathways are associated with higher risk of cancer (Mohrenweiser et al., 
2003).  Repair of DSBs is predominantly carried out via the NHEJ pathway via DNA-
dependent protein kinase, catalytic subunit (DNA-PKcs) belonging to the 
phosphatidylinositol 3-kinase-related kinase (PIKK) protein family encoded by 
PRKDC and function in cell cycle.  Mutations in any of its subunits that form a 
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hetreodimer complex with Ku70/80 result in radiosensitivity as displayed by DNA-
PKcs null mice with signs of hypersplasia, dysplasia and aberrant crypt formation 
(ACF) (Bailey et al., 1999).  
1.1.8 Radiotherapy risk factors 
Factors such as inflammation, poor nutrition, previous operations and presence of 
infections are factors known to exacerbate radiation induced injury, however, dose, 
rate, volume and mode of delivery remain the major risk determinants involved in 
the induction of early to late intestinal toxicity.  Intestinal radiation sequelae is more 
frequent in patients (11.3%) treated with a beam split into two sagittal halves when 
compared with a three or four field beam (2.3%) (Cerrotta et al., 1995) and tissue 
toxicity increases significantly when the dose exceeds 45 Gys, with the incidence of 
marked rectal changes rising from 8-51% compared to 33% changes in 
asymptomatic prostate cancer patients (Sugimura et al., 1990).  A clear dose-
response relationship for radiation associated malignancies is difficult to establish 
and tends to vary from organ to organ, type of tumour, age and the genetic 
variability in irradiation response.  Therefore, there is no upper or lower threshold 
that can be applied to radiation induced toxicity and or cancer induction, making it 
one of the most difficult carcinogens to study.    
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1.2 COLORECTAL CANCER RISK FACTORS 
1.2.1 Genetics and family history 
Genetics and family history are the most important risk factors of CRC, and play a 
key role in predisposition accounting for ~25% of all CRC patients.  Despite this 
relatively large estimate, mutations in single high penetrance genes account for only 
5-6% of all CRC (Table 1-1) (Lichtenstein et al., 2000; de la Chapelle, 2004).   
Table 1-1 Heritable colorectal cancer syndromes and lifetime risk of CRC 
development.  Familial adenomatous polyposis (FAP), Attenuated FAP (AFAP), 
Lynch Syndrome (LS), Aberrant crypt foci (ACF), Adenomatous polyposis coli (APC), 
Mismatch repair (MMR), MYH associated polyposis (MAP) 
Syndrome Clinical presentation and notes 
High risk 
gene(s) 
Absolute lifetime risk of 
CRC development 
FAP 
100-1000 colonic polyps and ACF – 
polyposis onset age of Age of polyposis 
onset 16, age of CRC onset 39 
APC 100% by age 45 
Attenuated 
FAP 
<100 polyps proximal colon 
Difficult to distinguish clinically from LS 
Age of polyposis onset 36, age of CRC 
onset, 54 
APC 
69% by age 80 
(Neklason et al., 2004) 
LS 
Clinical features encompassed by the 
Amsterdam Criteria 
MMR genes 
(MLH1 and 
MSH2, MSH6, 
PMS2) 
80% by age 75 (Vasen et 
al., 1999) 
MAP 
 
Multiple colonic polyps.  
Indistinguishable from FAP and AFAP 
with hyperplastic polyps.  Predisposition 
to duodenal adenomas.  Autorecessive 
disease 
MYH > APC 
80%, CRC often 
presented same time 
diagnosis usually by 60 
years of age (Farrington 
et al., 2005) 
Peutz-
Jeghers 
Small bowel multiple harmatomatous 
polyps.  Mucocutaneous pigmentation  
STK11 
39% by age 64 
(Giardiello et al., 2000) 
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Juvenile 
polyposis 
Self-limiting benign colonic and stomach 
polyps.  Rare and early onset 
SMAD4/PTEN 
17-68% by age 60 
(Desai et al., 1995) 
The remaining genetic burden is therefore attributable to a complex interplay 
between low penetrance alleles (Webb and Houlston, 2007), environmental 
variability and genetic modifiers (Figure 1-2) (Houlston and Tomlinson 2000).  
Modifiers alter disease severity by guiding the genetic and phenotypic consequence 
through direct or indirect interactions with the primary mutation and are supported 
by the varying degrees of clinical outcome as observed in human familial 
adenomatous polyposis (FAP) and Lynch Syndrome (LS) patients (de la Chapelle, 
2004).   
 
Figure 1-2 The influence of genetics and environmental factors in inherited and 
sporadic CRCs (de la Chapelle, 2004). 
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One of the earliest family based studies of CRC and familial inheritance was 
conducted in Utah families.  It was observed that the occurrence of polyps was 
influenced by genetic factors with a dominant mode of inheritance (Woolf, 1958).  It 
was also reported, that a higher number of deaths from CRC (3.9%) occurred within 
first degree relatives of CRC patients, compared with sex and age matched controls 
(1.2%).  This difference has since been replicated in numerous studies of various 
designs, (sample sizes, data validation, analytic methods and countries of origin) and 
the magnitude of CRC risk has been consistently found to be two to three-fold higher 
amongst first degree relatives of CRC affected cases.  This risk increases with the 
number of affected family members from 25% to 52% in second and third degree 
relatives (Slattery and Kerber, 1994) and more so if CRC is diagnosed at a younger 
age (<50 years) (Fuchs et al., 1994).  The relative risks from a systematic review and 
meta-analysis of familial CRC risk was reported by Johns et al, in a population study 
and summarised in Table 1-2 below.   
Table 1-2  Estimated relative risk of developing CRC from a positive family history, 
calculated using weighted average pooled from 27 case control and cohort studies 
(Johns et al., 2001). 
Relative risk of CRC and family history 
No family history  1 
One first degree relative with CRC 2.3 
More than one  first degree relative with CRC 4.3 
Family history of 1st degree relatives affected < 45 years of age 3.9  
Family history of 1st degree relatives affected between 45-59 2.3 
Family history of 1st degree relatives affected > 60 years of age 1.8 
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1.2.2 Inflammatory bowel disease 
As mentioned earlier, radiation injury from post pelvic radiotherapy leads to 
inflammation of the gastrointestinal tract a well known precursor of CRC (Balkwill 
and Mantovani, 2001; Folkman, 2002).  The relationship between inflammation and 
cancer has been known since 1925, when it was first described by Burrill Crohn 
(Crohn 1925).  Environmental factors (such as geography, cigarette smoking, 
sanitation and hygiene) are known to influence the ecosystem of the intestinal 
mucosal microflora and increase the occurrence of intestinal inflammation (Guarner 
1998).   
Inflammatory bowel disease (IBD) which includes Crohn’s disease (CD) and 
ulcerative colitis (UC) are idiopathic conditions of prolonged inflammation of the 
colon.  Patients with IBD have an inordinately high risk of severe intestinal toxicity 
following abdominal irradiation (Willet et al., 2000) with shared pathological 
features, such as the activation of mucosal cytokines, crypt distortion, and 
inflammation of crypts and cells of the lamina propria.  CRC accounts for 15% deaths 
in patients with IBD (Munkholm 2003; Vagefi and Longo, 2005) that increases by 
0.5% to 2% annually, 8 to 10 years after IBD is diagnosed (Herszényi et al., 2007, 
Ahmadi et al., 2009).  IBD CRCs arise from flat dysplastic tissue or dysplasia-
associated lesions or masses (DALMs) leading to intestinal lesions and the risk is 
higher for patients with childhood onset of IBD than those who develop the disease 
during adulthood (Itzkowitz and Harpaz, 2004).  Furthermore, genetic susceptibility 
to IBD was demonstrated in three European twin studies which showed an 
increased concordance rate of 20 to 50% in monozygotic twin compared to 10% 
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concordance rates in dizygotic twins (Tysk et al., 1988, Orholm et al., 2000, 
Halfvarson et al., 2003).   
1.2.3 Ulcerative colitis 
UC was rediscovered by Sir Samuel Wilks and Moxon in 1875, when it became clear 
that UC was different from other known large bowel (ulcerating) diseases which 
tended to occur from infectious agents such as dysentery and tuberculosis.  UC is 
restricted to the large bowel and characterised by severe ulcerations, predominantly 
located in the rectum (90% of the patients) and recto-sigmoid (40%), but sometimes 
affecting the entire colon (20%).  The peak incidence of UC is detected between 15-
30 years of age, affecting females more than males (Hanauer, 1996).  A 20-fold 
higher risk is associated with CRC in patients with UC which increases 1-2% per 
year after 10 years affected.  The length of time with UC, patient's age and extent of 
disease at diagnosis are strong independent risk factors for CRC in UC (Lashner 
1994).   
In the acute phase of inflammation, the mucosa typically becomes hyperaemic and 
friable and in most cases small mucosal haemorrhages and ulcers coalesce leading to 
irregular large ulcers.  In the more serious cases parts of the mucosa may disappear 
and be replaced by granulation tissue which, in a later stage, may be covered with 
new epithelium, that may protrude into the lumen giving a “cobblestone” 
appearance (pseudopolyps).  The mucosa bleeds easily giving rise to the main 
characteristic of UC; of blood with or without faeces.  Particularly important in active 
colitis are the epithelial changes that appear in the margins of ulcers leading to the 
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depletion of the mucus, inflammatory metaplasia and atypical dysplasia which is 
classified as low to high grade progression towards carcinoma.  Colitis-associated 
cancer has been investigated in mouse models which have highlighted the role of 
toll-like receptors (Tlr) and tumour necrosis factor-α (TNF-α) in the activation of 
nuclear factor κB (NFκB), which induces transcription of genes involved in 
tumourigenesis, including cyclooxygenase-2 (Cox2) (Westbrook et al., 2010) and 
defective tumour protein 53 (Tp53) signalling may be an early event in the 
progression of colitis induced dysplasia to cancer (Dirisina et al., 2011).   
1.2.4 Crohn’s disease 
In 1932 Crohn’s and associates defined a pathological condition ‘regional ileitis’ 
which today is more commonly known as CD and may involve any portion of the GI 
tract from mouth to anus, but most often the small intestine and colon are affected 
(Triantafillidis et al., 2009).  Though CD can occur at any stage of life, it is most 
commonly seen in patients between 15 – 30 years of age.  A higher occurrence is 
detected in smokers regardless of sex and in people of Ashkenazi heritage (Seksik et 
al., 2009, Podolsky, 2002).  As in the UC, a similar 20-fold higher risk of CRC are 
observed in CD patients compared to the general public and the risk in CD is also 
related to the amount of colon involved (Gillen et al., 1994).  There is an increased 
prevalence of IBD among first degree relatives of patients suffering from UC or CD 
(Orholm et al., 1991)  
In contrast to UC, in CD the inflammation extends through the entire wall of the 
intestine into the mesentery.  The affected colon shows mucosal inflammation, with 
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cell population of neutrophils, along with mononuclear cells, that may infiltrate the 
crypts, leading to inflammation or abscess.  Non-caseating granulomas, which are 
aggregates of macrophage derivatives, are found in 50% to 70% of cases and are 
specific for CD, indicating that they are not infectious.  The mucosa may give rise to 
numerous linear ulcers creating deep fissures which are separated by nodules, 
creating a "cobblestone” appearance.  More chronic mucosal damage is caused by 
atypical branching of the crypts, blunting of the intestinal villi and a change in the 
tissue type.   
1.2.5 Diet and smoking 
As already mentioned, dietary nutrients and carcinogens appear to modulate the 
biology of the intestine via the colonic mucus barrier within the colonic lumen.  
Physiological factors which determine the transition rate and the continuous 
exposure of dietary carcinogens to the lumen gives rise to epithelial cell 
abnormalities and apoptosis.  There is some evidence that DNA methylation can be 
influenced by the availability of methyl donors, such as folate and methionine from a 
fibre rich diet and therefore reduce the risk of CRC (Kim and Mason, 1996).  Folate 
and methionine levels are controlled by methylenetetrahydrofolate reductase 
(MTHFR) and methionine synthetase enzymes.  The most common polymorphism in 
the MTHFR gene, is Ala677Val (MTHFR C677T) which codes for reduced enzymatic 
activity.  Homozygotes for this variant have about 30% of normal enzyme activity 
and are associated with a higher risk of CRC (Hubner and Houlston 2007; Zhong et 
al., 2012).  Among micronutrients, red meat fat and processed meats have been 
implicated in the causation of CRC.  Recent meta-analysis have shown relative risks 
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below 1.50 and concluded that red meat and CRC are not statistically significant 
(Alexander et al., 2011).  However, the different study designs have led to different 
outcomes and it appears that the relationship between nutrient intake and human 
cancer risk is difficult to quantify, with aspects between diet and other risk factors 
being difficult to discern and isolate as independent factors.   
A causal relationship between smoking and CRC has been investigated and though 
not clearly demonstrated, a significant association between smoking and CRC in a 
Newfoundland and Labrador population was reported.  Both former and current 
smokers had an increased risk of CRC (odds ratio of 1.36 and 1.9, respectively) 
compared to non-smokers (Zhao et al., 2010).  However, the association with CRC 
varies with the number of years smoked, age of initiation and tumour site.  Other 
studies have shown that smokers have twice the risk of developing colon tumours. 
About a fifth of tumours (21%) showed microsatellite instability (MSI), which 
reflects an impairment of the cells ability to repair DNA damage (Slattery et al., 
2000).  In the case of CRC more research is needed to determine whether these 
associations are causal and if by avoiding certain risk behaviours or increasing 
protective behaviours would actually reduce cancer incidence.   
1.2.6 Drugs, vitamins and minerals 
Non-steroidal anti-inflammatory drugs (NSAIDS) and aspirin are thought to have 
chemopreventative benefits against the development of most cancers and provide 
relief from the symptoms of inflammation and pain.  Aspirin taken daily for 4 or 
more years is associated with an 18% reduction in overall cancer deaths, and if 
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taken for several years at 75 mg can be effective in reducing long-term incidence and 
mortality to CRC, with benefit being greatest for cancers of the proximal colon 
(Rothwell et al., 2013).  The mechanism is thought to involve interventions by drugs 
such as sulindac, celecoxib which inhibit adenoma growth by the suppression of 
COX-2 (Chell et al., 2005; Markowitz, 2007; Rothwell et al., 2013).  COX-2 is involved 
in the synthesis of proinflammatory prostaglandins with an extensive role in 
inflammation; prostaglandin E2 (PGE2), the product of COX2, is a target for treatment 
to prevent inflammation-associated cancers.  Evidence for the role of Cox-2 in CRC 
came from polyp regression observed mouse models of FAP with NSAIDs for anti-
inflammatory therapy (Beazer-Barclay et al., 1996).  In addition, clinical studies and 
mouse models show that probiotics are associated with the restoration of gut 
bacteria by producing conjugated linoleic acid to activate peroxisome proliferator-
activated receptor gamma (PPARG) which in turn inhibits COX-2 synthesis 
(Bassaganya-Riera et al., 2012).   
Hormone replacement therapy and the oral contraceptive pill have been shown to 
reduce the risk of CRC development, and this protective effect is thought to arise 
because of changes in bile synthesis and secretion, but remains controversial 
(Hoffmeister et al., 2007).  Vitamins, minerals and dietary supplements are 
advocated as preventative tools in cancer on the premise that antioxidants prevent 
oxidative DNA damage and are a part of the body’s natural defense against free 
radicals and reactive oxygen.  It has been long presumed that those with low levels 
of antioxidants are at higher risk of developing certain cancers including CRC.    
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1.3 MOLECULAR PATHOLOGY OF COLORECTAL CANCER  
1.3.1 Clonal expansion and cancer stem cells 
CRC is a disease characterised by the clonal expansion of cells that eventually 
become metastatic and immortal.  Adenomas and carcinomas are presumed to arise 
from single epithelial cells (or small subset of cells), which initiates tumour 
formation (Ponder and Wilkinson, 1986).  For a cell to gain a growth advantage over 
neighbouring cells and become neoplastic six fundamental properties must be 
acquired: self-sufficiency, proliferation, insensitivity to anti-proliferative signals, 
evasion of apoptosis, unlimited replicative potential, the maintenance of 
vascularisation and tissue invasion and metastasis for malignancy (Hanahan and 
Weinberg, 2000).   
The initial steps in the process of clonal expansion are currently a source of 
controversy and how early lesions develop from normal mucosa and then progress 
to cancer are debatable.  There are two main models of clonal expansion; the first, 
referred to as the ‘bottom up approach’, where mutant cells exist at the crypt base or 
stem cell compartment and migrate to the crypt apex to expand (Preston et al., 
2003).  The second model was proposed following a study on early non familial FAP 
adenomas, where dysplasia of cells were seen at the openings and luminal surfaces 
of colonic crypts (Shih et al., 2001).  The pathogenesis of this model suggests that 
mutant cells appear in the intracryptal zone between crypt cavities and, as the clone 
expands, the cells migrate laterally and downwards to displace the normal 
epithelium of adjacent crypts (Shih et al., 2001) in a ‘top-down’ fashion.  There are 
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studies which support both mechanisms but these remain highly debatable (Preston 
et al., 2003).  Despite the clonal origin of most tumours, their tremendous 
heterogeneity suggests that cancer progression springs from the combined forces of 
both genetic and epigenetic events.  These are triggered within a single cell to 
produce a diploid tumour cell, followed by clonal expansion.  The acquisition of 
irreversible genetic alterations creates a tumour formed of genetically 
heterogeneous cells with a growth survival advantage over normal cells (Kinzler and 
Vogelstein, 1996, Kleinsmith, 2006, Gerlinger et al., 2012, Martinez, et al., 2013).   
Cancer stem cells (CSC) are a proposed small subset of cells as clusters of tumour 
cells in a heterogeneous cancer cell population.  These are ultimately responsible for 
self-renewal, tumour initiation, metastasis and also confer resistance to therapy 
(Dean et al., 2005).  The therapeutic implications of CSCs are numerous; because 
these cells have the ability to repopulate the tumour either through enhanced repair 
mechanisms, hypoxic conditions (a state of low oxygen in tissues) or production of 
anti-apoptotic proteins.  Specific therapeutic drug targets have been partially 
successful and current research is being invested in this emerging field (Fisher, et al., 
2013) 
1.3.2 Intestinal stem cells  
The intestinal epithelial barrier is shaped into distinct compartments dedicated to 
the bidirectional cell lineage and differentiation of stem cells.  Stem cells are self 
renewing cells with a high proliferative capacity that produce cells that develop into 
all the differentiated cells of the tissue.  These processes depend on actively dividing 
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intestinal stem cells responsible for the maintenance of tissue homeostasis and any 
direct damage to the stem cells result in the loss of their dependent cell lineages and 
subsequent collapse of tissue.   
The identity of intestinal active stem cells has been proposed by the discovery of 
markers.  The, most notable is the Leucine-rich repeat-containing G-protein coupled 
receptor 5 (LGR5), a marker discovered from studying the mouse intestine (Barker 
et al., 2007).  Other markers including glycoproteins, CD133, CD44, CD166, alcohol 
dehydrogenase a1 (ALDHa1), polycomb ring finger oncogene (Bmi1) and epithelial 
cell adhesion molecule (EpCAM) have also been described in the intestinal stem cells 
(Lugli et al., 2010; Sanders et al., 2011).  Lgr5 positive crypt base columnar cells 
(CBC) have broad basal surface and are located interspersed among terminally 
differentiated Paneth cells (Barker et al., 2007, Barker and Clevers, 2012).  Loss of 
Lgr5 positive stem cells in murine studies of CRC with activated Wnt signalling 
increased tumourigenesis and produced an invasive phenotype of colorectal 
carcinomas suggesting an important role for Lrg5 in restricting stem cell expansion 
(Walker et al., 2012).   
Hua and colleagues reported that stem cells from bone marrow and hair follicle cells 
show radioresistance to p53 mediated cell damage with an increase in NHEJ 
mediated repair of radiation induced DNA DBSs (Hua et al., 2012).  Presumably this 
allows the stem cells to protect the bowel from radiation sensitivity and from 
accumulating potentially damaging mutations. Therefore, it is of importance to study 
the mechanisms underlying Wnt signalling and NHEJ mediated DNA repair and the 
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underlying genes which may confer resistance or sensitivity to intestinal cells during 
radiotherapy. 
Genetic instability has long been postulated to be an essential process of cancer 
development especially as most human malignancies are recognised cytogenetically 
by marked aneuploidy and chromosomal rearrangements which include 
translocations, DNA fragmentation and chromosomal fusion (Hackett et al., 2001; 
Feldser et al., 2003).  There are three major molecular subtypes of CRC instability 
pathways, the chromosomal instability (CIN) model, MSI pathway and CIMP 
pathway, defined as; (cytosine phosphate guanine) CpG Island Methylator 
Phenotype.  A fourth category of microsatellite and chromosome stable (MACS) 
cancers defines cancers which are neither CIN or MSI.   
1.3.3 Chromosomal instability 
The most common CRC pathway is driven by CIN and occurs in 80%–85% of CRCs 
(Grady and Carethers 2008).  Tumours that exhibit CIN phenotype are most often 
located at the distal side of the colon and are associated with better prognosis for 
the patient (Grady and Carethers, 2008).  They are often linked to genomic 
instability as a consequence of APC driven tumourigenesis where tumours arise 
through a stepwise combination of mutational activations of oncogenes and 
inactivation of tumour suppressor genes (TSGs) that drive the adenoma to 
carcinoma sequence (Shih et al., 2001, Alberici et al. 2007; Fearon and Vogelstein, 
1990).  Alterations in oncogenes are instrumental in promoting cancer while TSGs 
are involved in processes to prevent dysregulated growth.  Alterations in these 
 49 
genes lead normal colonic epithelium through hyperproliferation to dysplasia, 
adenoma and eventually to carcinoma (Figure 1-3) (Fearon and Vogelstein 1990; Su 
et al., 1993; Lengauer et al., 1998). 
 
Figure 1-3 A modified ‘Vogelgram’ showing the three main molecular changes 
involved in the sequential adenoma to carcinoma pattern in CRC: CIN, MSI and CIMP 
tumours 
Evidence for the adenoma-carcinoma sequence is substantiated by a number of 
observations: firstly, the incidence of adenomatous polyps precedes that of adenoma 
carcinomas (AC) secondly, small carcinomatous foci are found within advanced 
adenomatous polyps and finally cancer risk is directly related to the number of 
adenomas, as shown by the very high incidence of carcinoma in FAP patients with 
>100 polyps (Bujanda et al., 2010).  Furthermore, in a landmark study by Vogelstein 
of CRC specimens with a range of neoplastic stages, allelic deletions were assayed 
for chromosomes 5, 17, 18 and for mutations of CRC susceptibility genes.  Table 1-3 
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shows a summary model of the genes known to be implicated in CRC tumour 
progression and are discussed below in milieu of the adenoma-carcinoma sequence 
and clinical outcome (Vogelstein et al., 1988).  
Table 1-3 A summary of tumour suppressor genes implicated in CRC progression.  
(PM=point mutation, FS=frameshift, MS=missense, del=deletion, ins=insertion). 
TSG Function 
Germline 
mutations 
Somatic 
mutation 
Clinical 
Condition 
APC 
Gatekeeper 
cell adhesion, anterior-
posterior pattern 
formation, axis 
specification, cell cycle, 
cell migration, 
apoptosis, chromosome 
segregation and spindle 
80-85% are PM 
resulting in stop 
codon, small del, 
LOH, 1-2 bp ins 
result in 
truncated protein 
50% sporadic CRC 
FS, MS – resulting in 
premature stop codons 
mutations clustered in 
Exon 15 
20% mutations observed 
with TP53 mutation  
FAP, AFAP 
and related 
conditions 
 
TP53 
Gatekeeper 
Cell cycle, G1 DNA 
damage checkpoint 
Regulated 
transcriptional genes 
involved in cell growth, 
proliferation and 
apoptosis  
Arg>Pro at  
codon 72 
-No clear 
conclusive 
evidence this 
mutation is linked 
with cancer 
susceptibility 
MS, del, ins and splicing 
variants in exons 4-6 
(hotspots at codons 175, 
245, 248, 273 and 282) 
with 80% mutations from  
methylation of CpG region 
at 175, 248 and 273 (in 
bold)  
40-50% observed in CR 
carcinoma not adenoma 
Li-Fraumeni 
syndrome 
and greatly 
increase in 
susceptibility 
of all cancers 
MLH1 
Caretaker 
DNA Mismatch repair 
gene 
Del of codons 578 
and 632 
Mutations give 
rise to 
microsatellite 
instability 
Methylation of promoter Mainly 
responsible 
for LS 
MSH6 
PMS2 
Caretakers 
Both function in 
mismatch repair 
binding 
-CT del (exon 4) 
-in frame del, PM 
 LS via 
microsatellite 
instability 
AXIN2 
Gatekeeper 
protein has role in 
regulation of β-catenin 
Finnish Family 
study 
Is mutated in MMR 
deficient CRC cells, 
Hypodontia 
and CRC 
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 pathway via GSK-3β (1966 C > T 
mutation)  
possibly associated with 
epigenetic silencing 
Mutations result in 
stabilisation of β-catenin 
and T-cell factor 
signalling 
STK11 
Gatekeeper 
TSG of serine-threonine 
kinase sunction in cell 
cycle arrest 
FS, MS Give rise to polps in GI 
tract 
Peutz-Jeghers 
syndrome 
PTEN 
Landscaper 
negatively regulates 
AKT/PKB signalling 
known as mutated in 
multiple advanced 
cancers 
Results in cancer 
prone syndrome -
Cowden 
Syndrome  
Results of MLH1-MSH2 
deficiency in LS patients 
FS in MMR deficient cells 
Juvenile 
polyposis, 
Cowdens 
disease 
BMPR1A 
Gatekeeper 
Transmembrane 
serine-threonine 
kinase, type1 receptor 
FS, MS and SS 
mutations 
Rare substitution 
mutations observed in the 
protein kinase domain of 
large intestine tumours.  
Juvenile 
polyposis, 
Cowdens 
disease 
SMAD4 
Gatekeeper 
TGF β signalling, 
mediating signals from 
cell surface to nucleus 
Results in juvenile 
polyps 
Minimal LOH on 
chromosome 18q-21, 
though 4 bp del of exon 9 
in CRC resulting in stop 
codon. Del of SMAD4 in 
epithelial cancers 
FAP, 
Juvenile 
polyposis, 
Cowdens 
disease 
MYH 
Caretaker 
DNA glycosylase. 
Functions in oxidative 
DNA damage repair 
(BER) 
Tyr 82-Cys and 
Gly253-Asp affect 
glycosylase 
activity resulting 
in APC mutations 
in somatic cells 
MS and truncating protein 
mutations cause 3-fold 
increase in CRC risk 
MAP 
DCC 
Conditional 
Gatekeeper 
receptor for neptin-1 
(axonal 
chemoattractant).  In 
absence of ligand, it 
induces apoptosis but 
when neptin-1 is 
bound, it prevents 
apoptosis 
Rare germline 
mutations 
- 74% loss in CRC 
also observed in 
hepatocellular 
metastatic 
cancers 
Rare homogygous del 
120 to 300 bp expansion 
in exon 7, present in 10-
15 % of tumours that 
display genomic 
microsatellite instability  
Mainly 
neurological 
role 
Advanced 
CRC 
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1.3.4 Tumour suppressor genes  
TSGs were first recognised and described in epidemiological studies on familial and 
non-familial cases of human retinoblastoma by Knudson and colleagues (Knudson, 
1971).  He proposed the ‘two hit’ theory that both copies of the retinoblastoma gene 
(Rb) are inactivated for familial cancer cases to develop and the inheritance of one 
allele predisposes the individual to retinoblastoma when the second allele 
undergoes mutations.  This was later supported when Rb was discovered with 
mutations in both alleles of Rb tumours (Friend et al., 1986; Dryja et al., 1986).  Bert 
Vogelstein grouped TSGs into two classes of cancer susceptibility genes; gatekeepers 
and caretakers (Kinzler and Vogelstein 1997).  In 2004 a third classification of 
landscapers was proposed later (Michor 2004).   
APC is a classic example of a TSG. FAP patients inherit one mutated APC allele and 
inactivation of the remaining normal copy of the APC gene, by deletion or mutation, 
completely removes the ‘gatekeeper’ tumor suppressive function of APC, thus 
initiating the growth of adenomatous polyps.  The loss of functional mutations of 
APC occurs in over 80% of CRCs, which abrogates the normal function of the APC 
protein in controlling of β-catenin activity (Miyoshi et al., 1992; Kinzler and 
Vogelstein, 1996; Pietenpol and Volgelstein, 1993).  APC second mutational hits are 
not randomly selected, but interdependent and distributed according to the 
resulting levels of residual β-catenin involved in Wnt activation favourable for 
tumourigenesis, a process referred to as the ‘just right’ theory (Lamlum et al., 1999; 
Albuquerque et al., 2002).  According to the position of the germline mutation and 
the number of 20 amino acid repeats (20AARs) (β-catenin down regulations sites) 
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retained, three possible ‘second hits’ that can be expected (see 1-4).  Analysis of 
somatic or “second hit” events has led to the discovery of a new theory in which APC 
requires a ‘third hit’.  The most frequent third hit was copy number gain or deletions 
(Segditsas et al., 2009).  These hits are associated with the genotype-phenotype 
differences observed in FAP patients that affect the severity of colonic polyps and 
will be explained later in section 1.4.4 of this chapter.   
 
Figure 1-4 The interdependence of germline and somatic APC mutations associated 
with FAP, where the position and type of the second hit in FAP depends on the 
location of the germline mutation and the number of 20 amino acid repeats still 
present in the truncated protein.  Germline mutations leading to a truncated protein 
lacking all the 20AARs (a) acquire somatic second hits, resulting in truncated 
proteins with one or two repeats.  Somatic mutations and truncated APC protein 
with a loss of all 20AARs is observed in the second hit (b) and germline mutation 
with one 20AARs, the second hit will result mainly in allelic loss and produce a 
second homologous allele (c) (Albuquerque et al., 2002).   
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1.3.5 Oncogene   
The first oncogenes to be discovered were Ras by Jennifer Harvey and Werner 
Kirsten in the 60s and 70s (Harvery 1964, Werner 1972) and Src by Noble Prize 
laureates Michael Bishop and Harold Varmus in 1976 (Stehelin et al., 1977).  These 
were observed in the retroviral DNA of chicken and rats respectively.  By 1976 it 
was understood that oncogenes are in fact malfunctioning proto-oncogenes and 
found in many organisms with the ability to induce malignant transformation of 
human cells in vivo.  The same genes were later identified in humans with the same 
cell regulation, cell signalling, growth and differentiation functions (Parada et al., 
1982, Knudson, 1985).   
Ras proteins; HRAS, NRAS and KRAS, are all localised to the inner leaflet of the 
plasma membrane which is important for their biological function as monomeric 
GTPases.  They operate in cellular signal transduction pathways to regulate cell 
growth, differentiation and apoptosis.  Almost a third of human cancers carry a RAS 
point mutation at codons 12, 13 or 61 rendering the protein constitutively active 
and oncogenic.  HRAS and NRAS traffic to the plasma membrane via a series of post-
translational modifications, while the KRAS trafficking pathway is currently poorly 
characterised.  Mutations in KRAS are the most frequently observed of cancers: 
occurring in the pancreas (90%); the colon (50%); and the lung (30%); thyroid 
tumours (50%); and in myeloid leukaemia (30%), (Salhab et al., 1989; Roberts and 
Der, 2007).   
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Assays for KRAS mutations in CRC specimens indicate that the frequency of KRAS 
mutation increases from 9% in adenomas just under 1 cm in size to 58% in those 
over 1 cm, providing evidence that KRAS is involved in tumour growth promoting 
aspects and not CRC initiation (Vogelstein et al., 1988; Leslie et al., 2003).  The 
chronological order of mutations is important in CRC development, with the loss of 
APC representing the earliest and rate-limiting genetic event in CRC tumour 
initiation (Powell et al., 1992) leading to β-catenin nuclear localization. KRAS 
mutation is then a following step to promote adenoma progression to carcinomas 
(Vogelstein and Kinzler, 2004; Phelps et al., 2009).  
1.3.6 Deleted in colorectal cancer and SMAD tumour suppressor genes 
Further malignant progression along the adenoma to carcinoma sequence involves 
the allelic losses of chromosomes 18q and then 17p, which have been found to occur 
in a large proportion of both colorectal adenomas (CRA) and carcinomas (Fearon et 
al., 1987; Fearon and Vogelstein, 1990; Powell et al., 1992).   
Chromosome 18q is lost in 10 to 30% of early adenomas, 60% of late adenomas and 
70% of carcinomas (Leslie et al., 2003).  The first candidate TSG in this chromosomal 
interval to be described was the "deleted in colorectal cancer" (DCC) gene which 
encodes 1447 amino-acid transmembrane protein with four immunoglobulin-like 
and six fibronectin III-like domains (Hedrick et al., 1994).  DCC acts as a 
transmembrane receptor for netrins, which are key components involved in the 
lateralisation of the human nervous system via axon growth in neurons (Srour et al., 
2010).  The expression is detected in many tissues including the lung, colon, and 
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testis with the highest expression in normal brain tissue.  In addition to CRC, DCC is 
considered a TSG target gene for pancreatic (Murty et al., 1994) and testicular 
cancers (Strohmeyer et al., 1997).  In the absence of netrin or at low levels DCC 
induces apoptosis and may be involved in activating downstream signalling pathway 
that involves MAPK activation.  Subsequent activation of the transcription factor Elk-
1 and SRE regulated gene expression are pivotal to transducing extracellular 
mitogenic signals into a nuclear response and contribute to the pathogenesis of CRC   
Other TSGs found in this interval are SMAD family members (SMADs), which are 
signal transducers that mediate intracellular transforming growth factor-beta 
(TGFβ) signalling pathways.  SMAD proteins bind to TGFβ receptor 2 (TGFBR2) 
receptor to promote the formation of heterodimer with the TGFβ receptor 1 
(TGFBR1) and binds to its DNA translocation factors where the complex activates 
the transcription of genes responsible for a broad range of cellular functions 
including cellular growth inhibition, apoptosis, differentiation, and matrix 
production (Heldin et al., 1997; Duff and Clarke, 1998).  Mutations in SMAD2 or 
SMAD4 are mutated, TGFβ signal is not transduced into the nucleus of the cell.   
In addition, mutations in TGFβR1 have been identified in CRC cell lines (Ku et al., 
2007) and the most common variant TGFβR1*6A, (*6A) is located in exon 1, has a 
deletion of 3 alanines within a stretch of 9 alanines and has been suggested to be 
implicated in increased risk for several cancers, for example breast and ovarian 
cancer (38% and 41% respectively) (Kaklamani et al., 2003), and CRC (Pasche et al 
2004).  A significantly higher *6A frequency was observed amongst cancer patients 
than healthy controls (Pasche et al., 1998) and meta-analysis of 12 case control 
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studies in 7850 Caucasians, showed that 14% were carriers of the *6Ala genotype 
and are at a 20% higher risk of CRC and based on this the population attributable 
risk is predicted to be 3.2% (Pasche et al., 2004).  These findings have been 
confirmed by Zang et al showing 44% higher frequency of *6A in CRC cases than in 
controls (Zhang et al., 2005) which highlights that *6A susceptibility allele is 
common in the general population and the contribution to the total CRC burden is 
relatively high in spite of its modest relative risk (1.20).  TGFBR2 mutations are also 
frequently found to affect TGF-β signalling in CRC, mainly among MSI tumours but 
also in approximately 55% of microsatellite stable (MMS) tumours (Grady et al., 
1999).  Overall, there is convincing mutational evidence for the major role of TGF-β 
pathway inactivation in the adenoma-carcinoma transition and for SMAD2/4 as 
primary TSGs of CRC (Roberts and Derynck et al., 2001).   
Germline mutations in the SMAD4 and bone morphogenetic protein receptor, type IA 
(BMPR1A) have been shown to be associated with Juvenile polyposis syndrome (JPS) 
(He et al., 2004; Howe et al., 1998).  In addition, phosphatase and tensin homologue 
(PTEN) mutations are also implicated in JPS predisposing to benign and self-limiting 
hamartomatous polyps in the upper gastrointestinal tract, small bowel and colon 
(Chen and Fang, 2009).  The lifetime risk of developing GI cancers ranges from 9% to 
50% (Howe et al., 2004; Schwenter et al., 2011).  PTEN is a landscape TSG which acts 
indirectly through intracellular signalling and control of the microenvironment in 
which cells grow and contribute to the neoplastic growth of cells by creating an 
environment suitable for unregulated cell proliferation (Michor, 2004; Lengauer et 
al., 1997).   
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1.3.7 TP53 tumour suppressor gene 
Most malignant CRC are characterised by loss of the short arm of chromosome 17 
(17p) which harbours the TP53 TSG (17p13.1) in humans.  The gene spans 20 kb, 
with coding sequence in exons 2, 5, 6, 7 and 8, which show a high degree of 
conserved regions between vertebrates (May and May 1999).  Germline mutations 
of the TP53 TSG are responsible for the autosomal dominant condition Li-Fraumeni 
syndrome which is known to greatly increase susceptibility to cancer (Varley 2003).  
The associated risk of developing cancer is 90% by the age of 70, including 
sarcomas, leukaemia and malignancies of the breast, brain, and adrenal cortex 
(Petitjean et al., 2007).   
It is mutated in over 50% of all CRC (Hollstein et al., 1991, Soussi et al., 2007) and is 
very rarely found in benign lesions suggesting that functional inactivation of the 
TP53 gene is a late genetic event associated with the transition from adenoma to 
carcinoma (Vogelstein et al., 1988; Rodrigues et al., 1990).  TP53 is referred to as the 
“master watchman", due to ability to block cell proliferation via transcriptional 
activation of cyclin inhibitors, like p21 in the presence of DNA damage (Waldman et 
al., 1995).  In unstressed cells, TP53 is usually bound to murine double minute 
(Mdm2) oncogene, which promotes continuous degradation by acting as ubiquitin 
ligase and thus maintaining low levels in cells.  TP53 is activated by the 
phosphorylation of the N-terminal domain, involving 2 types of protein kinases: 
MAPK family which responds to several types of stress such as membrane damage 
and oxidative stress; or the second group; ATM, DNA-PKs, checkpoint homologs 1 
and 2 (CHK1, CHK2) family which responds to DNA damage initiated by genotoxic 
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stress and DNA double strand damage caused by UV, IR or carcinogens via DNA 
integrity checkpoints.  The major events that occur upon TP53 activation lead to an 
increase in its half-life and then a conformational change as a transcription factor to 
regulate stressed cells.  
1.3.8 Serine/threonine kinase 11 tumour suppressor gene 
Peutz-Jeghers syndrome (PJS), is caused by an autosomal dominant condition, with 
90-100% of all cases with a specific genetic mutation in Serine/threonine kinase 11 
(STK11) TSG also known as liver kinase B1 (LKB1) (Jenne et al 1998).  The gene 
encodes a member of the serine/threonine kinase and is involved in regulating cell 
polarity and functions also as a gatekeeper (Hemminki et al., 1998).  PJS Individuals 
carry a 20% lifetime risk of developing CRC (Lai et al., 2011).  The condition is 
associated with multiple harmatomatous polyps in the digestive tract and 
hyperpigmentation on the face, around the lips and hands which is often the first 
sign for diagnosis.  An increasing number of sporadic mutations in LKB1 are being 
reported in diverse cancers (Sanchez-Cespedes 2007); 30% of lung cancers show 
mutations in the LKB1 gene (Sanchez-Cespedes et al., 2002).   
1.3.9 Caretakers and microsatellite instability 
Mutations of ‘caretaker’ genes affect the maintenance of genomic integrity which 
occurs via cell cycle checkpoints and DNA repair and maintenance pathways, such as 
NER, BER, MMR and NHEJ (Levitt and Hickson, 2002; Michor et al., 2004).  The MSI 
pathway is associated with loss of DNA MMR proteins, which leads to the 
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accumulation of mutations.  MSI or replication error positive (RER+) has been 
identified amongst microsatellites, which are repetitive genetic loci prone to 
slippage during DNA replication resulting in small alterations at microsatellite loci.  
Inefficient MMR genes cannot repair these allelic changes and this allows for the 
formation of different sized alleles at the next round of replication (Aaltonen et al., 
1993).  Genetic and epigenetic changes will in turn cause an increased genomic 
mutation rate and may facilitate malignant transformation and so MSI has also been 
referred to as the mutator phenotype.  MSI caused by deficient MMR functions was 
found in about 15% of all sporadic tumours (Fridrichova, 2006) and 90% in LS 
tumours (Aaltonen et al., 1993, Wang et al., 1999).  However, not all LS patients have 
MSI and about 15% of non LS CRCs show MSI (Julié at al., 2008).   
1.3.10 Lynch syndrome 
The predisposition of some families to develop cancer at a young age was first 
recognised by Alfred Warthin in 1895, when his seamstress, predicted her own 
death from cancer from her family history.  By studying her family (Warthin’s family 
G) he found that gynaecological, colonic and stomach cancer occurred frequently.  It 
was not until the 1980s that Lynch developed the idea of cancer family syndromes, 
which became a fully accepted principle and the term LS was used for this condition 
(Lynch and Krush, 1971).  Initially, it was divided into type I and type II depending 
on whether individuals developed colonic cancers or not.  Later, it was discovered 
that both of these syndromes were due to inherited defects in the genes that 
regulate the excision of errors occurring during DNA replication of the mismatch 
genes.  The germline mutation was therefore classed as an autosomal dominant gene 
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with a high risk for familial predisposition to CRC and extracolonic cancers of the GI, 
urological, stomach and female reproductive tracts (Lynch and de la Chapelle, 2003).   
LS is the most common form of inherited CRC, accounting for 3-5% of all CRCs. 
These cancers do not display aneuploidy or the characteristic mutations nominated 
by Fearon and Vogelstein (Fearon and Vogelstein 1990).  It is usually diagnosed 
based on the Amsterdam II and Bethesda criteria (Rodriguez-Bizas et al., 1997; 
Vasen et al., 1999).  That is, familial aggregation of three or more relatives with 
histological verified CRCs, one of which is the first degree relative of the other two.  
CRC involving at least two successive generations, at least one relative diagnosed 
with CRC under the age of 50, exclusion of FAP, inclusion of endometrium, ureter, 
renal pelvis and small bowel cancers and to test the patient’s tumours for MSI 
(Peltomäki 2001, Scott et al., 2001).  LS patients have an 80% occurrence risk of 
developing CRC at around 45 years of age compared to 60 for other familial CR 
cancers (Rustgi et al., 2007).   
LS is caused by the inheritance of one defective MMR gene; MutL homolog 1, 
(hMLH1), MutS homolog 2 (hMSH2), MutS homolog 6 (hMSH6), and to a lesser extent 
postmeiotic segregation (PMS2), with more than 400 different predisposing MMR 
gene mutations reported, approximately 50% affect hMLH1, 40% hMSH2, 10% 
hMSH6 and less than 5% affecting PMS2 (Peltomaki 2001).  MMR proteins are 
required to recognise mismatches and are named according to their homology to the 
bacterial proteins, known as MutS, MutL and MutH and PMS2 (Leach et al., 1993).  
These proteins form complexes and have specific roles: hMSH2 and HMSH6 form 
MutSα complex to identify single base mismatches, where hMSH2 and hMSH3 
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together form the MutSβ complex that identifies short insertions or deletion errors.  
hMLH1 and hPMS2 combine in a heterodimer that interacts with the MutS 
complexes to excise and repair DNA (Plotz et al., 2006).   
While some studies report that CIN and MSI are mutually exclusive pathways of 
genetic instability in CRC (Lengauer et al., 1998), more recent studies indicate 
shared pathways, for example mutations in exon 3 of β-catenin are associated with 
malignant CRCs in LS tumours, and appear not to occur as a result of MMR 
deficiencies, indicating that genetic pathways maybe linked with an interplay 
between the Wnt pathway occurring at later stages of tumour development 
(Johnson et al., 2005).  The extent of overlap and shared features are unclear, and 
are likely to involve very small numbers of genes (Muleris et al., 2008, Pino and 
Chung 2010).   
1.3.11 Epigenetic events – CIMP and DNA methylation 
The third pathway CIMP was suggested by Toyota et al in 1999 and cancer 
development occurs via hypermethylation at several CpG loci converting cytosine to 
5-methylcytosine (Toyota et al., 1999; Shiraishi et al., 2002; Wheeler 2005; Jass, 
2007).  Approximately 1% of human DNA bases undergo DNA methylation, which 
involves the addition of a methyl group to DNA (Slagboom and Meulenbelt, 2002) 
and in adult somatic tissues. DNA methylation typically occurs at between 60-90% 
of all CpGs (Jones and Baylin, 2007; Calvanese et al., 2009).   
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In cancer, CpG islands, are present in the promoter regions of TSGs, where DNA 
methyltransferases (DNMT1, DNMT3a, DNMT3b) physically block the binding of 
transcriptional proteins causing inactivation or silencing of the gene (Vallbohmer et 
al., 2006; Butcher and Rodenhiser, 2007).  Findings from several studies have shown 
that tumours can stably maintain mutations in one allele of a TSG while the other 
allele is hypermethylated, leading to a functional inactivation of the gene (Myohanen 
et al., 1998; Grady et al., 2000).  This phenomenon has been described as the ‘third 
pathway’ in Knudson’s model of TSG inactivation in cancer (Kondo and Issa, 2004).  
Toyota and co-workers showed that CIMP positive tumours commonly occur in 35-
40% sporadic CRCs with MSI related to MLH1 hypermethylation affecting the 
mismatch repair process (Baylin et al., 1998, Toyota et al., 1999, Herman and Baylin, 
2003, Kondo and Issa, 2004).  Furthermore, CIMP has been showed to be strongly 
associated with BRAF mutation (V600E) (Weisenberger et al., 2006), where 
hierarchal clustering has identified three groups with distinct genetic and epigenetic 
profiles; CIMP negative tumours display rare methylation and TP53 mutation. CIMP1 
tumours are methylated at multiple loci and display MSI and BRAF mutations. In 
contrast, CIMP2 is methylated at a limited number of age-related genes and displays 
mutations in KRAS (Weisenberger et al., 2006, Shen et al., 2007).   
1.3.12 Haploinsufficiency  
Another interesting phenomenon involves the loss of only one functional allele, 
which may also be sufficient to produce a tumour phenotype in a diploid cell.  This is 
termed haploinsufficiency and at a TSG locus may overcome the need for the somatic 
loss or mutation of its wild type allele (Payne and Kemp 2005).  The onset of a 
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tumour phenotype occurs when the remaining copy does not provide sufficient 
messenger RNA (mRNA) to encode for a sufficient amount of functional protein 
(Payne and Kemp 2005; Fodde and Smiths, 2002).  To date, experimental evidence 
for haploinsufficiency in cancer predisposition comes from the analysis of tumours 
obtained from mouse models or from hereditary cancer patients carrying 
heterozygous null mutations at known TSGs.  The absence of the second hit in a 
subset of these tumours has been attributed to inactivation of the remaining allele 
by alternative mechanisms such as epigenetic silencing or mutations in non-coding 
sequences.  For example, mice heterozygous for the TSG gene Smad4, develop 
tumours as a consequence of halpoinsufficiency and initial retention of the wild type 
allele.  Although loss of a single gene copy is sufficient for tumour formation, LOH of 
the remaining Smad4 allele does occur later on in tumourigenesis (Alberici et al., 
2006; Xu et al., 2000).  Bona fide haploinsufficiency has been demonstrated for a 
subset of tumour suppressor loci including ATM (Lu et al., 2006), PTEN (Kwabi-Addo 
et al., 2001), LKB1 (Nakau et al., 2002) andTP53 (French et al., 2001). 
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1.4 FAMILIAL ADENOMATOUS POLYPOSIS  
FAP was first documented by Menzel in 1872 and later Virchow described a 15 year 
old boy with multiple polyps as “polyploidy colitis” in 1863.  Cockayne reported on 
the autosomal dominant mode of transmission in 1927 which was later confirmed 
by Dukes and Lockhart-Mummery who devised a clinical registry of cases and 
reported on the familial association and confirmed the disease process as Mendelian 
dominant (Lockhart-Mummery, 1934).  By 1955, FAP was well described and 
defined as multiple polyposis, a condition where hundreds and thousands of 
adenomatous polyps are found in the large intestine and rectum (Woolf 1958).  
Lipton and Tomlinson further reported the development of thousands of ACF within 
the intestinal tract of FAP patients (Lipton and Tomlinson, 2006).  FAP patients are 
at high risk of developing adenomatous carcinomas that tend to occur between the 
ages of 20 to 45 leading to virtually 100% occurrence of cancer if left untreated 
(Rustgi et al., 2007).  It is also generally accepted that the larger polyps transform to 
adenomatous carcinomas (Debinski et al., 1996).   
1.4.1 The structure and function of Adenomatous Polyposis Coli gene 
The genetic basis for FAP lies in germline mutations of the APC.  The discovery and 
physical mapping of the APC gene came from a patient with colorectal polyposis and 
mental retardation who had a deletion in the 5q sub-chromosomal region (Herrera 
et al., 1986, Bodmer et al. 1987).  Further segregation and linkage analysis in FAP 
families led to the mapping of the APC gene to 5q21 (Bodmer et al., 1987) which was 
cloned and characterised in 1991 to consist of 8535 base pairs that encode a 2843 
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amino acid multi-domain protein (Figure 1-5) (Groden et al., 1991; Nishisho et al., 
1991; Kinzler et al., 1991).  The main role of APC is to regulate β-catenin 
concentration in the cell cytoplasm via Wnt pathway but is also involved in cell-cell 
adhesion, microtubule stability, cell cycle regulation and apoptosis (Behrens, 2005).  
It is present in a variety of epithelial tissues, often diffusely distributed in the 
cytoplasm and can sometimes be found in the apical or lateral regions of epithelial 
cells (Midgley et al., 1997) suggesting APC mediates apoptotic control of cellular 
migration within colonic mucosa regulating cell formation and cell death.   
 
Figure 1-5 The 2843 amino acid (αα) adenomatous polyposis (APC) protein.  
Conserved domains within APC such as armadillo repeat and regions interacting 
with other proteins are shown.  N-terminus binds to the B56 regulatory subunit of 
protein phosphatase 2A.  β-catenin binding occurs at three 15 αα repeats (between 
1020 and 1169 αα) (in blue) and a second binding region with seven 20 αα repeats 
(in white, between 1342 and 2075 αα), which are interspersed by axin binding 
SAMP motifs.  The mutation cluster region (MCR) (approx 1250 to 1550 αα) 
encompasses β-catenin binding sites and mutations in this region produce the most 
severe phenotype in humans.  The C terminal portion of the APC protein is involved 
in binding to cytoskeletal microtubules (MT) and tubulin-binding protein (EB1) 
(McCart et al. 2008). 
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1.4.2. The Canonical Wingless-Int pathway 
The canonical Wnt pathway is an evolutionary conserved signalling pathway that 
plays numerous developmental and cellular roles in animals (Logan, 2004).  The 
deregulation of this pathway can lead to various types of cancers in particular CRC.   
The sequence of events that occur in the CIN pathway to cause cancer is fairly well 
documented. One of the first events is the activation of the Wnt signal transduction 
pathway via the loss of APC function (Figure 1-6).  In the intestine, differentiation of 
cells as they move up the crypt is under the control of Wnt and bone morphogenic 
protein (BMP) signaling: as Wnt decreases and BMP increases, cells differentiate and 
move towards the apex of the villi.  When Wnt is high in the bottom and the middle 
of the crypt, cells tend towards proliferation, but when Wnt is low and BMP is high, 
cells differentiate and eventually slough off from the top of the villus (Kosinski et al., 
2007).  This suggests that BMP signaling suppresses Wnt signaling, which is central 
to ensure a balanced control of stem cell self-renewal.   
In a normal cell, the absence of the Wnt signal, the wild type APC protein mediates 
its tumour suppressor function with the downstream binding of APC to β-catenin, 
glycogen synthese kinase-3β (GSK3β) and axin (Figure 1-6 a).  This complex 
phosphorylates β-catenin and leads to it degradation, regulating its concentration in 
the cytoplasm and promoting its breakdown.  Ultimately the degradation causes the 
suppression of the Wnt signal and prevents the transcriptional activation of β-
catenin target genes (Su et al., 1993; Sparks et al., 1998; Bienz and Clevers, 2000; 
van Es et al., 2001; Giles et al., 2003; Logan and Nusse 2004;).   
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Figure 1-6 The Wnt pathway: off (a) and on (b). Cytoplasmic β-catenin is 
phosphorylated and degraded by a complex of APC, axin and GSK-3β in the absence 
of Wnt.  In the presence of Wnt signal ligand bound to its receptor Frizzled (FRZ), 
Dishevelled (DSH) is recruited and inactivates the APC-axin-GSK-3β complex. β-
catenin may then escape degradation and enter the nucleus where, in conjunction 
with TCF/LEF, it up-regulates POL ribonucleic acid polymerase for the transcription 
of multiple target genes.   
In the presence of the Wnt signal, or with dysfunctional APC, Wnt binds to the cell 
surface receptors of the Frizzled family (FRZ), which recruit activated Dishevelled 
(DSH) family of proteins (Figure 1-6 b).  DSH is a key component of the Wnt receptor 
complex and inhibits the APC-β-catenin-GSK3β-axin complex from forming and 
initiating the ‘normal’ proteolytic degradation of the β-catenin (Bienz and Clevers, 
2000; Grohmann et al., 2007).  The pool of cytoplasmic β-catenin increases and 
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stabilises, leading the β-catenin to translocate to the nucleus where it 
heterodimerises with T-cell factor/lymphoid enhancer factor  (TCF4/LEF1) family 
transcription factors to promote activity of a variety of genes involved in 
proliferation and malignant transformation: the proto-oncogene c-MYC, the cell cycle 
activator CCND1 (cyclin D1), gastrin, fibronectin, matrix metalloproteinase 7 
(MMP7), and vascular endothelial growth factor (VEGF) amongst others (Mann et al., 
1999; Tetsu and McCormick, 1999, Behrens, 2005, Senda et al., 2007).  This is a key 
step in tumourigenesis and accumulation of nuclear β-catenin is associated with 
disease progression (Hugh et al., 1999; Bienz and Clevers, 2000; Clevers, 2006).   
1.4.3 Adenomatous Polyposis Coli mutations  
Mutations in the APC gene are very heterogenous, dispersed along 15 exons and 
more than 800 different germline APC mutations have been identified in FAP 
tumours and appear to be confined to the 5′ half of the APC gene (Miyoshi et al., 
1992; De Filippo et al., 2002; Nagase and Nakamura 1993; Fearon and Vogelstein, 
1990).  Approximately, 90% of all germline APC mutations result in the alteration of 
the reading frame and introduce premature stop codons leading to truncated 
proteins as a consequence (de la Chapelle 2004).  Béroud and Souss pointed out that 
30% inactivation of the APC protein was due nonsense point mutations (usually C>T 
changes) and 68% by frameshift mutations (Béroud and Souss, 1996).  Deletions 
involving exons or the entire APC are seen in 10% of FAP and 20% arise de novo.  
There are two frameshift mutational hotspots of 5 bp deletions at codons 1061 and 
1309; these are prone to spontaneous slippage and comprise of 12% and 18% of all 
 70 
germline APC mutations, respectively.  Other frameshift mutations include 2 bps and 
1 bps deletions at codons 565 and 1436, respectively.   
Mutational analyses of sporadic CRC tumours, like germline APC mutations, consist 
mainly of frameshift and nonsense but are clustered in the center of APC; known as 
the mutation cluster region (MCR) and dominate the sporadic mutational spectrum.  
This region spans codons 1286–1513 of exon 15 (Nagase and Nakamura 1993; 
Polakis 1997; SU et al., 2002) and accounts for 68% to 77% of all somatic mutations 
(Miyoshi et al., 1992).   
1.4.4 Familial Adenomatous Polyposis genotype-phenotype variations 
Genotype-phenotype correlation studies for the APC gene have shown that the 
location of a germline mutation provides some information about the polyp burden 
and the health problems associated with FAP.  Several reports have shown a 
correlation between disease severity and the site of APC mutation (Nagase and 
Nakamura 1993; Nugent et al., 1994; Groves et al., 2002).  In addition, a proportion 
of FAP patients are affected by extracolonic conditions such as osteomas, 
epidermoid cyst, congenital hypertrophy of the retinal pigment epithelium (CHRPE), 
upper gastrointestinal (UGI) polyps or adenomas, desmoid tumours, brain, thyroid, 
and biliary tract malignancies all which depends on the position of the inherited APC 
mutation.   
Classical polyposis leads to thousands or more adenomas, a polyp burden that is 
usually associated with mutations in codons 169 and 1600.  Patients with mutations 
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in codons 1250 and 1464 are associated with a severe polyposis phenotype (>1000 
polyps) which tend to present earlier, are more often symptomatic, and may be 
more likely to develop CRC (Debinski et a., 1996) Figure 1-7.  Similarly, the profuse 
phenotype, which is characterised by numerous intestinal tumours, also results from 
mutations between codon 1250 and 1464 (Nagase et al., 1992).  Truncations 
between codons 1-436 and in the extreme 5’ end of APC produce AFAP.  This is 
associated with a smaller number of adenomas, which appear later in life (Lynch et 
al., 1995).  Recent genotype-phenotype correlations showed that the age at 
polyposis onset and years of survival differed significantly by genotype.  Patients 
with APC mutation between codons 0-178 or 312-412 developed ‘late’ polyposis and 
survived longer, whereas patients with mutations in APC 1249-1549 developed 
polyposis earlier and did not survive as long (Newton et al., 2012).   
 
Figure 1-7 The location of mutant codons within the APC gene associated with the 
variation in polyp burden, development of extracolonic tumours in FAP patients.  1-
15 represents the exons of APC gene and the mutation cluster region (MCR).   
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CHRPE have been seen in some cases of FAP and tend to occur in patients with 
mutations in codons 543 and 1309.  Duodenal adenoma risk and extracolonic 
manifestations are highest between codons 976 and 1067.  The second highest 
frequency of extracolonic developments occurs between codons 1310 and 2011 
(Bertario et al., 2003).  The higher risk for desmoid disease amongst FAP patients 
arises due to biallelic APC mutations, with one change occurring distal to codon 
1399 of the APC.  Codons between 1310 and 2011 are also associated with a six-fold 
increase risk in desmoid tumours and considered high-risk region compared to the 
low risk region 159 and 495.  Desmoids tend to cluster in susceptible individuals, 
more in females than males and in patients with a positive family history of 
desmoids (Sturt et al., 2004, Bhandari et al., 2011).  Furthermore, aggressive 
fibromatosis is marked by the presence of desmoid tumours, a rare condition in the 
general population.  These tumours are benign, well differentiated, and overgrowths 
of fibrous tissue.  Though these are slow growing tumours without any metastatic 
potential, they are locally invasive leading to organ damage and dysfunction.   
There are a few germline mutations after codon 1700 which produce little or no 
phenotype (Muraoka et al., 1994).  The clinical variant Gardner’s syndrome is 
typically caused by mutations in the small region between codon 1403 and 1578 
(Fearnhead et al., 2001) and is also associated with osteomas (tumours of the bone); 
jaw, extra teeth, and soft tissue tumours including lipomas (fatty tissue) and 
fibromas.   
  
 73 
1.4.5 APC mutations in MYH-associated polyposis  
Individuals with an autosomal recessive form of FAP were known as MYH-
associated polyposis (MAP) syndrome are linked to biallelic mutations in the MutY 
homolog (MYH) gene (Al Tassan et al., 2002).  Presently, there is much clinical 
variability in features of MYH mutation carriers, however MAP patients are 
characterised by multiple colonic polyps, have a milder disease than FAP, but more 
severe than AFAP and carry a high risk of CRC progression.  MYH mutations are 
thought to cause cancer due to the accumulation of G:C to T:A transversions in APC 
suggestive of a defect in DNA repair system (Al Tassan et al., 2002; Seiber et al., 
2003; Lipton and Tomlinson, 2004).  Moreover, a few individuals have been 
diagnosed with CRC at 50 years or younger with few or no polyps (Wang and Cooper 
et al., 2004).  Aretz and colleagues also noted between 4% and 25% of individuals 
with biallelic MYH mutations also show duodenal polyposis (Aretz et al., 2006).   
MYH encodes DNA glycosylase involved in DNA damage repair via BER process.  
Oxidative damage can cause the mutant base 8-oxoguanine to be incorrectly 
included into DNA in place of guanine.  MYH removes adenine residues that are 
incorporated opposite 8-oxoguanine which have a tendency of mismatch at these 
bases.  Following replication in MYH deficient cells a thymidine can be incorporated 
opposite the adenine and consequentially lead to deficient glycosylase activity and 
therefore is a caretaker TSG which follows the ‘just right’ model.   
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1.4.6 The Adenomatous Polyposis Coli-I1307K gene variant 
Other variants of the APC gene (first described by Laken et al in 1997) such as  
I1307K are thought to act as a low penetrance allele associated with an increased 
CRC risk in Ashkenazi Jews and to cause AFAP like phenotype (Groves et al., 2002).  
The frequency of heterozygosity for this allele is 6.1% and 10.4% in Ashkenazim 
healthy and CRC affected individuals, respectively.  When stratified for family 
history, approximately 28% of all probands are carriers of the APC-I1307K variant 
(Laken et al., 1997).  Several studies have reported an increased CRC relative risk 
ratio of 1.58 (95% CI: 1.21–2.07) for carriers of the APC-I1307K variant (Houlston et 
al., 2008).  The missense mutation occurs in the MCR region of the APC at codon 
1307, which is thought to occur due to a hypermutable region prone to slippage of 
the A8 tract, responsible for replication-induced errors and gain/loss of an adenine 
resulting in a frameshift change.  However, the A8 is not observed in all polyps of 
these carriers and suggests additional genetic components may be involved.   
1.4.7 Modifiers of Adenomatous Polyposis Coli 
As previously mentioned, FAP patients with the same mutation in the APC gene can 
also show an intra-familial variation in polyp numbers and differences in disease 
occurrence (Su et al., 2002, Giardiello et al., 2000; Friedl et al., 2001; Houlston and 
Tomlinson, 2001).  Hence, the position of the germline mutation alone cannot 
explain this variation in disease severity.  The difference can be striking with some 
carriers with only a few polyps, while others may have more than 100 and still 
others may manifest a variety of neoplasias, including osteomas, sarcomas, and 
 75 
carcinomas (Leppert et al., 1990; Spirio et al., 1992).  Such diversity is thought to be 
due to environmental factors, especially diet which are highly likely to influence the 
onset of CRC.  It is also suggested that these variations are probably due to genetic 
modifier genes, which may have a modulating influence on the outcome of APC 
mutation.  This scenario has been repeated in mouse models of APC, which under 
laboratory controlled genetic and environmental conditions yield differences in 
polyp burden, thus substantiating the evidence for modifiers.  In animals, modifier 
effects are usually attributed to the genetic background (distinct from the disease 
locus) and are inherited as polygenic traits leading to quantifiable differences in 
disease phenotype with quantitative trait loci (QTL) studies providing examples of 
genetic modifiers of APC.   
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1.5 THE USE OF MOUSE MODELS 
1.5.1 Historical introduction 
The concept of inbred mice developed from the popular hobby or ‘fancying’ of 
collecting and breeding of mice with different coloured coats, which started in Japan 
in the 1700s.  The popularity grew into Europe by 1800s.  William Castle, along with 
his student Clarence Little began research in 1902 and produced a series of seminal 
papers on coat colour genetics by buying mice from a local mouse fancier.  This led 
to the development of ‘lab mice’ or the inbred strains that are used today.  Little’s 
first inbred mouse, dilute brown non-agouti (DBA) was developed in 1909 and the 
more famous strain C57BL/6 was developed in 1921.  By 1929 Little had set up the 
Jackson Laboratory in Maine, USA, which is the most renowned centre for mouse 
genetics and plays a major role in research into mammalian biology.   
Mouse models are powerful tools in cancer research as tumours arise under 
genetically and environmentally controlled conditions, the supply of tumours is 
plentiful and allows for significant analysis and follow-up studies on the influence of 
mutations which drive tumourigenesis.  Mice are small in size, relatively easy to 
handle and to take care of.  Their short generation time, rapid tumour growth and 
high tumour incidence make them ideal for cancer research.  On the other hand, 
selective pressures used to perpetuate laboratory mouse strains have resulted in 
limited genetic diversity as a consequence of ancestry and many regions in the 
genomes of the laboratory mouse are highly correlated, resulting in spurious false 
associations and real ones being missed (Su et al., 2010).  Outbreeding strategies 
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and designing of collaborative crosses to create genetically more distinct mice do 
offer increased allelic variation and can remove the possibility of population 
structure to prevent false positive associations.  Such outbred mice also have low 
levels of linkage disequilibrium (LD) and high minor allele frequency averages 
(Yalcin and Flint, 2010).  Recent years have seen an increase in genetically 
engineered mouse models (GEMMs) in research and preclinical studies.  Their 
application to human complex genetics is not always straightforward, but with the 
use of a number of genetic and predictive tools it is possible to interrogate the 
findings and bind to relevant human genes and or proteins.   
1.5.2 Apcmin/+ (Min Mouse) model of intestinal tumourigenesis  
Many Apc GEMMs have been generated in attempt to accurately model the 
mutations common in FAP families and those implicated in sporadic CRCs of which 
ApcMin/+ is the first model used to investigate multiple intestinal neoplasia (Min).  
The ApcMin/+ mouse was identified following random mutagenesis with 
ethylnitrosurea (ENU) and described by Moser et al, (1990) (Moser et al., 1990).  
These mice were subsequently found to have a single change mutation from leucine 
to a stop codon at position 850 of Apc (Su et al., 1992).  The ApcMin/+  mouse 
polyposis differs from the human condition as adenomas (>90%) are generally 
localised to the small intestine whereas in FAP patients, polyps are much more 
common in the colon (Caldwell et al., 2007; Silverman et al., 2002; Halberg et al., 
2000; Moser at al., 1990).  Adenoma formation in ApcMin/+ mouse is thought to occur 
within the first few weeks of life, with a full complement of adenomas being attained 
by approximately 9 weeks of age (60–67 days of age).  After this time, adenoma 
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multiplicity is thought not to change, although adenoma size may still increase.  
ApcMin/+ mice become anaemic and have a shortened life span of roughly 120 days 
(Moser AR., 1990; Shoemaker et al., 1995; Chiu et al., 1997).   
The polyp multiplicity in ApcMin/+ mouse is greatly influenced by genetic background, 
and was discovered as a result of linkage studies to map the ApcMin/+ mutant.  Mice 
heterozygous for Apc mutation developed approximately 29 small intestinal polyps 
when on the C57BL/6 background.  William Dove and colleagues performed a series 
of backcrosses and discovered that the Apc phenotype is fully penetrant a 
characteristic shared in human FAP patients.  In addition, backcrosses between F1 
offspring from C57BL/6 (B6) ApcMin/+ mice with AKR/J strain (AKR) or castaneus 
(CAST) mice demonstrated a significant decrease in polyp number as well as life 
span (Dietrich et al., 1993).  The difference in polyp number suggests that certain 
inbred strains carry modifier genes that can reduce or increase polyp multiplicity in 
ApcMin/+ mice.   
1.5.3 Modifiers of Min (Mom) 
Tracing the inheritance of genetic markers in the backcross (BC) by QTL analysis 
enabled the first of the modifiers (Table 1-4), modifiers of Min (Mom1), to be 
localised to the distal region of mouse chromosome 4.  This was further refined to a 
4cM interval on distal chromosome 4 using congenic strains (Gould et al 1996b).  
Additional analysis of inbred strains showed that certain inbred mice carried the 
Mom1 resistant (Mom1R) alleles; AKR, CAST, SWR/J, DBA/2J and BALB/c, while B6, 
BTBR and 129/SvJ each carry a Mom1 susceptible (Mom1S).  Mom1 is estimated to 
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account for approximately 50% of polyp number variation and is classed as a semi-
dominant modifier of intestinal polyposis, and suggests that other modifier genes 
with weaker effects exist (Dietrich et al., 1993, Gould et al., 1996a).  Candidate gene 
analysis identified that secretory type II non-pancreatic phospholipase A2 (Pla2g2a) 
mapped to the same region as Mom1 and showed 100% concordance between 
Pla2g2a genotype and Mom1 phenotype in mouse strains (Dietrich et al., 1993, 
MacPhee et al., 1995).   
Table 1-4 Summary of selected modifiers of Min phenotype.  TSG=tumour 
suppressor gene, LOH=loss of heterozygosity, RI=recombinant inbred, 
B6=C57BL/6J, MA=MA/MyJ, CAST=CAST/EiJ, BTBR=BTBR/Pas and AKR=AKR/J 
mice 
Mom Location Phenotype/comments 
Candidate 
gene/marker 
References 
Mom1 
Mapped to 5cM 
interval to distal 
chromosome 4, 
syntenic to humans 
1p35-36 (high 
frequency for LOH) 
Semi-dominant allele 
Control 50% genetic 
variation in 3 different 
strains (AKR, CAST and 
MA) 
Pla2g2a and D4mit64 
- involved in 
phospholipid 
metabolism and 
inflammatory 
responses 
MacPhee et 
al., 1995 
Mom2 
Mapped to distal 
chromosome 18 
which is syntenous to 
human 18q  
Resistant allele.  8-11 fold 
reduction in polyp 
multiplicity 
Atp5a1. 4bp 
duplication. 
excluded Smad 
genes, Dcc and Tcf4  
Silverman 
et al., 2002 
Mom3 
Mapped to 
chromosome 18 – 
linked to Apc 
Broad range of polyps (39-
494) median of 107.  Polyp 
variation segregated into 6 
RI lines, also linked to 
pregnancy 
- 
Haines et 
al., 2005; 
Suraweera 
et al., 2006 
Mom7 
Mapped to 
chromosome 18, 
syntenic to human 
chromosome 5. 
7.4Mbp interval 
2 alleles of Mom7- enhancer 
increases intestinal 
tumours by 3 -fold (in 
BTBR and AKR) and 
suppressive effects in B6 
- 
Kwong et 
al., 2007 
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High levels of Pla2g2a expression were detected in the intestines of mouse strains 
resistant to polyp formation, such as AKR and CAST, while extremely low levels were 
detected in the susceptible B6 strains (MacPhee et al., 1995).  Resistant Mom1R allele 
carried a wild type Pla2g2a, while susceptible B6 strain failed to suppress polyp 
numbers showed that Pla2g2a was disrupted by a frameshift mutation in exon 3, 
resulting in an inactive gene product, lacked in enzymatic activity and carried the 
null Pla2g2a gene (Gould et al., 1996a, Gould et al., 1996b, Kennedy et al., 1995, 
MacPhee et al., 1995).  This data strongly implicated that Pla2g2a is a dominant 
inhibitor of polyp multiplicity in ApcMin/+ mice.  Transgenic mice were constructed 
where the Mom1R AKR allele of Pla2g2a was introduced into a susceptible B6 
background, the Apcmin/+ offspring over expressed the Pla2g2a cosmid transgene and 
showed evidence that the Pla2g2a gene reduces the polyp development by two-fold 
with a significant reduction in polyp size (Cormier 2000).  Also, the reduction in 
polyp number was not restored to wild-type levels, which suggests either a failure to 
restore transgene expression to wild type, or the Mom1 phenotype is the result of 
several closely linked genes.  This would indicate, therefore, that wild type copy of 
the Pla2g2a gene could greatly reduce polyp multiplicity in ApcMin/+ mice, indicating 
Pla2g2a gene encodes the Mom1 locus and to act as a modifier.   
The homologous human Pla2g2a locus has been mapped to the human chromosome 
1p35-p36 (Praml et al., 1995, Riggins et al., 1995, Tomlinson et al., 1996).  This 
region is frequently found to be deleted with LOH in various human cancers 
including CRC, as well a large proportion of sporadic colorectal tumours (Praml et 
al.,1995; Dobbie et al., 1997, Tomlinson et al., 1996).  Human functional studies did 
not confirm Pla2g2a as a major modifier of CRC risk in humans because polymorphic 
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variation did not appear to account for significant variation in susceptibility to CRC 
(Riggins et al., 1995; Tomlinson et al., 1996).  Nevertheless, the detection of Pla2g2a 
has been informative, as it plays a part in the synthesis of prostaglandin pathway.  
Asprin and sulindac and other NSAIDs markedly reduce susceptibility to polyps 
probably by interfering with Cox-2 activity within this pathway (Torrance et al., 
2000; Takeda et al., 2003).  The involvement of Cox-2 is supported by the 
observation that ApcMin/+ mice deficient for Cox-2 have reduced polyp numbers 
(Oshima et al., 1996).  Although, Mom1 did not identify a gene that modulates the 
susceptibility of CRC in humans, it has revealed a pathway that has led to 
pharmacological advancements in treatment and management of intestinal 
tumourigenesis,   
Likewise, a second locus, Mom2 (Mom2), can suppress ~90% of polyps in ApcMin/+ 
mice and was traced to a B6 ‘founder male’ who had been mated with DBA/2J female 
(Silverman et al., 2002).  ApcMin/+ males which do not carry the Mom2 R mutation 
exhibit on average 90 polyps and a 95% incidence of colon polyps by 6 months of 
age.  The effects of reducing polyps in the small and large intestine are stronger in 
Mom2 locus than the Mom1 locus.  Genetic linkage studies of the Mom2 locus resides 
within 10cM interval and is syntenic with human chromosome 18q21 and 18q23 
(Silverman et al., 2002, Radice 2000).  Chromosome 18q21 frequently undergoes 
LOH in human CRC (Takagi et al., 1996) and family of SMAD genes have been 
identified in this region, two of which have been shown to result in intestinal 
neoplasia; SMAD2 and SMAD4 (Koyama et al., 1999, Miyaki et al., 1999).  Atp5a1 
gene was also identified following a spontaneous mutation in this gene in mice 
(Baran et al., 2007), but not observed in human CRC cell lines (Seth et al., 2009). 
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The Mom3 modifier has been mapped to the proximal region (within the first 25cM) 
of chromosome 18 in an interval closely linked to the ApcMin/+.  This modifier was 
detected following selective breeding to establish two recombinant strains that 
demonstrated a high and low polyp range.  However, the high scoring line had an 
increase in polyps (range 289-494 polyps per mouse) and a shorter life span (Haines 
et al., 2005).  The lack of additional polymorphic markers, along with the unknown 
genetic background prevented further positional refinement.  The significant 
variation was probably caused by strain contamination, with the B6 not on the 
supposed B6 background.  In a separate study Mom7 locus mapped to a similar 
location as Mom3, located within the first 7.4Mb of chromosome 18 (Kwong et al., 
2007).  There are probably 5 segregating alleles, which amongst the different inbred 
strains.  It has been speculated that both Mom3 and Mom7 may influence LOH of 
distal elements of chromosome 18, but whether these represent the same 
underlying modifier requires resolution by complementation testing and a thorough 
candidate gene search through sequenced regions of the mouse genome.  The nature 
of any candidate genes and or functional polymorphisms remains unclear for both 
Mom3 and Mom7 (Haines et al., 2005; McCart et al., 2008).   
1.5.4 Genetically engineered Apc mice 
Following on from the ApcMin/+ mouse, mouse models with various mutations in the 
Apc gene have been engineered to reflect the mutations found in FAP kindreds and 
sporadic CRC.  A summary of the different Apc mouse models and their polyp 
burdens are shown in Table 1-5 and Figure 1-8.  The quantifiable nature of Apc 
mutation phenotypes and the use of different inbred background provides a suitable 
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way to investigate the susceptibility loci of moderate to low penetrance and link 
these observation to CRC initiation and progression in humans (McPeek 2000, Mott 
et al., 2000; Johnson and Todd 2000).   
 
Figure 1-8 Genetically engineered mutations used to create adenomatous polyposis 
coli mouse models used in the study of intestinal polyposis.  The bars represent 
induced mutations and numbers indicate where the codon affected and Apc protein 
is truncated.   
The histology of intestinal tumours between ApcMin/+, ApcΔ716/+ and Apc1638N/+ are 
similar but considerable differences in tumour numbers show that the genetic 
mutation affects the tumour burden despite being on the same genetic background.  
However, localised affects as demonstrated when the targeting cassette is not 
excised from the ApcΔ716/+, may influence gene expression up and downstream of 
Neo (Colnot et al., 2004).  Furthermore, Oshima et al noticed failure in tissue 
building with the additional layer of villous epithelium indicated that this may be 
responsible for the increase in adenoma numbers (Oshima et al., 1996).  These data 
suggest that other factors that may account for polyp variation may exist, though 
conclusive evidence is not present. 
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Table 1-5 Tumour multiplicity models in adenomatous polyposis coli mice: 
comparison to the phenotype observed in the classical familial adenomatous 
polyposis model ApcMin/+.  SPF= specific pathogen free, ACF=Aberrant Crypt Foci, 
AA=amino acid, MCR=mutation cluster region. 
GEMM Mutation 
Polyp 
burden 
Histology/pathology of 
neoplasia 
References 
ApcMin/+  
 
Armadillo 
repeat 
Truncating mutation 
at codon 850.  
Chemical 
mutagenesis; ENU 
induced 
~30 ->100 
Polypoid, papillary and sessile 
polyps.  Cystic crypts no ACF 
10% incidence of mammary 
tumours 
Moser et al., 
1990 
Apc1638N/+  
 
SAMP 
repeats 
Apc protein truncated 
at codon 1638  
Neomycin inserted 
into exon 15  
<10 
Colonic polypoid hyperplastic 
lesions.  Intestinal tumours 
with infiltration into mucosa 
and submucosa.  Elongated 
colonic crypts.  Desmoids and 
spontaneous ACFs 
Fodde et al., 
1994 and 
Smits et al., 
1998 
ApcΔ716/+ 
 
Armadillo 
repeat 
Apc protein truncated 
at codon 716.  
Neomycin inserted in 
antisense into exon 15  
~300 
Nascent polyps, covered by 
normal epithelium of a single 
villus.  Dysplastic crypts.  No 
colonic ACF 
Oshima et 
al., 1996 
Apc580S 
 
Conditiona
l allele 
frameshift mutation at 
codon 580.   
Intronic LoxP 
insertions  around 
exon 14 and exposure 
to adenovirus 
encoding Cre 
recombinase 
~5 
Adenomas localised near to 
the anus 
Shibata et al., 
1997 
Apc1638T/+ 
 
SAMP 
repeats 
Apc protein truncated 
at codon 1638.  
Hygromycin inserted 
in Smal site in sense 
orientation into exon 
15 
Tumour/pol
yp free 
Absence of preputial glands 
and nipple-associated 
cutaneous cysts associated 
with abnormal follicular 
development 
Smits et al., 
1997 
ApcΔ474/+ 
Armadillo 
Insertional target 
vector to duplicate 
~>100 
similar to 
Sessile with central 
depression.  18.5% incidence 
Sasai et al., 
2000 
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repeat codons 7-10 (7-8-9-
10-7-8-9-10) and 
produce frameshift at 
codon 474 
ApcMin/+ and 
Apc1309/+ 
phenotypes 
of mammary adenomas; 
adenoacanthomas (2cm 
formed between 3-5months.  
Hyperproliferation of 
intestinal glands 
Apc1309/+ 
 
15AA 
repeats 
(MCR) 
Frameshift mutation 
at codon 1309 
~35-100  
Similar polyps to ApcMin/+ 
(throughout the duodenum to 
colon) 
Niho et al., 
2003 
ApcΔ14/+ 
Frameshift at codon 
580 following deletion 
of exon 14 using Cre-
loxP 
~65 
More severe 
than ApcMin/+ 
Earlier death 
and rectal 
prolapse 
observed 
from 4 
months 
 
Increase in polyp numbers in 
animals housed in SPF a 
condition, which was also 
associated with, ACF and 
rectal prolapse.  Tubular 
adenomas and invasive 
carcinomas observed in >12 
month old animals. 
Shift in distal and colon 
adenomas 
 
Colnot et al., 
2004 
ApcneoR 
ApcneoF 
 
Full-length 
hypomorp
hic alleles 
Neomycin inserted 
into an enhancer site 
of intron 13 in the 
reverse (R) and 
forward (F) 
orientation  
1 and 0.3  
  
Dysplastic polyps and 
reduction of 50 and 19% of 
tumour incidence within 15 
months of ApcneoR and ApcneoF, 
respectively 
Li et al., 
2005 
Apc580 
 
Armadillo 
repeat 
Keratin 4, promoted 
excision of exon 14, 
frameshift at codon 
580 and truncated 
protein at 605  
~120 
Similar 
phenotype to 
ApcΔ14/+ 
Intestinal polyposis with 
extracolonic manifestations in 
the skin, thymus and dental 
Kuraguchi et 
al., 2006 
Apc Δ15/+ 
Apc flanked by LoxP 
sites at codon 15 
creating a truncated 
protein at codon 667 
~185 
Small (2mm) polypoid or flat 
adenomas, 77% developed in 
small intestine, 1-2 cutaneous 
cysts and infrequent desmoids 
Robanus-
Maandag et 
al., 2010 
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However, Apc mouse models have provided considerable insight into the role of the 
Wnt pathway components and thus elucidating the molecular pathways essential in 
phenotypic diversity.  Cyclin D1-/- inducible Apc deficient models showed a reduction 
in adenoma burden, indicating Cyclin D1 is not involved in tumour initiation but 
tumour progression.  Compound Apc mouse models have shown that Myc plays an 
important part in the early Apc-driven tumour initiation step; inducible loss of both 
Apc and Myc demonstrated how the loss of Myc abolishes the crypt development 
associated with Apc deficiency (Sansom et al., 2007).  Furthermore, ApcMin/+ mice 
have been used to show how Apc can be inactivated by epigenetic silencing via 
promoter methylation of RAS association domain family 1 (RASSF1A) and its 
subsequent loss mediates degradation of β-catenin and leads to increased and 
accelerated intestinal tumourigenesis (Weyden and Adams, 2007).   
In summary, the ApcMin/+ model has identified phenotypic aspects specific to the 
strain background, FAP related genotype-phenotype and the involvement of the Wnt 
signalling pathway.  It is reasoned that the ApcMin/+ mouse model, on different 
genetic backgrounds and using controlled environmental exposures, is a very useful 
tool to isolate modifiers that modulate the number of adenomas appearing in the 
mouse intestine.  QTL analysis using linkage based on the ApcMin/+ mouse crossed 
with a mouse with discordant genetic and traits features is a well-established 
protocol for quantitative trait genetics leading to the identification of equivalent 
genetic elements in humans.   
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1.6 QTL AND LINKAGE ANALYSIS 
1.6.1 Historical introduction  
The Laws of inheritance (Laws of segregation and independent assortment) were 
published by Gregor Mendel (1866) and remained largely ignored until 1900 when 
the mode of inheritance of traits with strong allelic effects was studied by Carl 
Correns, Hugo de Vries and Eric von Tschermak-Seysenegg.  Francis Galton and Karl 
Pearson developed statistical foundations to quantify heritability including 
correlation, regression, standard deviation, principle component analysis and 
partitioning of genetic variance into additive and non-additive components (Galton 
1869; Galton 1889; Pearson 1990).   
The discovery of gene mapping is credited to Bateson and colleagues for their work 
on the sweet pea (1905) (Bateson et al., 1906), which led Alfred Sturtevant to 
construct the first genetic map covering six loci in Drosophila (Sturtevant 1913).  
East in 1910 (East 1910) proposed the concept of quantitative traits and, 
subsequently, QTL mapping, was envisaged by Sax (Sax 1923) after Sir Ronald 
Fisher (1918) who described the combinational action of multiple genes.  Penrose 
(1935) described the expected frequency allele sharing of affected sib pairs (ASPs).  
Haldane and Smith converted the occurrence of recombination events or 
recombination fraction (rf) into physical distance and by estimating the rf between 
markers and QTLs which led to the idea behind QTL mapping.  Newton Morton 
tested linkage analysis in humans in 1955 using the logarithm of the odds (LOD) 
score method (Morton 1955).  By 1961 Thoday had conceptualised the idea of 
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quantitative traits as a complex ‘polygenic’ model.  Following the discovery of 
molecular markers, the very first genome map was created in maize and tomato 
using restriction fragment length polymorphism (RFLP) (Helentjaris et al., 1986) 
and the idea has since been used in families to trace quantitative inheritance of 
complex traits.  Risch and Merikangas (1996) demonstrated that complex traits 
involving several predisposing variants of small effects are difficult to unravel with 
linkage (Risch and Merikangas, 1996) and so recent research has to turned to 
investigate the common disease/common variant (CDCV) hypothesis summarised 
by Peto and Houlston (Peto and Houlston, 2001) and Pharoah et al (Pharoah et al., 
2002).  They state that the disease phenotype results from the aggregate effects of 
modifiers and low penetrance that individually confer a small risk, but in 
combination act additively or multiplicatively.  It is believed that if such alleles occur 
at high frequency within a population and are involved in multiple biological 
pathways this may explain some of the ‘unknown’ genetic risk for heritable cancers.   
1.6.2 Linkage and association studies 
The study of complex traits can be mapped in healthy and affected human 
populations, or using animal models with linkage or association studies.  While 
linkage studies seek to identify loci that co-segregate with the trait within families, 
association studies seek to identify a causal variant which is associated with the 
phenotype are usually conducted at the population level.  The two are not mutually 
exclusive but complimentary to one another and both have been used in human 
studies.  Work on familial aggregation and patterns of inheritance date back to 
Mendels first hybridisation of peas experiments and these have dominated linkage 
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studies.  The human genome project and the availability of genetic markers have 
since enabled widespread mapping and association studies based on populations 
leading to the discovery of susceptibility variants. 
1.6.3 Linkage using human sib pairs 
Sib pair linkage studies have been a widely used technique to map modifier genes 
and qualitative traits in pedigreed populations (Rogus and Krolewski 1996; Fulker 
et al., 1996; Kruglyak and Lander 1995).  These studies are based on sharing and the 
probability of identify by descent (IBD) between siblings that express similar 
quantitative trait values as a phenotype.  The power to detect linkage depends on 
the deviation of allele penetrance of loci contributing to the genetic trait and the 
deviation from sharing IBD from its null expectation and also discordant sib pairs 
(DSPs).  The prospects further depend on the number of loci and whether loci act 
multiplicatively or additively.  The selection and size of family sampling is important, 
larger families present higher costs and higher possibility of siblings contributing 
different information.  This is further implicated by considerations of late disease 
onset, large number of phenocopies, gene-environmental interactions and locus 
heterogeneity.  Though sibships and smaller families which are easier to identify and 
recruit are often preferred, it is estimated that 500-1000 families are required to 
produce adequate power to detect genetic risk factors that are consistent with 
population and familial prevalence of CRC (Kerber et al., 2008).  As CRC is associated 
with environmental factors, higher sample sizes are required which represent a 
major recruitment challenge and in turn accrue higher costs, taking many years 
before any conclusions can be drawn.   
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1.6.4 Transmission disequilibrium test - family based quantitative trait loci 
mapping 
Family based designs to study association are based on trios (two parents and one 
affected child) and hypothesis testing that genetic association is present between 
marker and disease (HA) against the null hypothesis (H0) that states no association 
between marker and disease exist (Rubenstein 1981).  Later Ott (1989) added a 
second alternative hypothesis that both linkage and association must exist, followed 
by the third null hypothesis by Spielman et al when they introduced transmission 
disequilibrium test (TDT) method (Ott, 1989; Spielman et al., 1993).  They tested for 
linkage in a setting of known association and therefore (HO: association but no 
linkage).  There has been much success with the analysis based on TDT and this has 
been extended in context of quantitative mapping in extended pedigree, nuclear 
families and mapping studies.  This has also formed the basis for haplotype 
association mapping (Spielman and Ewens, 1998).  The test assumptions are based 
on the parental genotypes being accurate and correct and therefore incorrect 
genotyping can lead to false inferences (Hirschhorn and Daly, 2005).  The other 
hampering feature includes the lack and reliability of statistical methods to detect 
and test multiple covariates, genes and interactions under a family-based design.   
1.6.5 Genome wide studies based on Association  
Modern complex trait mapping in humans utilises LD based on genome wide 
association (GWA) studies involving the correlation of several hundred thousand 
markers spaced throughout the genome with trait variation in the population based 
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samples.  The scalability is much greater than with genome wide QTL scans.  Risch 
and Merikangas were the first to note that small genetic effects could be detected 
with greater power by association analysis and proposed GWAs (Risch and 
Merikangas, 1996).  Since the Human HapMap and the development of high-
resolution LD maps and single nucleotide polymorphism (SNP) chips, GWA studies 
have so far detected 21 CRC risk associated loci (Table 1-6), individually these are 
estimated to contribute to less than 1% of the CRC but may have up to 6% collective 
CRC risk (Tomlinson et al., 2007; Tomlinson et al., 2008; Tenesa et al., 2008; Dunlop 
et al., 2012).  Most CRC risk variants map to regions of the genome that do not 
contain known genes or reside in intronic, intergenic regions, however, a small 
proportion have been mapped at or close to genetic components which are involved 
in TGFβ signalling pathway and bone morphogentic protein pathway; SMAD7, 
GREM1, BMP2, RHPN2 and LAMA5.  These findings suggest variants could be in 
strong LD, involved in complex epistasis and or additive effects with neighbouring 
and distant genes and risk mechanisms.  One promising approach is to delineate 
gene and protein expressions as quantifiable traits and use these in QTL mapping 
strategies such as expression QTL (eQTL) analysis.  Such studies have provided an 
abundance of genome wide patterns at a transcriptional level and several studies 
have shown an overlap between trait associated and eQTL variants suggesting 
possible interactions between near (cis) and distant genes (trans) via eQTL (Loo et 
al., 2012; Nica et al., 2010).   
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Table 1-6 The colorectal cancer susceptibility risk variants detected by genome 
wide association studies to date.  bp=position, MAF= minor allele frequency 
extracted from 1000 Genomes and variants mapped to NCBI dbSNP Build 134.  
Ancestral allele in bold 
Locus SNP / position (bp) 
Candidate 
/closest gene 
Major / 
minor 
allele 
MAF Reference 
1q41 rs6691170 22045446 Intergenic G/T 0.25 (T) 
Houlston et 
al., 2010 
3q26.2 rs10936599 169492101 MYNN C/T 0.30 (T) 
6p21 rs1321311 36622900 CDKNA C/A 0.27 (A) 
8q23.3 rs16892766 117699864 EIF3H (intron) A/C 0.08 (A) 
Tomlinson et 
al., 2008 
8q24.21 
rs6983267 128413305 Intergenic G/T 0.43 (T) 
Tomlinson et 
al., 2007 
rs10505477 128407443 intergenic A/G 0.46 (G) 
rs7014346 128424792 POU5F1B G/A 0.32 (A) 
9q24.1 rs719725 6365683 Intergenic A/C 0.31 (C) 
Le Marchand 
et al., 2007 
10p14 rs10795668 8701219 Intergenic G/A 0.26 (A) 
Tomlinson et 
al., 2008 
11q23.1 rs3802842 111171709 ORF 93 C/A 0.31 (C) 
Tenesa et al., 
2008 
11q13.4 rs3824999 74345550 POLD3 T/G 0.38 (G) 
Dunlop et al., 
2012 
12q13.13 
rs7136702 50880216 Intergenic T/C 0.49 (C) 
Houlston et 
al., 2010 
rs11169552 51155663 Intergenic/ATF1 C/T 0.21 (T) 
14q22.2 rs4444235 54410919 BMP4 (intron) T/C 0.45 (C) 
Houlston et 
al., 2008 
15q13.3 rs4779584 32994756 GREM1 C/T 0.48 (T) 
Tenesa et al., 
2008 
16q22.1 rs9929218 68820946 CDH1 (intron) G/A 0.24 (A) 
Houlston et 
al., 2008 
18q21.1 rs4939827 46453463 SMAD7 (intron) C/T  0.38 (T) 
Tenesa et al., 
2008 
19q13.1 rs10411210 33532300 RHPN2 (intron) C/T 0.22 (T) 
Houlston et 
al., 2008 
20p12.3 rs961253 6404281 Intergenic C/A 0.29 (A) 
Houlston et 
al., 2008 
20q13.33 rs4925386 60921044 LAMA5 (intron) C/T 0.42 (T) 
Houlston et 
al., 2010 
Xp22.2 rs5934683 9751474 SHROOM T/C 0.37 (C) 
Dunlop et al., 
2012 
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More often than not, GWA studies depend on extensive collaborative efforts and 
require large sample sets to overcome the low statistical power of associations, but 
the greatest challenge presented by GWA studies is to elucidate the influence these 
risk variants have on the chances of developing CRC.  Other problems include 
refining the estimates of heritability and the mode of inheritance.  Another key 
question asked is how best to identify networks of genes that act together to 
influence cancer susceptibility, which may provide more information to 
understanding the remaining trait variance and in particular the rare small-effect 
size variants (Dunlop et al., 2012; Houlston et al., 2010).  The most notable reason 
for these drawbacks is the inconsistent phenotype penetrance due to varied 
environmental factors and confounding susceptibility alleles that exist in human 
populations.  In addition, it is not possible to analyse susceptibility alleles as 
quantitative traits in human studies even if they are of sizeable effects.  Experiments 
in mice have shown the additive, epistatic interactions affect tumour susceptibility 
(Demant et al., 2003) and using such models in a QTL genome wide scan may in part 
reduce some of the major complexities presented by human GWAS.   
1.6.6 Linkage using quantitative trait loci mapping in mice 
QTL mapping in experimental crosses involves comparing means of progeny 
inheriting specific parental alleles and is the main focus of the work carried out here.  
This is a much simpler and more powerful approach and is supported by many 
statistical methods (Kruglyak and Lander 1995).  The main principle goal of QTL 
genetics in mice is to perform statistical analysis of the association between the 
phenotype and genotype to identify genomic regions that may harbour candidate 
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gene(s) and then using the close homology between mouse and human genomes to 
subsequently search for human homologs (Bedell et al., 1997; Balmain 2002) further 
mention of comparative analysis between mouse and humans in mentioned under 
section 1.6.10 of this thesis.  QTL mapping using inbred mice for CRC relies on the 
genetic analysis between a highly susceptible strain, which carries a Mendelian 
mutation and is crossed to a resistant strain that confers phenotypic differences.  
These are either spontaneously, chemically or irradiation induced to enhance 
genetic predisposition and recombination events allow the segregation of 
susceptible and resistant alleles affecting different phenotypic outcome (Dragani et 
al., 1995, Balmain 2002).  The high degree of polymorphism at microsatellite loci 
among inbred laboratory strains allows for the construction of genetic linkage maps.  
Genetic mapping is determined by the recombination events which occur between 
sister chromatids during meiosis and the linkage is based on the frequency between 
two markers with which they recombine.  The closer they are to each other, the less 
likelihood of chromosomal crossover will occur between them and genes far apart 
are unlinked, and assort independently.  The rf is the probability for recombination 
to occur ranging from 0 for completely linked to 0.5 for unlinked loci and is used to 
calculate the genetic distances.  The backcross used in this study expects rf to be 
<0.5.  By using markers that co-segregate with the phenotype can be an indication 
that the allele responsible for the phenotype is located close to the marker.  Mice are 
phenotyped for the tumour number, location, size, and genotyped at each marker 
loci and the correlation between the distribution of marker alleles and susceptibility 
phenotypes allows the detection of chromosomal locations which may confer 
susceptible loci.   
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1.6.7 Quantitative trait loci mapping approaches  
The basic laws of QTL mapping were formulated by Soller in 1979 (Soller et al., 
1979) and Lander and Botstein strengthened these in 1989 (Lander and Botstein, 
1989) and are referred to as parametric analysis.  The main mathematical rule that 
underlies QTL mapping is that the power to detect a QTL is proportional to the size 
of its effect, which is the difference between the alleles that are present in the cross 
and expressed as a portion of the total variance.   
Techniques include single marker mapping, interval mapping (IM), composite 
interval mapping (CIM) and multiple QTL mapping (MQM).  Single marker 
regression is the simplest method for the analysis of QTL mapping data by 
considering each marker individually, splitting the individuals into groups, 
according to their genotypes at the marker and comparing the groups’ phenotypes 
averages using analysis of variance (ANOVA) or t test.  Evidence for a QTL is 
measured by LOD score: the log10 likelihood ratio comparing the hypothesis that 
there is a QTL at the marker to the hypothesis that there is no QTL anywhere in the 
genome; the null hypothesis.  This process offers statistical simplicity, but fails to 
provide separate estimates of the QTL location and QTL effects between markers.  
The QTL location is confounded and based on the marker which indicates the 
highest difference between genotype averages and the QTL effect will be less than 
the true QTL effect.  The most important disadvantage of single marker is the limited 
ability to separate linked QTL and to assess possible interactions among QTL.  
However, in the absence of missing marker information, single marker regression is 
robust and highly suitable approach. 
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1.6.8 Interval, composite and multiple QTL mapping 
In IM, the recombination model is based on Hidden Markov model (HMM) and forms 
the core methodology for probabilistically connecting unobserved genotype to 
observed genotype.  Interval mapping is similar to single marker regression, instead 
the target locus is replaced by a position (hypothetical QTL Q) in a target interval 
where the expected QTL genotypes are calculated using the flanking markers.  IM 
fixes (Q) between marker intervals, calculating the rf at incremental steps and thus 
generating a genetic map (Lander and Botstein, 1989).  This method allows for the 
inference of QTLs between markers and provides better estimates of the QTL effects 
addressing the issues set out by single QTL mapping.  Furthermore, IM accounts for 
missing data at markers by considering data from the nearest flanking markers for 
which genotype is available, making it more robust to genotyping errors than simple 
marker mapping and has become the most commonly used mapping technique.  The 
probability that each individual has the genotype AA or AB at Q is calculated based 
on four conditional probabilities central to the rf between the left flanking marker 
(L) and Q and Q and the right flanking marker (R) Table 1-7.   
The expression to calculate the genotype probabilities of Q depends on genetic 
mapping function; Kosambi, which is the same as human inference, and assumes 
intermediate interference: where the chance of one or more break points in an 
interval depends on the occurrence of break points in another interval (Kosambi 
1944).  Carter-Falconer mapping function is the closest to that of a mouse, which 
shows extreme crossover inference with crossovers seldom being separated by 
<20cM.  Other mapping functions include Haldane (assumes no inference, therefore 
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allows for multiple crossovers) and Morgan (assumes complete interference and no 
multiple crossovers.   
Table 1-7 Inference of QTL genotype probabilities given the marker genotypes at 
two flanking markers: left (1) and right (2) and markers separated by recombination 
fraction (rf) for individuals in a backcross. 
Marker 
genotype 
QTL genotype 
Left Right AA AB 
AA AA (1-r1Q)(1-r2Q)/(1-r12) 
probability of no recombination in 
both L-Q and Q-R in a non-
recombinant interval 
r1Qr2Q/(1-r12) 
probability of recombination in both L-
Q and Q-R in a non-recombinant 
interval 
AA AB (1-r1Q)r2Q/r12 
probability of recombination 
between Q-R only in a recombinant 
interval 
r1Q(1-r2Q)/r12 
probability of recombination in L-Q 
only in a recombinant interval 
AB AA r1Q(1-r2Q)/r12 
probability of recombination in L-Q 
only in a recombinant interval 
(1-r1Q)r2Q/r12 
probability of recombination 
between Q-R only in a recombinant 
interval 
AB AB r1Qr2Q/(1-r12) 
probability of recombination in both L-
Q and Q-R in a non-recombinant 
interval 
(1-r1Q)(1-r2Q)/(1-r12) 
probability of no recombination in 
both L-Q and Q-R in a non-
recombinant interval 
Once the genotype probabilities are determined, individuals are split into genetically 
identical genotype groups contributing to the phenotype (two for a backcross and 
three for intercross).  The residual variance (σ2) for each group will be entirely non 
genetic and due to measurement error, environmental variation and individual 
noise.  Three simplifying assumptions are made; first, the residual variance is 
constant (homoscedastic) within each group: second it follows a normal curve 
distribution with different phenotype averages: and third, QTL act additively and the 
effect of QTL remains regardless of the genotype at the other loci.  Deviation from 
additivity implies epistasis: in a statistical sense epistasis is measured in individuals 
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of a backcross, split into four groups according to their joint genotypes at two QTL 
and when the genotype at one QTL depends on the genotype of another QTL, the 
QTLs are said to interact.   
The phenotype average and the phenotypic variance are estimated by a maximum 
likelihood function (calculates the observed/expected ratio) using the expectation 
and maximisation (EM) iterative algorithm.  The E-step calculates the conditional 
probability that the individual is in QTL genotype groups given its marker data, 
phenotype and current estimates of residual variance and phenotype averages.  In 
the M-step, the estimates are repeated using weights until they converge (and 
estimates stop changing).  Once the maximum likelihood scores are calculated the 
LOD under the null hypothesis that there is no QTL anywhere in the genome is 
compared.  Though IM is more powerful than single marker approaches, there is one 
major disadvantage with IM that it still only considers a single QTL interval and the 
possibility that the LOD profile can indicate multiple QTLs or ghosts QTLs.  The one 
dimensionality of IM does not allow interactions between multiple QTLs to be 
considered.   
Statistical approaches for locating multiple QTLs are presented with the ultimate 
challenge to search every position in the genome simultaneously for linked and or 
interacting epistatic QTLs.  The statistical implementation of a simultaneous search 
is quite difficult due the large number of possible QTLs involved that can be involved 
along with the heavy computational demand.  CIM introduced by Zhao-Bang Zeng in 
(1994) and multiple QTL mapping by Ritsert Jensen (1993) extend the idea of IM to 
include a subset of marker loci as covariates outside a defined window, with the 
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purpose to remove any association of linked QTLs and reduce the residual variance 
effects.  The selection of markers to serve as covariates is the key problem and the 
markers closest to the QTL are the obvious choice.  This approach is however 
restricted to a one dimensional searching and the multiplicity of epistatic QTL 
effects remains a challenge.  Though, CIM procedures generally increase the 
resolution of IM by accounting for linked QTLs or false QTLs while reducing the 
residual variation.  The ideas underlying CIM have influenced the development for 
MQM.  MQM has three advantages: by controlling for QTLs of large effect, the 
residual variance may be reduced and so the better to identify QTLs of modest 
effect; the separation of linked QTL is achieved by comparing the fit of two-QTL 
model to the best single-QTL model in an exhaustive 2-dimensional search;, and 
finally epistasis can be considered via models that take multiple QTLs in to account 
simultaneously.  Epistasis is considered by exploring ‘models’ using both a forward 
and backward elimination search. T he former starts with no QTLs in the model, 
then adds each QTLs beginning with a QTL with the highest LOD score.  Additional 
QTLs are then selected on to give the greatest increase in LOD score. The reverse of 
the forward selection is backward elimination, which starts with all QTLs in the 
model, and then removes each QTL one at a time so as to give the smallest decrease 
in the LOD score.  These processes involve testing at each step for improvements to 
an additive only and an additive-interactive QTL model to allow the identification 
and assessment of a subset of loci.  This permits consideration of multiple acting 
QTLs that may control trait phenotype (Baum et al., 1970). 
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1.6.9 Statistical significance 
Non-parametric bootstrapping resampling (Efron and Tibshirani 1993) and 
permutation resampling methods (Good 2005) are useful means to randomise the 
trait data for the purpose of evaluating the test statistic under a null hypothesis that 
tests for a true QTL.  False-positives in QTL mapping indicate linkage merely as a 
result of chance within the genome and are generally high if the size of the study and 
data are large.  Permutation testing is the random assignment of trait values to no 
more than one individual compared to bootstrapping method which differs by more 
than one individual might receive the same random trait value, changing the mean 
variances and trait summary information.  Both techniques are computationally 
demanding and require resampling in excess of 1,000 times to generate precise 
correction factors (Churchill and Deorge 1994; Sen and Churchill 2001) and set 
stringent significance thresholds to avoid false positives.  Nominal significance 
criteria of 99.8% or more for any single QTL are usually necessary to assure a 
genome-wide threshold significance at 5% genome error.   
When a QTL is defined, the genomic regions that are identified are usually in range 
of 10-30 Mbp.  Identifying the genes underlying QTLs is the biggest hurdle and a 
challenging task (Nadeau and Frankel, 2000; Korstanje and Paigen, 2002; Flint et al., 
2005).  One of the common ways to increase precision toward QTL gene 
identification is to breed congenic mice.  In this approach, breeding transfers the 
susceptibility allele at a particular locus from one strain on to the genetic 
background of the other.  This process is time taxing, involves extensive breeding 
that significantly increases cost.  Though congenic mice offer a more enhanced 
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mapping approach it is, however, not as successful as expected due to the reduction 
in genetic heterogeneity and segregating alleles often missing QTLs.   
1.6.10 Comparative genetics.   
Another approach to narrow the QTL region is to apply comparative genetics.  Since 
the Mouse Genome Sequencing Consortium first published a high-quality draft 
sequence of the genome of C57BL/6J mouse in 2001 and researchers of the 
International Human Genome Project (HGP) subsequently sequenced the entire 
mouse genome (Waterston et al. 2002).  Comparison of general features between 
the human and mouse genome showed that there are striking similarities; the 
estimated size (bp) of the human genome is calculated at 3 billion bps (over 46 
chromosomes) and the mouse at 2.9 billion bps over 40 chromosomes with 
approximately the same number of genes (~30,000) and this provides an entry 
point into comparative genetics.  Further to this, about 40% of the human and 
mouse genomes can be directly aligned with each other with 80% of human genes 
having equivalent orthologues in the mouse genome (Reymond et al., 2000; Gitton et 
al., 2002, Lander et al., 2001) (Figure 1-9).  With this information to hand and the 
application of the vast comprehensive genomic data, comparisons of discrete 
segments and aligning homologous DNA from different species to discover 
biologically relevant genes is made possible.   
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Figure 1-9 Conserved segments between the human and mouse chromosomes. A 
minimum of two genes whose order is conserved in the mouse genome are shown as 
block colours for e.g. human chromosome 20 corresponds entirely to a portion of 
mouse chromosome.  (Image from International Human Genome Sequencing 
Consortium; Lander et al. 2001) 
The integration of QTL analysis and genomics is crucial in order to identify 
underlying DNA sequences, which are involved in controlling trait phenotype.  A 
single QTL can consist of more than a hundred genes and so meta-analysis combines 
data from different sources to assist in QTL candidate gene discovery (Goffinet and 
Gerber, 2000).  QTL mapping studies carry wide applications to construct gene 
pathways in the elucidation of underlying causal genes; the application of functional 
genomics and classical bioinformatics will lend a hand in the biological 
interpretation of the quantitative genetic models in our work.   
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1.6.11 Tumour quantitative trait loci identified in mice 
The use of mouse models and computational genetics in QTL has so far successfully 
been used to map resistant and susceptibility QTLs for tumours arising in many 
tissues such as the lung (Slucs), colon (Css), intestinal (Mom1, Ssic1) and skin (Skts) 
(Demant,  2003; Dragani, 2003, Ruivenkamp et al., 2002, Fijneman et al., 1996).  
Tumour susceptibility QTLs; Pctrl and Mom1 loci were among the first of tumour 
susceptibility and resistance phenotypes identified by genome scans using RFLP and 
simple sequence length polymorphism (SSLP) markers, respectively.  Ptprj is a 
candidate gene for CRC susceptibilty to colon cancer 1 (Scc1) in the mouse where 
50% of human cancers also show LOH of this gene (Ruivenkamp et al., 2002).  More 
recently, Lei Quan and colleagues have shown common linked QTLs which exist in 
both lung and CRC and suggest that underlying genes could be identical or related 
(Quan et al., 2011).  Galvan and colleagues support these findings with the loci 
Lsktm1 which is presumed to modulate both lung and skin tumourigenesis.  These 
data suggest that by comparing organ specific susceptibility genes greater 
knowledge of tumour susceptibly mechanisms can be determined (Galvan et al., 
2012).   
1.6.12 Radiosensitive QTLs identified in mice 
Mouse QTL mapping approaches have been applied to dissect the genetic basis of 
radiosensitivity and tissue injury.  Two radiation-induced pulmonary fibrosis 
(Radpf1 and Radpf2) QTLs have been detected to reveal regions of irradiation 
induced lung responses: pneumonitis, alveolitis and fibrosis to chromosome 17 and 
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chromosome 1 respectively (Haston et al., 2002).  Currently, no other radiation 
induced QTLs have been mapped in mice, and strain dependent contribution 
towards radiation induced intestinal damage has been investigated in only a few 
studies.  
So it can be seen that QTL methodology is a powerful tool to identify genomic 
regions that are associated with traits.  While the majority of the QTLs are large 
genomic regions, these studies continue to develop and enhance the understanding 
of complex traits, quantitative variation and also the complex interactions.  Newer 
methodologies and software are being written to tackle issues such as QTLs and 
epistasis.  Most importantly, the use of comparative genomics and bioinformatic 
techniques facilitated by databases has made it possible to narrow the search for 
candidate genes and QTL candidate genes.  The combination of QTLs and 
bioinformatics should accelerate candidate gene identifications.  After which 
comparisons can be investigated between mouse and human genomes due to the 
degree of homology, co-localisation and synteny of genes that exist on the same 
chromosome (Dermitzakis et al., 2002; Burgess-Herbert et al., 2008; DiPetrillo et al., 
2005) and tested in human based studies and or functional studies for confirmation 
(DeBry and Seldin, 1996). 
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1.7 APPROACH TO THE STUDY 
Predisposed genetic susceptibility and exposure to environmental factors contribute 
significantly to an individual and population’s risk of CRC development (Lichtenstein 
et al., 2000).  One key example involves the exposure of radiation which affects the 
cellular processes of DNA repair and chromosomal instability.  Both are an intrinsic 
feature of cancer.  Primary radiation responses show variation in humans (BEIR V 
1990) and this scenario is repeated in mice populations (Followill et al., 1993).  As 
radiation toxicity to the gastrointestinal system is a major side effect, observed in 
6,000 individuals undergoing pelvic radiation therapy (Andreyev 2007).  This 
suggests that the increased susceptibility may result from radiation-induced DNA 
damage and that deficiencies in DNA repairing may be responsible for the 
pronounced radiosensitivity.   
It is well established that the heterogeneity of APC mutations lead to varying degrees 
of adenoma multiplicity and disease severity of CRC.  Furthermore, inter-individual 
variation in polyp numbers is observed in human FAPs demonstrating APC modifier 
genes with different gradients of penetrance and effects thought to be involved in 
complex genotype-phenotype correlation.  As previously mentioned the ApcMin/+ 
mice mimics the human condition FAP and the germline mutation at nucleotide 
2549, codon 850 leads to the onset of Min, a condition of numerous adenomas 
throughout the intestines, though mainly in the small intestine.   
Our earlier studies, which compared the effects of irradiation on a population 
derived between ApcMin/+ on C57BL/6J (B6Min/+) and radiosensitive BALB/c strain, 
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showed two segments of chromosome 16 (D16Mit189 and Prkdc) to modify 
adenoma multiplicity within the small intestine (Degg et al., 2003).  The 
recombinant inbred line (Line I) on a B6Min/+ background was chosen as the resistant 
line out of 6 with limited intra line variation in adenoma numbers (Haines et al., 
2000; Haines et al., 2005).  Polyp multiplicity was investigated in N2 ApcMin/+ mice 
using a BC strategy involving B6Min/+; donor parent of the dominant Apc transgene 
carrying the mutation at codon 850 to be transferred onto the BALB/c background.  
This mutation will generate the underlying trait of interest and produce variations 
in polyp multiplicity for the detection of possible modifiers involved in intestinal 
adenomas. 
1.7.1 Breeding program and induction of polyps 
Female BALB/c mice were obtained from Harlan United Kingdom Ltd. (Bicester, 
United Kingdom) and crossed with C57BL/6J (B6Min/+) males from a recombinant 
inbred colony derived from a separate cross (Haines et al., 2005).  Briefly, a single 
B6Min/+ male mouse (Imperial Cancer Research Fund, Clare Hall, South Mimms, U.K.) 
bred with two female C57BL/6J mice (Radiation and Genome Stability Unit, Medical 
Research Council, Harwell, U.K.).  Subsequent intercrossing gave rise to six distinct 
polyp scoring recombinant lines showing interline variability in polyp numbers.  The 
lowest polyp scoring line (Line I) was selected from the six recombinant ApcMin/+ 
lines.  N1 males carrying the ApcMin/+ mutation were then BC to female BALB/c to 
produce N2 ApcMin/+ offspring.  The recombinant Line I carried the susceptible alleles 
of Mom1 (Mom1S) .  Studies and confers a resistance to polyp multiplicity and was 
selected as the resistant strain.  Studies involving crosses between the ApcMin/+ mice 
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and other inbred mice showed fewer numbers of polyps were scored when crossed 
with BALB/c (Moser et al., 1990) and suggests that BALB/c carried the dominant 
tumour resistance alleles of Mom1 (Mom1R).  To eliminate the modifier effect of 
Mom1S we used the principle of BC to ensure that only Mom1R derived from BALB/c 
in the filial (F1) would be selected.  These were crossed with the recurrent BALB/c 
parent ensuring that each N2 ApcMin/+ was positive for at least one copy of the 
BALB/c derived modifier of Min (Mom1) dominant resistance allele (Mom1R).  
Therefore, any effects of genetic modification will be independent of Mom1S.  
BALB/c is also susceptible to IR-induced tumours (Degg et al., 2003) and carries two 
natural polymorphisms of Prkdc involved in DNA double strand break (DSB) repair 
(Mori et al., 2001; Yu et al., 2001).  In this setting, our BC scheme favoured the 
transfer the ApcMin/+ mutation onto the BALB/c background and thus the isolation of 
chromosomal region(s) susceptible to irradiation and, because of the nature of the 
cross, the N2 ApcMin/+ will consist of a random set of genes with 75% alleles from 
BALB/c (maternal parent) and 25% from B6Min/+ (parent) allowing the investigation 
of BALB/c alleles in linkage with the Apc gene.  
Irradiation was used to detect susceptibility loci, which co-segregate with BALB/c 
alleles that are possibly involved in DNA damage or repair following irradiation.  The 
BALB/c mouse is model of sensitivity to radiation-induced damage as it is more 
susceptible to tumour development.  The BALB/c carries two natural functional 
polymorphisms in the DNA repair gene of Prkdc, one of which shows a decrease in 
the DNA-protein kinase activity (Smith et al., 1999; Bailey et al., 1999; Yu et al., 
2001; Degg et al., 2003) and leads to defective DNA repair of DSBs.  The partial 
defects in Prkdc are also considered to be involved in the susceptibility to mammary 
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tumours and lymphatic neoplasia induced by irradiation in the BALB/c strain 
(Roderick, 1963).  More importantly, there is sufficient evidence provided by Degg 
and colleagues that two segments of chromosome 16 (D16Mit189 and Prkdc) from 
BALB/c mouse interact with ApcMin/+ by specifically enhancing IR-induced adenoma 
development in the upper part of the small intestine (Degg et al., 2003), This 
observation forms the basis of our investigations.   
143 N2 ApcMin/+ mice at 2 days of age were split into two groups: 84 males and 58 
females and received 2Gys of irradiation; and 111 N2 ApcMin/+ mice (60 males and 51 
females) were sham irradiated (0Gy) as the control group (Degg et al., 2003).   
1.7.2 Intestinal polyposis  
Immediately after sacrifice the small and large intestine was removed and opened 
longitudinally.  The intestinal digesta was washed from the mucosal surface with ice 
cold phosphate buffered saline (PBS), PH 7.0 and the small intestine tracts of all N2 
ApcMin/+ mice were separated into the following three sections; small intestine (SI) 
which was divided into two equal portions with the upper small intestine (USI) 
segment containing all of the duodenum and jejunum and the lower small intestine 
(LSI) segment containing the proximal and distal ileum.  The third section was the 
ascending and descending part of the large intestine (LI).  Surface intestinal polyps 
were counted using a light microscope and 0.5% methylene blue in 70% ethanol 
stain in sections of the irradiated and sham irradiated mice and recorded against 
their age and sex.  Other data recorded included whether the mice suffered from 
rectal prolapse, mammary tumours and had rectal bleeding.  No polyps were 
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identified in the oesophagus or stomach and are generally a rare occurrence in the 
ApcMin/+ mouse.   
 By using tissue collected from 253 N2 mice and the phenotyped data (number of 
polyps) collected by Jackie Haines, we aim to further the work carried out by Degg et 
al and carry out a genome wide scan by increasing the number of genotyped data to 
uncover irradiation-induced QTLs through genetic mapping to identify modifiers 
involved in spontaneous and irradiation-induced polyp multiplicity.  By applying 
this approach we aim to expand the possibility of identifying other modifiers 
involved in addition to the ones investigated by Degg et al on chromosome 16 and to 
establish to what extent these genes are involved.  Furthermore, by looking at the 
different parts of the gut, we will investigate for the first time whether radiation 
sensitivities are the same along the intestine and if they share common loci.   
The identification APC modifier genes and discovery of their roles in the causation of 
radiation induced carcinogenesis will ultimately be important for the development 
of methods for prediction of risk and radiotherapy for human cancers, based on 
their genotype.  This also provides a rationale for the design and development of 
approaches for the treatment of radiation-induced late normal tissue injury and may 
reduce uncertainties for radiosensitive exposed groups.  Therefore, the 
identification and characterisation of such modifier genes or susceptibility loci 
associated with IR-induced DNA damage repair pathways continues to be important.   
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1.7.3 Hypothesis  
The hypothesis is that QTLs exist in the mouse genome in addition to those on 
chromosome 16 that control radiation induced adenoma multiplicity in the intestine 
of ApcMin/+ 
To test the hypothesis I aim to carry out a genome wide QTL scan based on the 
correlation of genotype-phenotype data using the ApcMin/+ mouse model to identify 
modifiers which may interact directly or indirectly with the Apc mutation.  For this 
investigation new microsatellite markers were selected and genotyped to create a 
genome wide panel across the N2 mice.  With the use of newly emerging 
bioinformatics and statistical techniques I plan to reduce the usage of animals in 
research and provide a methodical approach to identify underlying genetic 
determinants of spontaneous and radiogenic elements associated with polyp burden 
and CRC.   
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1.7.4 Aims  
Thus, the key objectives of this thesis are to 
Investigate QTL regions which control interactions of the main effects QTLs 
- To confirm QTLs detected by Degg et al  (Chapter 2, section 2.3.4) 
- Identify new QTLs responsible for spontaneous and irradiation-induced 
polyposis (Chapter 2, section 2.3.4 and 2.3.6) 
- To construct a gene model of quantitative traits in the different segments of 
the intestine (Chapter 2, section 2.3.5) 
- To construct multiple gene model of quantitative traits involving main-effect 
QTL (Chapter 2, section 2.3.7) 
- Haplotype analysis around detected QTLs (Chapter 2, section 2.3.9) 
 
Investigate epistatic interactions of the main effects QTLs 
- 2D, two QTL pair wise scan on all traits (Chapter 3, sections 3.3.1-3.3.5) 
- To investigate cis-epistasis between QTL pairs (Chapter 3, section 3.3.3) 
- To create QTL-objects and investigate the effects of QTL pairs (Chapter 3, 
sections 3.3.6 – 3.3.8) 
- Explore multiple mapping models using forward and backward selection 
model (Chapter 3, section 3.3.9)  
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To identify candidate genes that are implicated in CRC mechanisms using genomic 
data and integrative bioinformatics tools; 
- In silico sequence modelling based on BALB/c specific SNPs and 
predictive SNP analysis (Chapter 4, section 4.3.1) 
- Assess the profile of all SNPs within genomic regions (Chapter 4, section 
4.3.2) 
To test and validate underlying genes to further select target genes using 
- Sequencing all target genes and nsSNPs (Chapter 5, section 5.3.1) 
- mRNA expression of targets in wild type parental mice (Chapter 5, section 
5.3.2) 
- Literature based evidence summary of candidate genes (Chapter 5, 
sections 5.4.1 & 5.4.2) 
- Discuss possible mechanisms of cancer risks (Chapter 6) 
  
 113 
2. CHAPTER 2 GENETIC MAPPING OF QUANTITATIVE 
TRAIT LOCI FOR MOM RADIATION-INDUCED POLYP 
SUSCEPTIBILITY OF THE MOUSE INTESTINE 
2.1 INTRODUCTION 
This chapter describes the work carried out to identify additional and novel 
candidate regions in a genome wide approach using tissue from the pre-existing 
intraspecific BC; [BALB/cByJ x C57BL/6J ApcMin/+] x BALB/cByJ) to extract DNA, 
perform genotyping and analysis using microsatellite markers to achieve genome 
wide coverage.  In further analysis of the the backcross using interval mapping (IM) 
and permutation testing I will search for genomic regions that affect polyp 
multiplicity in irradiated mice to define modifiers as Mom (Modifier of Min), 
radiation-induced polyp susceptibility (Mrip) loci and also include the dissection of 
loci based on the different segments of the mouse intestine using a panel of N2 
ApcMin/+ mice.  Similarly I will search for spontaneous modifiers of Apc using the 
sham irradiated which will also be used to compare against any Mrip loci identified. 
The identified QTL regions are highly likely to contain genes of susceptibility to 
polyp multiplicity in the ApcMin/+ mouse.  Within these regions candidate genes may 
be selected  
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2.2 MATERIALS AND METHODS 
2.2.1 Genotyping the N2 ApcMin/+ population  
Microsatellite markers are a subset of simple sequence (di-, tri-, or tetra-nucleotide) 
repeats found in non-coding regions such as introns and intergenic sequences that 
tend to exist at high frequency within the genome (Hamada et al. 1982).  A complete 
set of microsatellite markers (n=112) (Table 2-1) were selected on the basis of a 
12bp predicted allele size difference between the founder strains of mice as 
indicated in the Whitehead Institute at MIT Center for Genome Research (WICGR), 
(Genetic and Physical Maps of the Mouse, Database Release 1999); 
http://www.broad.mit.edu /cgibin/mouse/sts_info).  The database was searchable 
using the genetic distances determined by the MIT F2 intercross by Dietrich 
(Dietrich et al., 1996) and used with data from the Centre for Inherited Disease 
Research (CIDR) http://www.cidr.jhmi.edu/mouse and http://www.informatics. 
jax.org, for the physical (Mbp) and genetic position (cM)  of each marker. 
Initially 60 markers were selected for genotyping using the Cancer Research UK 
genotyping facility in Oxford.  The genetic data of these markers was analysed using 
Genescan Software v3.0 (Applied Biosystems) and set up in a relational database 
using FileMaker Pro version 8.5.  A scan was performed The preliminary genome 
wide scan based on marker regression and IM using Map Manager QTX (Manly et al 
2001) revealed broad QTLs covering large genomic regions.  An additional 52 
markers were then selected and genotyped in house and added to the original 
database of 60 markers to increase marker density between 15-20cM intervals.   
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Table 2-1 Microsatellite markers used for genotyping N2 ApcMin/+ BC progeny.  
Marker positions are based on The Jackson Laboratory's online Mouse Genome 
Informatics resource (http://www.informatics.jax.org).  Location for syntenic markers 
were taken from CONTIG data* (MGI database, 1999); CONTIG13 (D3Mit51), CONTIG17 
(D7Mit362), CONTIG8 (D16Mit5), CONTIG11 (D19Mit6) or published QTL papers¥; 
D6Mit198 (Griff et al., 1995); D12Mit17 (Pataer et al., 1997); D18Mit208 (Drayton et al., 
2006)  
Locus 
Position 
(cM) 
Locus 
Position 
(cM) 
Locus 
Positio
n (cM) 
Locus 
MGI 
Position 
(cM) 
D1Mit430 4.3 D5Mit168  76.2 D9Mit336 35.4 D14Mit127 18.7 
D1Mit169 9.9 D5Mit409 85.2 D9Mit335 32.0 D14Mit174 19.4 
D1Mit132 39.5 D6Mit1  6.7 D9Mit347 55.1 D14Mit60 24.6 
D1Mit495 55.8 D6Mit83 5.7 D9Mit201 69.4 D14Mit102  34.4 
D1Mit17 95.0 D6Mit123 27.8 D9Mit151 72.4 D14Mit107  66.1 
D1Mit292 96.3 D6Mit284 41.1 D10Mit189 7.7 D15Mit100  19.3 
D2Mit327 40.9 D6Mit287 52.1 D10Mit106  11.7 D15Mit70 38.0 
D2Mit395 60.0 D6Mit194  62.9 D10Mit194  24.5 D15Mit159 42.0 
D2Mit411 80.0 D6Mit15  77.7 D10Mit31 35.3 D16Mit182 2.6 
D2Mit229  89.0 D6Mit198¥ 67.0 D10Mit42  39.7 Prkdc 10.1 
D2Mit148  100.5 D7Mit178  2.0 D10Mit95 47.1 D16Mit4 25.4 
D2Mit230  103.0 D7Mit117  17.3 D10Mit233  61.6 D16Mit5* 32.8 
D3Mit178 14.3 D7Mit228 25.6 D10Mit103 73.6 D16Mit189 46.8 
D3Mit51* 25.5 D7Mit276 34.4 D11Mit216 19.2 D16Mit106 57.7 
D3Mit320 66.8 D7Mit323 54.5 D11Mit339 39.5 D17Mit143 4.9 
D3Mit352 75.0 D7Mit101  69.0 D11Mit177  40.4 D17Mit51 19.7 
D4Mit227 4.4 D7Mit362*  67.8 D11Mit179  54.6 D17Mit180 26.7 
D4Mit18 6.0 D8Mit155 2.1 D12Mit182 5.5 D17Mit20 29.7 
D4Mit193 14.0 D8Mit124 7.6 D12Mit91 30.1 D17Mit142  49.7 
D4Mit348 39.4 D8Mit289 16.5 D12Mit143 36.4 D18Mit222 8.1 
D4Mit308 57.7 D8Mit292 21.2 D12Mit17¥ 55.0 D18Mit208¥ 38.0 
D4Mit256 86.2 D8Mit45 42.2 D13Mit115  7.3 D18Mit49 51.3 
D5Mit387 14.4 D8Mit211 52.0 D13Mit179  21.7 D18Mit4  57.3 
D5Mit352 18.4 D8Mit213 57.5 D13Mit142  32.5 D19Mit28 10.8 
D5Mit201 39.6 D8Mit49 72.4 D13Mit107  50.2 D19Mit106  20.2 
D5Mit157  48.5 D9Mit250 2.5 D13Mit260 63.7 D19Mit90 36.0 
D5Mit188  57.5 D9Mit90 17.8 D13Mit78 67.2 D19Mit103 48.5 
D5Mit139 64.2 D9Mit285 21.4 D14Mit126 11.9 D19Mit6* 57.9 
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2.2.2 DNA preparation  
For the additional 52 markers, genomic DNA was extracted from ear snips using a 
QIAamp® DNA Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s 
protocols.  Approximately 12mg was cut into small pieces and underwent protein 
degradation by incubation overnight in Buffer ATL (180 μl) and Proteinase K (20 μl) 
at 56ºC. This was then spiked with a further 20μl of Proteinase K and incubated 
overnight at 56ºC.  
Cells were lysed in Buffer AL (200 μl) by incubation for 10 minutes at 70ºC. 100% 
ethanol (200 μl) was then added to each sample and after mixing by pulse vortexing, 
samples were added to a spin column, with a silica-gel membrane, in a 2 ml micro 
centrifuge tube. The column, sample and tube were then centrifuged at 8,000 rpm 
for 1 minute to facilitate the adsorption of DNA onto the membrane. The filtrate was 
discarded and 500 μl of wash buffer (AW1) was added to the column, prior to 
centrifugation at 8,000 rpm for 1 minute. Again, the filtrate was discarded, and 
washing was repeated with 500 μl of wash buffer (AW2) with centrifugation at 
13,000 rpm for 3 minutes. The spin column was then placed in a new 1.5 ml 
eppendorf tubes and 200 μl of elution buffer was added to the column and left to 
incubate for 10 minutes at room temperature. After centrifugation at 8,000 rpm for 
1 minute, the eluate containing purified DNA was collected and stored below -20ºC 
for future use.  
The concentration and purity of the double stranded (ds) DNA samples were 
performed on a NanoDrop™ ND-1000 spectrophotometer (NanoDrop Technologies, 
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Wilmington, USA).  The optical density (OD) readings at wavelength (λ) 260nm to 
measure DNA concentration and λ 280nm for protein concentration was used as a 
means to assess the purity of the sample.  A ODλ260 / ODλ280 ratio of 1.8 to 2.0 was 
considered adequately pure for subsequent PCR reaction.  Qiagen company protocol 
yielded high quality DNA ranging from 25-200ng/µl.   
2.2.3 Oligonucleotides and PCR amplification. 
For the additional 52 markers, primers were selected from the database release 
1999 (as mentioned above) and purchased from Sigma Genosys UK.  The lyophilized 
primers were diluted to their supplied optical density readings to a stock 
concentration of 100 µM and stored at 20 ºC.  Working dilutions were then made to 
a concentration of 10 µM.  PCR amplification were carried out in a Perkin-Elmer 
9600 thermal cycler and was performed with 1 μl genomic DNA in a total volume of 
25 μl using the PCR solutions shown in Table 2-2.   
Table 2-2 Polymerase chain reaction reagents for preparation of 25µl reaction using 
0.1µl Taq DNA Polymerase for genotyping N2 ApcMin/+ mouse DNA. 
Stock Solution 
Volume per 
25µl reaction 
(µl) 
Final concentration per 
reaction 
10x Buffer Containing [15mM] MgCl2 2.5 1X 
Forward Primer [10 µM] 1.25 1 µM 
Reverse Primer [10 µM] 1.25 1 µM 
dNTP (each dNTP [10mM]) 2 200 µM of each dNTP 
DNA template (25-200ng/µl) 1 1-20ng 
Q solution 5 1X 
Sterile PCR H20 12 - 
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The melting temperature (TM) for each primer varies and was calculated at 2ºC 
below suppliers TM which considers factors such as total number of nucleotides in 
the oligo; (GCs and TAs) and the presence of ~50mM monovalent cations (Mg+) per 
PCR reaction.  These calculations determine the optimal annealing temperature for 
the PCR procedure and determine the conditions of cycling.  We used PCR annealing 
temperatures in the range of 55-65ºC, but typically the primers annealed at 60 ºC.  A 
PCR program where sample mix is denatured for 15 minutes at 95ºC, followed by 37 
cycles (95ºC for 10 seconds, annealing at 55-65ºC for 45 seconds and elongation at 
72ºC for 45 seconds) and final elongation at 72ºC for 10 minutes.   
2.2.4 Agarose gel electrophoresis 
The DNA fragments were resolved by 2% denaturing agarose gel electrophoresis.  
Agarose (UltraPURE Gibco BRL) was added to 0.5X TBE buffer (44mM Tris, 45mM 
boric acid, 1mM EDTA) PH8 and melted in a microwave medium power for 16 
minutes and ethidium bromide was added to make a final concentration of 0.5µg/ml 
to allow visualisation under ultraviolet light.  DNA molecular weight markers –100 
kilobase pair DNA ladder (SigmaAldrich, UK) was loaded in the first row of the gel.  
DNA samples were loaded with 6X gel loading dye, blue (0.015% bromophenol blue, 
11mM EDTA, 2.5% Ficoll 400) obtained from New England BIO labs.  
Electrophoresis was carried out at 120 volts for 1- 1.5 hours and viewed under UV 
transilluminator (Bio Rad Gel Doc™ XR+ System) and images were captured using 
Bio Rad Image Lab™ Software as shown in Figure 2-1.   
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Figure 2-1 Representative gel electrophoresis (2%). image of D7Mit178 
microsatellite marker.  Lane 1=1-100 bp DNA ladder, Lanes 2-17=N2 (Apc Min/+) mice 
genotyping and verification of D7Mit178 polymorphism between B6Min/+ (165 bp) 
and BALB/c (201 bp allele). A=homozygote, H=heterozygote alleles 
2.2.5 Linkage analysis 
Map Manager QTX analysis (Manly et al., 2001) was used to perform IM.  The 
genotype data were abbreviated to either ‘A’ or ‘H’ which references the 
homozygous and heterozygous genotypes respectively.  Missing data was encoded 
using ‘0’ which Map Manager QTX either excluded from interval mapping and 
permutation testing unless it can be estimated as an expected genotype effect using 
the flanking markers.  Map Manager QTX places the markers in order, defines the 
intervals and calculated the segregation pattern of alleles based on the genotype 
code.  Physical and genetic maps were generated and the crossover events were 
calculated using one of the four conditional probabilities to determine the rf as 
intended by the Kosambi’s mapping function (Kosambi 1944).   
Three quantitative traits (adenoma frequency in the USI, LSI and LI) were simulated 
for each of the 19 autosomes in the mouse genome.  The likeliest position of a QTL 
on a chromosome and the association with a given trait were determined by the 
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‘peak’ statistic value described as the likelihood ratio statistic (LRS).  LRS is a 
measure of the ratio between likelihoods under the null and test hypotheses and can 
be converted to Logarithm of Odds (LOD) by dividing by 4.61 (twice the natural 
logarithm of 10).  The linkage search criterion was set to p < 0.05, as a cut off value 
to assess the initial marker to trait association and a constrained additive-effects 
model was used to validate the additive effect of alleles at a QTL using one degree of 
freedom.   
For significance the observed LRS was tested against the null hypothesis: that there 
are no QTLs and the ones observed in this study did not occur by chance in the 
genome using permutation testing for each interval.  Empirical p-values for the 
highest LRS were calculated under the null hypothesis and ranked for significance 
based on threshold values.  Permutation tests were performed to determine three 
thresholds for QTL detection (Churchill and Doerge, 1994) of 1%, 5%, and 63%.  
QTLs with LOD scores above the 1% threshold were highly significant, while those 
above 5% and 63% were significant and suggestive, respectively (Lander and 
Kruglyak, 1995).  We identified QTLs at a 5% genome wide error rate for each 
individual trait (USI, LSI, and LI).  IM analysis was also performed using R-qtl 
Version 1.25-15 (Broman et al., 2003) for corroboration and further analysis of 
results.   
Linkage maps were generated using Map Manager QTX.  Failure of markers during 
regression can occur if the population shows extreme segregation distortion or non-
recombinant markers which are redundant and not separated by recombination 
events and the genotype data is the same for the marker pair and therefore 
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uninformative.  Redundant markers were observed on chromosome (Chr) 3 
between D3Mit320 and D3Mit352 and were hidden or removed from IM analysis 
and did not appear to have any significant impact on QTL mapping with Map 
Manager.   
The MQM approach was explored initially to investigate linked QTLs and was 
conducted using R-qtl.  This model used the QTL with large effects as either an 
additive or interactive covariate to enhance the identification of multiple QTLs, to 
increase precision of QTL positions and their effects, and to identify any interaction 
patterns between linked QTLs (epistasis).  A more in-depth analysis of MQM to 
construct multiple QTLs and epistasis will be discussed in the next chapter.    
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2.3 RESULTS  
2.3.1 Data visualisation  
Positioning of the 112 genome-wide microsatellite markers constructed a genetic 
map using Map Manager QTX and confirmed using R-qtl.  The average interval space 
between the markers was calculated at 17 cM based on Kosambi’s distances for 
linkage analysis (Figure 2-2).   
 
Figure 2-2 Genetic map, constructed using Rqtl makers.  This involved the following 
markers in genome wide mapping; chromosome (Chr) 1, D1Mit430, 169, 132, 495, 
17 and 292; Chr2, D2Mit327, 395, 411, 229, 148, and 230; Chr3, D3Mit178, 51, 320 
and 352; Chr 4, D4Mit227, 18, 193, 348, 308 and 256; Chr5, D5Mit387, 352, 201, 
157, 188, 139, 168 and 409; Chr6, D6Mit1, 83, 123, 284, 287, 194, 15 and 198; Chr7, 
D7Mit178, 117, 228, 276, 323, 101 and 362; Chr8, D8Mit155, 124, 289, 292, 45, 211, 
213 and 49; Chr9, D9Mit250, 90, 285, 336, 355, 347, 201 and 151; Chr10, 
D10Mit189, 106, 194, 31, 42, 95, 233 and 103; Chr11, D11Mit216, 339, 177 and 179; 
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Chr 12, D12Mit182, 91, 143 and 17; Chr13, D13Mit115, 179, 142, 107, 260 and 78; 
Chr13, D13Mit; Chr14, D14Mit126, 127, 174, 60, 102 and 107; Chr15, D15Mit100, 70 
and 159; Chr16, D16Mit182, Prkdc, 4, 5, 189 and 106; Chr17, D17Mit143, 51, 180, 20 
and 142; Chr18, D18Mit222, 208, 49 and 4; Chr19, D19Mit28, 106, 90, 103 and 6.   
The percentage of individuals genotyped were 89.1% and 88.1% for 0Gy and 2Gy, 
respectively and the composition was 50.1% (A) and 49.9% (H) for 0Gy, 49.3% (A) 
and 50.9% (H) for the 2Gy indicating an overall good coverage of the observed 
marker data across the N2 ApcMin/+ panel (Figure 2-3).  The proportion of missing 
values appeared to be low and was randomly distributed in the population except in 
the cases of Chr 3, 7, 9, 15 and 18.  We inspected the areas of missing genotypes for 
Chr 3 (10.5%), 7 (21.6%), 9 (14.7%), 15 (10.4%) and 18 (34.8%) of the 2Gy dataset 
using plot.geno function of R-qtl to indicate any likely errors (data not shown).  No 
apparent genotyping errors were noted from the observed data.  It was therefore 
postulated that the effects of this missing information will not affect QTL analysis.  
Overall investigations of 0Gy and 2Gy genotyping errors were conducted using the 
‘errorlod’ function of R-qtl as described by Lincoln and Lander (1992).   
A LOD score was calculated for each individual mouse at each marker; large error 
LOD scores indicated higher possibility of genotyping errors with error LOD score < 
4, which can be ignored.  The cutoff was set to the recommended p= 0.01 and no 
errors (LOD score set >4) were observed in both datasets.  The Prkdc status for each 
N2 ApcMin/+ was noted as homozygote (B/B) (Prkdc BALB/c/BALB/c) or heterozygote 
(B6Min/+ /B) (Prkdc B6Min/+ /BALB/c) and the expected 50:50 ratio was observed in both 
the 0 and 2Gy groups (Degg et al., 2003). 
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Figure 2-3 Missing genotype for irradiated (0Gy) and sham-irradiated (2Gy) data.  
Missing values are shown in black 
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2.3.2 Irradiated N2 ApcMin/+ mice have increased intestinal polyp multiplicity.   
The sham irradiated control group (0Gy) were used to identify regions linked to 
spontaneous modifiers and to compare these regions and polyp multiplicity with the 
radiation (2Gy) group.  Animals were assessed for adenoma multiplicity in USI, LSI 
and LI at time of sacrifice (all mice >80 days; mean: 0Gy, 241 days; 2Gy, 180 days).  
The 2Gy-irradiated animals had a 1.8 fold higher polyp incidence in the USI 
compared with the unirradiated mice 0Gy thus illustrating that radiation causes an 
increase in polyp burden (Degg et al., 2003).  Furthermore, the distribution pattern 
of our phenotype data showed properties that adenoma multiplicity in our dataset is 
a quantitatively inherited trait and controlled by QTLs (Figure 2-4).  In N2 ApcMin/+ 
mice, the (USI) (duodenum and jejunum) was more sensitive than the LSI (ileum) to 
radiation-induced adenoma formation indicating that there may be modifiers that 
influence tumour multiplicity.   
2.3.3 Linkage analysis identified quantitative trait loci  
Linkage analysis was conducted by Map Manager QTX to calculate empirical p-
values for the highest ‘peak’ LRS value using permutation scans.  The individual trait 
(USI, LSI, and LI) threshold values were defined using Kosambi’s mapping function 
using informative progeny.  Individual permutation tests were performed for each 
chromosome showing evidence of linkage from marker regression; a ‘suggestive’ 
threshold value was defined if the observed LRS value appears 20, if the value 
appears 200 then this was considered ‘significant and ‘highly significant if 500.   
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Figure 2-4 Phenotypic frequency of adenomas to demonstrate irradiation influence 
on polyp multiplicity.  Adenoma number shown for the duodenum and jejunum; 
USI=upper small intestine, proximal and distal ileum; LSI=lower small intestine and 
LI=large intestine for irradiated (2Gy) and sham-irradiated (0Gy). 
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The overall genome wide threshold value of 2.5 LOD was calculated from over 18 
separate permutation tests (p < 0.05) and was set to attain significant association of 
QTLs (shown in Figure 2-5).   
We identified several main-effect QTLs, which contributed to polyp multiplicity in 
the irradiated sample group and found only suggestive QTLs in the sham irradiated 
group.  No apparent over lapping genomic positions were detected between the 0Gy 
and 2Gy thus, implying at this stage of our analysis that radiation-induced loci are 
important and specific to the effects of irradiation using this model.   
2.3.4 Modifier loci map to chromosome 2, 5 and 16 
In the irradiated cohort of mice, markers on chromosome 2, 5 and 16 segregated 
with high polyp multiplicity and a total of 5 QTLs; one significant and four highly 
significant QTLs were detected on these chromosomes.  These loci were designated 
Mrip (Mom radiation-induced susceptibility); Mrip1-5 and were distinctly associated 
with the USI (Table 2-3).  Susceptibility loci on chromosome 16, designated Mrip 4 
and 5 were identified previously and reported by Degg et al (Degg et al., 2003), and 
re-analysed for the completeness of the genome scan undertaken here.  Two highly 
significant Mrip loci (Mrip2, 3) were detected on chromosome 5, in the intervals 
between D5Mit201-D5Mit157 at position 22cM of the genetic map constructed by 
QTX, (p < 0.00001, 95% confidence interval (CI) of 13.5cM) and D5Mit188-
D5Mit139, (p < 0.00001, 95% CI of 10cM) at position 49cM of the genetic map.  A 
significant Mrip locus was located on chromosome 2 and designated Mrip1, at 
marker D2mit395 QTX derived genetic map position of 48cM, (p < 0.0003, CI 
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21.5cM) and one suggestive locus on chromosome 17 (p<0.008, CI 39M).  Suggestive 
QTLs were not assigned as Mrip, however these were included in further analysis.  
These QTLS contributed an overall 68% phenotypic variation observed in polyp 
multiplicity in the 2Gy cohort and confirm the trend towards worsened polyposis in 
the duodenum probably involving differential expression of genes.  Results are 
summarised in Table 2-3 and Figure 2-5. 
Table 2-3 Quantitative trait loci detected by interval mapping for 2Gy irradiated 
mice.  LRS=likelihood ratio statistic, empirical p values calculated for each trait-
genotype data, %=percentage variance, CI=confidence intervals (95%) and the 
association level attained from interval mapping.  USI=upper small intestine, 
LSI=lower small intestine, LI=large intestine, HiSign=highly significant, 
Sign=significant, Sugg=suggestive based on LRS thresholds assigned using separate 
permutation tests. cM calculated by QTX genetic map 
Trait Chr Locus or Interval (cM) p-value (LRS) % 
95% 
CI 
Sign 
(threshold) 
USI 
Chr2 Mrip1 D2Mit395 (48) 3.2x10-4 (12.9) 9 ±21.5 Sign (≥ 12) 
Chr5 Mrip2 D5Mit201-157 (22) <0.00001 (24) 15 ±13.5 HiSign (≥ 20.2) 
Chr5 Mrip3 D5Mit188-139 (49.0) <0.00001 (28.6) 19 ±10 HiSign (≥ 20.2) 
Chr16 Mrip4 Prkdc (10) 4x10-5 (19) 11 ±16.5 Sign (≥ 12.6) 
Chr16 Mrip5 D16Mit189 (29) <0.00001 (22.2) 14 ±13.5 Sign (≥ 12.6) 
Chr17 D17Mit180 (18) 8.2x10-3 (7) 5 ±39 Sug (≥ 6.76) 
LSI 
Chr1 D1Mit495-17 (85) 4.4x10-3 (8.6) 6 ±33.5 Sug (≤ 12) 
Chr6 D6Mit194 (56) 2.6x10-3  (8.8) 6 ±30 Sug (≤ 12.8) 
Chr7 D7Mit178-117 (8) 7x10-3 (12.2) 6 ±38 Sug (≤ 12.5) 
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Figure 2-5 Genome scan shows significant quantitative trait loci for adenoma 
multiplicity identified in the upper small intestine of 2Gy irradiated mice.  Strong 
effect QTLs were found on chromosomes 2, 5 and 16 and determined by 
MapManager QTX.  The horizontal line above the y axis represents a 2.5 LOD 
significant threshold score (p=0.05).   
  
Chr8 D8Mit211-213 (62) 0.007 (9.5) 7 ±38 Sug (≤ 12.7) 
LI 
Chr1 D1Mit292 (95) 6x10-3 (8.4) 6 ±32.5 Sug (≤ 13.1) 
Chr2 Mrip1 D2Mit395 (48) 1.2x10-3 (12.7) 8 ±24 Sign (≥ 11.6) 
Chr7 D7Mit228-276 (29) 1.2 x10-3 (9.9) 7 ±35 Sug (≤ 13.1) 
Chr8 D8Mit124-289 (12) 2.7x10-3 (13.6) 6 ±30.5 Sign (≥13.2) 
Chr14 D14Mit126 (0) 3.8x10-3 (8.4) 6 ±33 Sug (≤ 12.6) 
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The USI results were investigated for corroboration with R-qtl for chromosomes 1, 
2, 3, 5, 16, 17, and 18 (Figure 2-6).  No major differences were observed between the 
two software packages except in chromosome 3: as already mentioned in the case of 
chromosome 3 (D3Mit320 and D3Mit352) markers failed regression and where 
removed from analysis.  Single marker regression was possible with Rqtl.     
 
Figure 2-6 Comparison of Interval mapping single marker regression for the QTLs 
detected for adenoma multiplicity in the upper small intestine of 2Gy irradiated 
mice.  Interval mapping was performed using Expectation-Maximisation (EM) 
(black) algorithm and single QTL analysis using Haley-Knott (red).  Minor 
differences were noted concerning Mrip1 and 3 with slightly higher LOD scores with 
single QTL analysis.   
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Four suggestive QTLs were detected in the LSI on Chr: 1 at an interval  marked by 
D1Mit495-D1Mit17 (85cM) with peak LRS of 8.6 (p=0.0044; CI, 33.5); Chr 6, at 56cM 
at D6Mit194 locus with peak LRS of 8.8 (p=0.0026; CI, 30cM); Chr 7 at 8cM within 
D7Mit178 – D7Mit117 interval with peak LRS 12.2, (p=0.007, CI, 38cM); and Chr 8, 
D8Mit211-D8Mit213, peak LRS of 9.5 (p=0.007; CI, 38cM) (Table 2-3).   
2.3.5 Common modifier loci mapped to chromosome 2 in USI and LI 
 
Figure 2-7 Genome scan shows significant quantitative trait loci for adenoma 
multiplicity identified in the large intestine of 2Gy irradiated mice.  Main-effect QTLs 
detected on chromosome 2 and 8, suggestive QTLs on Chr 1, 7 and 14. The 
horizontal line above the y axis represents a 2.45 LOD significant threshold score 
(p=0.05).   
For the LI trait in this cohort, significant QTLs associated with the LI were detected 
on chromosome: 2, D2Mit395 (p=0.0012; CI, 24 cM) and 8, D8Mit124 (p=0.0043, CI, 
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30cM) (Table 2-3 and Figure 2-7).  Suggestive QTLs emerged on Chr: 1, D1Mit292 
(p=0.006; CI, 32.5cM); 7, D7Mit276 (p=0.0012; CI, 35); and 14, D14Mit126 
(p=0.0067; CI, 33cM).  Mrip1 appears to be a common loci involved in the USI and LI 
as shown in Figure 2-8 
 
Figure 2-8 Six significant quantitative trait loci detected in upper small intestine 
and large intestine of 2Gy irradiated mice.  Strong effect QTLs associated with upper 
small intestine adenoma multiplicity on chromosomes (Chr) 2, 5 and 16; with Chr 2 
common to USI and LI.   
IM analysis was repeated for the irradiated cohort of mice using Cartographer QTL 
(Basten et al. 2004; Basten et al., 1994) to confirm QTLs from Map Manager QTX.  
Permutation tests (1,000 tests at 2cM window) with all markers for each of the four 
traits for 2Gy dataset provided similar LRS threshold values as QTX. The only 
exception was D2Mit395, which showed borderline significance when analysed 
using Map Manager, but with Cartographer the marker fell just below the 
significance threshold (LOD of 2.7; significance  a LOD score of 2.8).  The 
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computations for 2Gy were also analysed using R-qtl to compare Haley–Knott (HK) 
regression (1992), expectation–maximization (EM) algorithm (Lander and Botstein 
1989) and multiple imputation (Sen and Churchill 2001).  Similar LOD profiles were 
obtained as Map Manager QTX, however the large effect QTLs Mrip2 and Mrip3 
(Chr5) appeared to be sharper peaks with overall higher LOD scores (data not 
shown).  The borderline suggestive QTL detected by QTX on chromosome 7 of the 
LSI between markers D7Mit178–D7Mit117 was defined as significant (p=0.03) at 
D7Mit117 (17.3cM) by R-qtl (LOD score of 2.84 and p=0.05 threshold 2.63).   
2.3.6 Suggestive loci mapped in the 0Gy mice data 
The 0Gy dataset yielded only suggestive QTLs on Chr 3 and 13 for the USI; on 
chromosome 6 for the LSI; and chromosome 1 for the LI as shown in Table 2-4 and 
Figure 2-9).   
Table 2-4 Quantitative trait loci detected by interval mapping for 0Gy, sham-
irradiated mice Data presented shows the trait and loci marker position.  
LRS=likelihood ratio statistic, empirical p values were calculated for each trait-
genotype data, %=percentage variance, CI=confidence intervals (95%) and the 
association level attained from interval mapping.   
Trait Chr Locus(cM) P value (LRS) % 
95% 
CI 
Sign 
(threshold) 
USI 
Chr 3  D3Mit352 (100) 3.5x10-3 (8) 8 ±32.5 Sug (12.2) 
Chr 13  D13Mit179-142 (25) 3.7x10-3 (9.2) 8 ±33 Sug (≤12.2) 
LSI Chr 6  D6Mit83 (6) 7.8x10-3 (7.1) 7 ±39 Sug (≤12.3) 
LI Chr 1 D1Mit495-117 (72) 0.04 (7.5) 4 ±56.5 Sug (12.1) 
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For the USI, no definite overlap of main-effect QTLs were detected (Figure 2-9).  
Chromosome one revealed a suggestive QTL at 72cM associated with LI of the 0Gy. 
Similarly, 2Gy mice also showed suggestive association at 95cM (D1Mit292) for LI 
and at 85cM between D1Mit395-D1Mit17 interval for LSI and could suggest possible 
overlapping loci are involved.  
 
Figure 2-9 Genome wide scan comparison of 0Gy and 2Gy for the upper small 
intestine trait.  Suggestive novel QTLs were detected on chromosomes 3 and 13 in 
the 0Gy mice (shown in blue) with no overlapping QTLs in the 2Gy mice data.  
2.3.7 Genome scan while controlling for the effects of Mrip3 
The presence of a large-effect QTL (Mrip3) was seen on chr5 (D5Mit139) of the USI, 
the genome scan was repeated while controlling for this locus to see if loci with low-
moderate effects can be made more apparent.  The results are plotted together in 
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Figure 2-10  against the original genome scan.  By controlling for Mrip3 a decrease in 
the LOD values was detected for Chr4, Mrip2 and 3 (Chr5), Mrip4 and 5 (Chr16) and 
increase was observed in chromosome 1 and 7 which were observed in the LI and 
substantive suggesting additional common loci between USI and LI.   
 
Figure 2-10 LOD curve changes when Mrip3 was used as an additive covariate (red) 
from the standard genome scan based on multiple imputation method (black).  The 
majority of the chromosomes and Mrip1 were unchanged 
2.3.8 Calculation of physical and genetic maps 
Physical and genetic maps are determined as the number of base pairs (bp) which 
separate two adjacent loci and the amount of recombination occurring between 
them (cM), respectively.  The reliability of genetic maps depends on the number of 
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crossovers observed in meiosis, transmission of alleles, the physical distance 
between loci and the statistical methodology applied.  The use of genetic maps has 
increased advances in the development of identifying susceptibility genes which 
influence a trait.  It is therefore important that the differences between the physical 
and genetic maps are reconciled which can otherwise present challenges in accuracy 
and relating the physical and genetic distances when searching for underlying genes.  
As the exchange of genetic information during meiosis to form recombinant 
chromosomes is the principle component, therefore the rf is then in part a function 
of the physical distance between two loci.  We calculated the recombination ratio 
(Mb/cM) of the physical and genetic distances for each Mrip1-5 interval to compare 
with the average recombination rate for each chromosome.   
Mrip1 candidate interval flanked by D2Mit327 – D2Mit395 with 50Mbp interval and 
47.6cM (D3Mit327 starts at 0cM) from our genetic mapping and N2 ApcMin/+ cross 
data has an average rate of 1.05Mb.  Compared to the rate of chromosome 2, which 
at 118Mb and 103.9cM (Mouse Genome Database) has an average of 1.14Mb/cM, 
with similar averages it is likely that this interval represents a candidate region 
representative of chromosome 2.   
Using the same principle, the average chromosome 5 rate is calculated at 
1.6Mbp/cM.  The recombination rate of Mrip2 and 3 intervals are calculated as 
3.0Mpb/cM and 0.65Mbp/cM, respectively and their average is 1.85Mbp/cM.   
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The average chromosome rate is calculated at 1.69Mpb/cM for chromosome 16 and 
the recombination rates for Mrip4 compares at 1.67Mbp/cM and Mrip5 at 
2.19Mbp/cM, like Mrip1 these are likely to represent candidate regions.   
2.3.9 Haplotype analysis at Mrip2 and Mrip3  
Haplotype analysis at Mrip2 and Mrip3 inherited in the N2 ApcMin/+ irradiated mice 
was investigated and shown by the haplotype diagram in Figure 2-11.  There remain 
17 and 14 BC mice exhibiting recombination between Mrip2 and Mrip3, respectively.  
This indicates that the BC still holds the potential to narrow these candidate regions 
further by mapping more polymorphic markers located within the flanking markers.   
 
Figure 2-11 Haplotype analysis of recombinant mice at Mrip2 and Mrip3 intervals of 
chromosome 5 using the 8 markers listed.  Numbers indicate the number of 
individuals with that particular genotype (heterozygote in black, homozygote in 
pink and missing data in green).   
At the time we screened potential markers using WICGR database which would lie 
between marker intervals for Mrip2 and Mrip3.  Three out of four markers located 
within the critical regions were not selected because the polymorphism between B6 
and BALB/c alleles did not meet our criteria of exceeding 12bp allelic difference 
between our strains.  D5Mit139 was selected and genotyped in 242 mice, interval 
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mapping of the initial candidate region was reduced from 33.3cM to 21.6cM, the 
flanking markers positioned according to MGI at 118.3Mbp and 137.5Mbp saw a 
reduction in the interval from 19.2Mbp to 7.6Mbp.  The paucity of markers in this 
region and the potential remaining in the BC led this study to explore bioinformatics 
tools and analysis on existing available data to serve as alternative methods for 
candidate gene identification.   
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2.4 DISCUSSION 
We were able to identify five independent Mrip loci (p < 0.05) (Mrip1-5) that 
influenced adenoma multiplicity in the USI irradiated ApcMin/+ recombinant mice 
(Table 2-3).  Mrip1 revealed a marginally significant QTL with co-dominant allele 
effect.  ApcMin/+ mice, which are both homozygote and heterozygote for the Mrip1 
locus are involved in polyp multiplicity.  Mrip 2-5 were detected as highly significant 
QTLs with recessive allele effects, where the homozygote ApcMin/+ mice showed a 
stronger influence on polyp numbers.  These loci account for approximately 68% of 
the observed phenotypic variance indicating that they play a major role in 
irradiation induced susceptibility to intestinal adenoma development in ApcMin/+ 
mice.  A further two significant QTLs were detected in LI trait of the 2Gy which are 
considered to be of importance as FAP is characterised by polyps in the large 
intestine.   
Interestingly, no QTLs in the 0Gy sham irradiated mice were detected which 
overlapped with any of the Mrip regions from the 2Gy following a QTL scan, 
presumably due to the contribution of irradiation induced affects on Mom1R in 
B6Min/+ and BALB/c.   
Additionally, it is unclear why the interval recombination rate average is so varied 
for Mrip2 and Mrip3 compared to the average recombination rate for chromosome 5.  
One possible explanation is that this could be due to segregation distortion (SD) of 
certain alleles.  It appears that the chromosomes bearing the underlying genes of 
Mrip2 and Mrip3 could be over-represented in offspring or involved in meiotic drive, 
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in favour of one parental allele over the other, which is supported by the fact that 
Mrip2 and 3 favour the homozygote ApcMin/+ mice allele (BALB/c).  These markers 
were initially tested as segregation distortion loci (SDL) by removing them from QTL 
scan and assessing the recombination fractions and observing the QTL detection.  No 
major differences were noted other than a reduction in the power to detect Mrip2 
and Mrip3 which rules these markers out as SDL.  It should be borne in mind that the 
theory of QTL mapping with SD and how these affect QTL detection especially where 
linked loci are involved is unclear with a statistical model yet to be designed.  In 
summary, these results indicate that there are strong genetic component of Mrip2 
which are inherited by the N2 ApcMin/+ offspring from the BALB/c parent.   
2.4.1 Previous Moms 
Some of the previously reported Mom loci (Mom1, 2, 3 and 7) on Chr 18 and 4 were 
detected and confirmed in our study in both the 0Gy and 2Gy samples.  However 
these were detected with very weak effects; low LOD scores ranging from 1.14, 
(p=0.165) to 0.33 (p=0.83) and therefore not attaining significance levels.  Our data 
would suggest that these loci have no, or a very weak influence, on adenoma 
multiplicity that would require substantially more mice to investigate.  Mom6 was 
the exception and not detected in either dataset.  The genetic effects are unclear and 
this finding may not be surprising given the genetic makeup of our BC: N2 ApcMin/+ 
offspring carry at least one copy of the BALB/c-derived modifier of Apcmin/+ (Mom1) 
dominant resistant allele.  Mom2 on chromosome 18 is a spontaneous mutation that 
is not carried by the mice used here.  Mom3, the recessive allele conferring 
susceptibility to severe spontaneous disease is not carried by the ApcMin/+ mice used 
 141 
here.  Mom6 appears to be carried by AKR and is difficult to distinguish from Mom1; 
there are a number of alleles of Mom7 segregating among mouse strains and it is 
unclear how the BALB/c allele would influence adenoma number in our crosses.   
The ability to detect weak QTLs is a function of sample size and the detection of very 
weak influences would require substantially more mice to investigate, the fact that 
other than the three suggestive spontaneous QTLs none map to chromosome 18 
suggest that Mom2, 3 and 7 are not involved in determining adenoma multiplicity in 
this genetic background.  This highlights the fact that substantially larger numbers of 
mice would be needed to distinguish modifiers with very small effects in addition to 
those we have identified.  The number of animals required precludes us undertaking 
such an investigation and increasing markers would not, in the context of our 
experiment, increase the power of detecting spontaneous QTLs.  It however, remains 
to be seen whether the effects of the Mom2, 3 and 7 on chromosome 18 are made 
more distinguished or visible using interactive and additive covariates with MQM 
mapping using R-qtl. 
2.4.2 Multiple QTLs 
Several studies have reported two or more QTLs on the same chromosome (Spelman 
and Bovenhuis, 1998; Heyen et al., 1999, Velmala et al. 1999) using a two QTL model 
designed as an extension of marker regression analysis.  The selection of 
appropriate markers is critical for MQM models in order to analyse two or more 
QTLs on the same chromosome.  In addition the use of genetic markers near a large 
effect QTL as a covariate helps to reduce residual variance and clarify QTLs.  
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Establishing further evidence for linked QTLs or interacting QTLs will be 
investigated in the next chapter within the context of multiple QTL models where we 
plan to use an automated scan procedure to control for large effects QTLs and select 
suitable markers as covariates.   
The present study has investigated susceptibility of BALB/c mice carrying the 
Apcmin/+ (Mom1) dominant resistant allele to irradiation induced adenoma 
multiplicity by examining the incidence of polyps in the progeny of mice.  We have 
identified numerous QTLs with differing degrees of QTL effects.  These QTLs begin 
to provide insight in whether there is a link in reduced Prkdc activity, polyp 
multiplicity and potentially CRC susceptibility.  Thus overall, it appears from our 
data that certain loci are important and associated with radiation induced 
tumourigenesis pathway(s) which may be suggestive of radiosensitive genes 
involved in secondary CRCs caused by radiotherapy.   
As complex traits are under the effect of multiple genes with weak individual effects 
and possibly strong epistatic interactions, we opted out of fine mapping and and 
extensive breeding programs to produce congenic mice which is no longer necessary 
due to the information content available in databases.  Instead we decided to 
improve the definition of our QTLs by modelling statistic epistasis to pave the 
inference of genetic pathways and identify causal variants within our regions.  
Therefore, my next chapter investigates the use of advanced mapping techniques to 
refine QTL regions, search for interactions and begin the identification of genes 
involved in polyposis.    
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3. CHAPTER 3 THE GENETIC EPISTATIC BASIS FOR 
IRRADIATION INDUCED POLYPS IN APCMIN/+ MICE: 
INTERACTION AND MULTIPLE QTL MODELLING OF 
THE MAIN EFFECT-QTLS.  
3.1 INTRODUCTION 
Genetic dissection of complex traits attempts to link single variants to a specific 
phenotype, however the extent to which a phenotype is likely to arise is composed 
of multiple genetic elements that interact in complex ways (Flint and Mackay 2009).  
Similarly, no one-to-one causal link exists with CRC genes, instead genes tend to 
aggregate and cluster in families and the variation in phenotype are likely to be 
influenced by multiple modifier genes.  The interaction between genetic variants 
that results in a phenotypic effect is conditional on the combined presence of two or 
more variants known as epistasis (Storey et al., 2005; Nagel, 2005; Nagel, 2001; 
Nagel and Steinberg, 2001).  It becomes apparent that the products of genetic 
epistasis and action of modifier genes are possibly ‘one and the same’ and therefore 
it is necessary to model the effect of these genes or modifiers in interacting groups 
(Clark et al., 1997; Cordell 2002; Storey et al., 2005).   
Since most quantitative traits are due to the affect of multiple genes, MQM allows for 
more information to be extracted from the data to make correct inferences about the 
genetic makeup and interactions of trait complexes (Korol et al. 1998; Jiang and 
Zeng 1995; Knott and Haley, 2000; Marlow et al., 2003).  Traditionally, most 
statistical models used in QTL mapping do not model polygenic variation despite 
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considerable evidence that interaction between loci affect quantitative traits (Barton 
and Keightley 2002).  This difficulty arises primarily because it is unclear which 
variant combinations should be tested and under which model of epistasis.  
Furthermore, multiple confounding factors such as computational burden, 
correction for multiple testing, false positives, sample size and defining an 
interaction model have led to the dissemination of numerous quantitative genetic 
models and much confusion over definitions and interpretation of epistasis.  There is 
no shortage of epistatic QTL mapping software tools available which have been 
proposed to model simultaneously the effects of multiple QTLs and their 
interactions (Kao et al., 1999; Jannink and Jansen, 2001; Sen and Churchill, 2001; 
Carlborg and Andersson, 2002; Boer et al., 2002; Kao and Zeng, 2002; Yi and Xu, 
2002; Ljungberg et al., 2004).   
To date, MQM studies have been most feasible in model organisms involving genes 
that have been well characterised; one of the best examples of epistasis is coat 
colour in mice, where an adaptive transition from dark to light coat colour involves 
structural changes to the agouti and Mc1r loci as mice of dark coloured fur move 
from the forest to the beach (Steiner et al., 2007).  Obesity in mice has been 
discovered to involve a network of epistatic interactions on Chr 4, 17 and 19 
controlling regulation of fat pad deposits and body weight (Stylianou et al., 2006).  
Gerlai showed evidence of epistasis by demonstrating that null-mutant mouse 
phenotype was dependent on modifier genes at many loci (Gerlai 1996) which was 
also seen in fruit fly (de Belle and Heisenberg 1996).  Fijneman and colleagues also 
showed that the quantitative variation in mice susceptible to lung cancer was 
significantly influenced by interactions among QTLs (Fijneman et al., 1996).  The 
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majority of the published examples involve some knowledge about existing genes, 
which can be sculpted to display a particular phenotype.  In contrast, it is far more 
challenging to identify and test interactions where biological clues of gene function 
are unknown (Cordell, 2009).  Cordell and colleagues evaluate the degree to which 
statistical tests of epistasis in experiments can actually elucidate underlying 
biological interactions and pathways and propose this to be more limited than 
originally estimated (Cordell et al., 2002).  In addition the extent of epistasis and 
identification of loci has highlighted the importance of examining phenotype 
variance using a more global approach where tests in different genetic backgrounds 
could possibly uncover new variants.  It is also unclear whether epistasis observed 
at the population level can be useful to infer epistasis at an individual level.   
Despite these challenges the prevalence and biological significance of epistasis is of 
great interest, especially in the new arena of GWAs and eQTL mapping.  The rapid 
and modern development of molecular technologies has seen a renewed interest in 
mapping QTLs at multiple levels in genome-wide case-control studies (Storey et al., 
2005; Boone et al., 2007).  To search for n QTLs in n-dimensional scans impacts on 
the computational processes significantly, especially when using permutation tests 
to obtain empirical significance thresholds.  Therefore, the framework of most 
epistatic QTL tools based on this condition can be broadly classified into two groups: 
exhaustive that explicitly test every possible interaction in a enumerate manner 
(Marchini et al., 2005) and non-exhaustive which uses a genetic algorithm such as 
DIRECT to scan the genomic space for interactions and is non-iterative.  DIRECT was 
originally presented and adapted by Jones and colleagues to divide the search space 
systematically into smaller boxes, calculating the LOD scores for the center of each 
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box and using a genetic optimization algorithm to optimize output of each box 
(Jones, 1993; Carlborg 2000).  This process continues until convergence of a defined 
LOD value until it locates a region of global optimum.  DIRECT is an efficient 
mapping method for investigating epistatic pairs while reducing the search space 
size by omitting the calculation of QTL pairs (Carlborg 2000).  Programs such as 
GeneNetwork and Pseudomarker, implement rapid DIRECT algorithms to efficiently 
search epistatic interactions (Ljungberg et al., 2004).  These programs use the ‘pair-
scan’ function to evaluate non-parametric significance of joint LRS values between 
QTL pairs; it has a quicker run time but is sensitive to outliers and sample size.  As 
this approach is based on the assumption that low LOD values are ‘not of interest’, 
detection of biologically relevant interactions may be omitted.   
Traditional exhaustive search engines calculate all LOD scores, as evidence of 
suggestive and or marginal QTLs (Dupuis et al., 1995).  These can be shown to be 
involved in interactions between epistatic QTL pairs with much larger effects than 
their individual effects (Gurganus et al., 1999; Carlborg et al., 2000) and it is feasible 
to apply this approach without the risk of spurious detection, possibly missing 
interactions, computer and memory failures.  Karl Broman's R-qtl software is free 
and open source multi-platform software.  R-qtl is implemented as an add-on 
package for the statistical language/software R (R Development Core Team, 2010) 
and is made available from http://www.rqtl.org/ and implements an exhaustive 
search using the "scantwo" function.  It is designed to cope with large datasets to 
handle larger calculations with greater provisions for controlling spurious 
associations which reflective of high through put data generation from eQTLs 
experiments.   
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As mentioned in chapter one, the identification of the specific genes underlying QTLs 
is a major challenge and while critical to localising influential regions this tends to 
be achieved with relatively low resolution.  Intervals are typically localised to 10-40 
centimorgans (cM) which can harbour hundreds to thousands of genes, any number 
of which could play a plausible role in, for example, the irradiation induced 
polyposis model investigated here.  Clearly, additional methods aimed at narrowing 
the QTL interval are vital if the specific genetic variations are to be realistically 
determined.  Though this resolution can be improved marginally by using more 
markers, the most effective way to improve resolution is to increase pedigree size 
and the number of recombination events and use advanced animal crosses including 
congenics.  However, this approach has significant cost implications because of the 
animal husbandry requirements.   
The well documented difference in polyp severity between BALC/c and B6 mice 
offers the opportunity to study how genetic differences between the two strains 
influence polyp multiplicity via their additive effects and to identify modifiers that 
may also influence the trait via gene-gene interactions.  We have detected QTLs with 
significant and suggestive levels of significance within the different segments of the 
intestine (Table 2-3 and 2-4 for 2Gy and 0Gy, respectively).   
Next, we will create sets of two-locus models to look at the possible interactions, 
encompassing all marker pairs to identify any interaction and their statistical 
importance in a ‘scantwo’ 2-dimensional exhaustive scan.  I now aim to use our QTL 
model to study epistasis at a genome wide level.  The possibility that main effect 
QTLs may be involved in an epistatic role can be investigated using this approach 
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and in a broad statistical sense; we aim to create multiple dimensions between 
markers with two-locus genotype combinations and measure effects by taking the 
additive element away to account for a model of interaction.  We will consider 
epistasis as the effects of one or more genes involved in polyp multiplicity and are 
modified by the presence of other gene(s), therefore to be the deviation from the 
additivity of the genotype values as outlined by Cordell (Cordell 2002).  Our method 
takes into account the additive effects of two loci that confer risk independently and 
epistatically.  Therefore, this chapter considers the interaction modelling of our 
main-effects QTL modelling to determine epistatic basis for polyp multiplicity in 
Apcmin/+ mice.   
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3.2 MATERIALS AND METHODS 
3.2.1 A two-dimensional, two locus genome scan 
The possibility of epistatic effects was investigated using R-qtl program written for 
the R statistical language programming environment as described by Broman and 
colleagues (2003). The program uses Hidden Markov Model (HMM) (Baum et al., 
1970) algorithms to estimate the most likely genotype and location of pseudo 
markers at fixed intervals which are then matched to representative markers or 
main-effect QTLs identified by IM.  The R programming scripts written by Karl 
Broman were edited and adapted as required to perform analysis according to our 
data and QTLs detected from chapter one (Broman et al., 2003).   
Starting with a null model we performed a single-QTL genome scan, using ‘scanone’ 
at 256 imputations of unknown genotypes based on observed marker data were 
made at 2.5cM intervals and considered sufficient to generate a precise map.  The 
position (and representative marker) with the highest LOD score was selected and 
missing genotype data were filled at this marker using the ‘geno.fill’ action.  A two-
dimensional QTL scan using ‘scantwo’ function was implemented using multiple 
imputations method to reveal and further evaluate pairs of intervals (loci) across the 
genome to determine how much of the variability in the trait can be explained 
jointly by two putative QTLs and may epistatic interactions.  This function evaluates 
epistasis using four linear models: the ‘Full’ (additive plus interaction between 2 
QTLs); ‘Additive’ (additive of 2 independent QTLs); ‘One’ (single QTL exists on any 
one chromosome); and each of these models were tested against the fourth ‘Null’ 
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model of no QTL.  We considered five maximum LOD scores (log10 likelihood for 
QTL) over a pair of chromosomes; Mf, Ma, Mi, Mfv1, Mav1 and M1 that are defined using 
the models mentioned above.  Mf considered the fit of the full two-locus model as 
log10 likelihood ratio comparing the full model with QTLs on two chromosomes to 
the null model. Ma was equivalent for a two-locus additive model and indicated the 
presence of at least one QTL, assuming no interaction.  Mi was derived, therefore, to 
examine interaction by comparing the full model with the additive model (Mi = Mf - 
Ma).  Mfv1 and Mav1 provided evidence for a second QTL, where Mfv1 allows for 
epistasis by compared the full model for a QTL pair to the single model (M1) that one 
single QTL exists to the null model (Mfv1 = Mf – M1) and Mav1 compared the equivalent 
additive LOD to a single QTL model indicating a second QTL assuming no epistasis 
(Mav1 = Ma – M1). Mfv1 allows for epistasis between the QTLs in a two-locus model 
and, in the absence of epistasis Mav1, would give greater power to detect a second 
QTL with additive effects. Hence, the two-dimensional genome scan and ‘scantwo’ 
method of pairs of markers across the genome will permit the identification of 
marginal QTLs for LOD scores that are most likely to be epistatic QTLs using the 
multiple imputation method.  Significance thresholds (Tf, Ta, Ti, Tfv1, Tav1 and T1 were 
set at 5% significance level for false positives as suggested at 6.50, 4.34, 4.52, 5.43, 
2.93 and 2.51 for Mf, Ma, Mi, Mfv1, Mav1 and M1 respectively.  These are the estimated 
95th percentiles of the null distributions of the corresponding LOD scores, obtained 
by 1,000 permutations based on the USI dataset.  In order to identify loci of interest 
from the 2D two-QTL genome scan, the distribution of five LOD scores under the null 
hypothesis was set.  Using the following criteria a pair of QTL was declared of some 
interest if either of the following held true: 1. Mf, ≥ Tf, (LOD 6.5) or [Mfv1 ≥ Tfv1 (LOD 
5.43), or Mi ≥ Ti, (LOD 4.52)]; 2. Ma  ≥ Ta (LOD 4.34) and Mav1, ≥ Tav1, (LOD 2.93). 
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3.2.2 Statistical modeling using ANOVA and effect plots 
In the second part of our strategy following a 2D scan of the main-effect QTLs the 
interaction of epistatic pairs we used the ‘makeqtl’ function (Broman et al., 2003) to 
create a model, hereafter referred to as a QTL-object, which consisted of multiple 
QTLs specified according to QTL pairs.  The ‘fitqtl’ function then fitted a specific QTL 
model in a two-locus hypothesis testing framework, a full model of interaction and 
principal additive effects was compared with a reduced model in which QTLs are 
removed sequentially and evaluated by the LOD score to test for the significance of 
each QTL and associated interactions within the QTL-object. Up to seven pairs of 
QTLs were matched and investigated under a multi-component ANOVA model.  In 
order to perform more precise mapping the ‘refineqtl’ function was used to refine 
the estimates of QTL positions in the current model where the maximised positions 
for full and additive models maybe different from the pair positions. Pairs of QTL 
loci, which surpassed the LOD full threshold and showed statistical evidence for 
interaction using ANOVA (p value >0.05), were analysed using effect plots (Fox et al., 
2003) to illustrate the interaction effects between markers.  The interaction is 
measured as the change in the phenotypic mean over the mean of another locus as a 
function of QTL genotypes and by considering two QTLs at a time. The possibility of 
an interaction existed when the differences at one genotype depend on the genotype 
at the second loci visualized on an effect plot when the lines describing the main-
effects do not run in parallel to each other.   
Pairs of QTL loci which surpassed the LOD full threshold and showed statistical 
evidence for interaction using ANOVA were analysed using effect plots to illustrate 
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the effects between markers which are not independent but linked for interesting 
interactions based on QTL pairs following a 2D genome scan.  The interaction is 
measured as the change in the phenotypic mean over the mean of another locus as a 
function of QTL genotypes, considering two QTLs at a time.  The possibility of an 
interaction exists if the lines describing the main effects were not parallel.   
The R-qtl ‘fitqtl’ function provided estimates of the QTL effects which are derived as 
a matter of recoding the homozygous and heterozygous markers to -0.5 and +0.5 
respectively and reporting the differences between the averages.  While it is useful 
to consider the QTL effects involved in epsitasis, there is generally considerable bias 
which was likely to vary from the true QTL effect.  QTLS that are above a certain size 
and of statistical significance are likely to be reported and therefore overestimated; 
the detection of weak effects QTLs was likely to be missed to due to the low power in 
detection.  In addition, modelling genes in humans using any organism model the 
QTL effects and the actual alleles might not be involved in the same way functionally 
and so the relevance in measured QTL effects to human diseases will remain open to 
question and for these reasons not much emphasis was placed on measuring the 
epistatic QTL effects.   
3.2.3 Exploration of models of multiple interacting QTLS  
Multiple interacting QTLs were investigated using a forward and reverse stepwise 
search and penalised LOD (pLOD) criterion (Manichaikul et al., 2009).  The pLODs 
are weighted according to each main-effect QTL and each pairwise interaction to 
control the rate of false interacting QTLs calculated from 2D scantwo of 10,000 
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permutation tests simulated on salt-induced hypertension in mice data from 
Sugiyama and colleagues, which consisted of 250 male backcross individuals and 
markers spaced at 10cM (Sugiyama et al., 2000) and set at 2.69, 2.62, 1.19 LOD for 
main-effects (Tm), heavy (Th) and light interactions (Tl), respectively.  The pLOD 
score took into account the initial LOD of the model and calculated the penalty based 
on the number of QTL in the model that are main-effects (Pm), the number of 
pairwise interactions that will be given a heavy interaction penalty (Ph) and the 
number of pairwise interactions that will be given a light interaction penalty (Pl).  
Differentiation between heavy and light interactions was made based on whether 
the interactive QTL of the model was disconnected or connected to other QTLs, 
respectively. A model was chosen that had the largest model comparison criteria 
using the pLOD score among all the models visited.   
The forward search starts with no QTLs in the model, then adds each QTLs 
beginning with a QTL with the highest LOD score.  Additional QTLs are then selected 
on to give the greatest increase in LOD score. The reverse of the forward selection is 
backward elimination, which starts with all QTLs in the model, and then removes 
each QTL one at a time so as to give the smallest decrease in the LOD score. These 
processes involve testing at each step for improvements to the model and the 
process is completed when there is no further improvement in the model.  Here, two 
models are considered: an additive only and an additive-interactive QTLs. These 
models allow the identification of a subset of loci and permits consideration of 
multiple acting QTLs that may control trait phenotype (Sillanpä et al., 1998). 
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3.3 RESULTS 
3.3.1 2D two-QTL scan performed on all trait data of 2Gy 
A 2D two QTL scan for epistatic QTL pairs was modelled using the 2Gy data on the 
USI, LSI and LI.  The reported LOD scores for the full model which accounted for the 
combined main additive effects of the two loci plus interaction between the marker 
pairs was calculated as the additive affect deducted from the null model.  We focused 
our analysis on the 2Gy to model the main effect QTLs as the 0Gy yielded suggestive 
QTLs and so the power to detect interaction effects from these marginal QTLs was 
further limited and subject to caution.   
Following a 2D two-QTL scan for epistatic effects 27 QTL pairs were detected for the 
2Gy dataset where the LODf (full model) value equalled or exceeded the LOD 
threshold of 6.0 and 1 QTL pair which fell just below this threshold was included due 
to the inferred location of the second QTL in close proximity to Mom7 on chr18.  
Interactions between QTL pairs are shown in Table 3-1 where LOD scores for full 
models > 6.5 threshold (set at 5% genome wide error rate). All other QTL pairs 
which did not reach above the 6.0 LODf threshold were not investigated.   
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Table 3-1 28 Quantitative trait loci pairs detected from 2D two QTL genome scan 
involving main-effect loci.  USI=upper small intestine, LSI=lower small intestine, 
LI=large intestine, cM=R-qtl generated positions, Add=additive model, 
Int=Interactive model. 
 
Chromosome 
(C) 
QTL 1 (cM) QTL 2 (cM) 
LOD 
Full 
(Mf) 
LOD 
Add 
(Ma) 
LOD 
Int 
(Mi) 
Modelling 
USI 
C2:C5 
D2MIT395 
Mrip1 (60.0) 
D5MIT139 Mrip3 
(64.2) 
9.79 8.37 1.41 
QTL pairs 
involving 
two main-
effect QTLs 
C2:C16 
D16MIT189 Mrip5 
(46.8) 
7.29 6.76 0.53 
C5:C16 
D5MIT201 
Mrip2 (39.6) 
D16MIT189 Mrip5 
(46.8) 
10.4 9.63 0.77 
C5:C17 
D5MIT139 
Mrip3 (64.2) 
D17MIT180 (26.7) 8.51 7.62 0.89 
C16:C17 
Prkdc Mrip4 
(25.4) 
D17MIT180 (26.7) 6.8 6.03 0.77 
C5:C9 
D5MIT201 
Mrip2 
D9MIT90 (17.8) 8.03 6.83 1.19 QTL pairs 
central to 
Mrip2 
(39.6cM) 
C5:C10 D10MIT106 (11.7) 7.1 6.04 1.06 
C5:C14 D14MIT102 (34.4) 6.9 6.01 0.89 
C5:C1 
D5MIT139 
Mrip3  
D1MIT132 (39.5) 8.64 7.17 1.47 
QTL pairs 
central to 
Mrip3 
(64.2cM) 
C5:C4 D4MIT308 (57.7) 6.88 6.42 0.46 
C5:C12 D12MIT91 (30.1) 6.75 6.17 0.58 
C5:C13 D13MIT78 (67.2) 7.69 6.48 1.21 
C5:C15 D15MIT100 (19.3) 7.01 5.94 1.06 
C5:C18 D18MIT222 (8.1) 7.71 6.62 1.1 
C5:C3 
D5MIT139 
Mrip3  
D3MIT320 (66.8) 7.01 7.01 0 
No QTL 
object model 
due to low 
LOD Int (Mi)  
C5:C6 D6MIT194 (62.9) 6.93 6.63 0.3 
C5:C7 D7MIT228 (25.6) 7.25 6.94 0.31 
C5:C8 D8MIT292 (21.2) 6.53 6.33 0.19 
C5:C11 D11MIT216 (19.2) 7.01 6.66 0.35 
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C5:C19 D19MIT106 (10.8) 6.59 6.54 0.05 
C6:C6 
D6MIT83 
(5.65) 
D6MIT1 (6.65)  6.54 5.58 1.96 
cis-epistasis C5:C5 
D5MIT201 
Mrip2 (39.6) 
D5MIT139 Mrip3 
(64.2) 
6.93 6.9 0.03 
C16:C16 
D16MIT189 
Mrip5 (46.8) 
D16MIT106 (57.7) 6.95 5.73 1.22 
LSI 
C6:C3 D6MIT194 
(63.2) 
D3MIT320 (51.8) 6.95 3.36 3.59 
  C6:C18 D18MIT222 (23.1) 5.33* 2.31 3.02 
C3:C3 
D3Mit51 
(34.3) 
D3MIT320 (51.8) 6.56 3.2 3.27 
LI 
C2:C8 
D2MIT395 
Mrip1 (63.4) 
D8MIT292 (27.1) 6.64 5.75 0.89 
  
C8:C9 
D8MIT211 
(47.1) 
D9MIT335 (27.5) 6.01 4.01 2 
3.3.2 Most detected QTLS pairs of the upper small intestine involve interactions.  
From the 23 detected QTL pairs of the USI involved interaction, 6 putative 
interactions involved main-effect QTLs on both chromosomes and were investigated 
as QTL-object 1 a total of 22 QTL pairs involved at least one main effect QTL and 
second QTL inferred on a non main-effect QTL.  18 QTL pairs were central to Chr5; 
Mrip2 (D5Mit201) and Mrip3 (D5Mit139) and investigated as QTL object models.  
Three QTL-pairs were found to exist in the same chromosome and investigated for 
cis-epistasis as outlined in Table 3-1.   
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2D-2QTL scan of upper small intestine (2Gy) 
 
Figure 3-1 LOD scores from a 2D two QTL genome scan of the upper small intestine 
trait on all chromosomes of 2Gy irradiated mice data.  LOD interaction (LODi) is 
displayed in the upper left triangle; LOD full (LODfv1) is displayed in the lower right 
triangle which allows for epistasis as evidence for a second QTL by a measure of the 
LODf – M1 model (a single QTL).  The colour scale on the right and numbers to the 
left and right correspond to the LOD i and LOD f, respectively.   
The lower triangle (LODfv1) of the 2D scan (Figure 3-1) shows evidence for QTLs on 
Chr 2, 5 and 16 and other multiple marginal affects QTLs as detected in our previous 
chapter.  Evidence for putative interaction between QTL pairs is shown in the upper 
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left involving significant or suggestive main-effect QTLs between Chr 2:5, Chr 2:16, 
Chr 5:16 ,Chr 5:17, Chr 16:17 (QTL object 1).   
Interactions central to Mrip2 or Mrip3 on Chr 5 were investigated in the following 
sequence: Mrip2 with Chr 9, 10, or 14 (QTL object 2) and Mrip3 with Chr 1, 4, 12, 13, 
15 or 18 (QTL object 3).  These models were tested using ANOVA analysis and effect 
plots to confirm interaction in subsequent sections of this chapter.  Additional 
putative QTL interactions between: Chr 6:8, Chr 1:11, Chr 11:14, Chr 14:15, Chr 
14:19 which indicated strong interactions were excluded from further analysis due 
to low LODf (ranging between 2.0- 3.0) and similarly, low LODfv1 and LODav1 values 
which did not sufficiently indicate the presence of second interactive and additive 
QTLs.   
3.3.3 Quantitative trait loci pairs assessed for cis-epistasis  
Linked QTLs by repulsion or in coupling which may suggest cis-epistasis were 
analysed for Chr 5, 16 and 6 of the USI and no evidence for cis-interaction was 
detected on either of these chromosomes.  Chr5 double peaks confirmed separate 
unlinked QTLs analysis using R-qtl.  ANOVA and interaction plots confirmed that 
these loci are unlinked and act additively (Figure 3-2 A) and the effect of Chr 5 Mrip2 
locus is the same for each of the two genotypes at Chr 5 Mrip3 and vice versa and 
therefore loci have the same sign with individuals (AA) having higher polyp 
numbers.   
 159 
 
Figure 3-2 Investigation of cis-interactions involving tightly linked QTLs on Chr 5 
(A), Chr6 (B) and Chr16 (C) of the USI trait.  Dot plots to show the polyp numbers of 
individuals against genotype clearly showing that very low number of individuals 
exist between recombinant classes (AA/AB).  Effect plots to show phenotype 
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averages against two-locus genotypes.  A=BALB/c allele (homozygous) and 
B=ApcMin/+ allele (heterozygous). Black circles =observed genotypes, red=imputed 
for missing data. 
The effect plots for Chr 16 (Figure 3-2 C) show that the markers have effects of the 
opposite sign; individuals AA for D16Mit189 marker and AB for D16Mit106 have the 
greatest number of polyps, however the inference of the second QTL; D16Mit106 is 
based on a few individuals.  Cis-epistasis on Chr6 was investigated between two 
markers which were typed at a 1cM distance from each other and appeared to be 
linked in repulsion with the opposite effect; that is whether an individual is AA at 
one marker and AB at the second or vice versa the outcome of high polyp numbers is 
observed.  In both cases, Chr16 and 6 cis-interactions were considered artefacts on 
the basis of only a few individuals shared the genotype of the second inferred and 
not substantive and considered an artefact (Figure 3-2 B).   
3.3.4 Quantitative trait loci pairs detected for the lower small intestine trait.  
A total of nine QTL pairs were detected for the LSI trait; eight were selected with 
LODf >6.0 and 1 QTL where LODf = 5.33 (Figure 3-3).  One of the two QTL pairs 
involving a main-effect QTL on Chr 6 (D6Mit194) confirmed trans-epistasis (p = 
0.0401) using ANOVA with Chr 3 QTL, but no interaction was noted for the QTL pair 
on Chr18 (region close to the Mom7).  Seven QTL pairs involved the same 
chromosome (on Chr 1, 3, 4, 8, 11, 12, 18) and were suggestive of tightly linked 
QTLs.  Except for Chr 3 the QTL pairs were either 5cM or 10cM apart and not typed 
by a separate marker therefore declared as artefacts and Chr 3 QTL pair did not 
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confirm cis-epistasis despite being typed by a different marker and a distance of 
17.5cM the rest (data not shown).   
2D-2QTL scan of lower small intestine (2Gy) 
 
Figure 3-3 LOD scores for all chromosomes, from a 2D, two QTL genome scan of the 
lower small intestine trait on all chromosomes of 2Gy irradiated mice data.  LOD 
interaction (LODi) is displayed in the upper left triangle; LOD full (LODfv1).  The 
colour scale on the right and numbers to the left and right correspond to the LOD i 
and LOD f, respectively.   
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3.3.5 Quantitative trait loci pairs detected for the large intestine trait. 
Two QTL pairs were detected at LODf for the LI trait; one pair involved a significant 
mains effect QTL on Chr 2 D2Mit295 with Chr 8 (D8Mit292) and the second QTL pair 
involved novel and previously undetected QTLs, D8Mit211 and D9Mit335 (Figure 3-
4).  No significant interactions were noted for either of these QTL pairs.   
2D-2QTL scan of large intestine (2Gy) 
 
Figure 3-4 LOD scores for all chromosomes, from a 2D, two QTL genome scan of the 
large intestine trait on all chromosomes of 2Gy irradiated mice data.  LOD 
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interaction (LODi) is displayed in the upper left triangle; LOD full (LODfv1).  The 
colour scale on the right and numbers to the left and right correspond to the LOD i 
and LOD f, respectively.   
3.3.6 Interaction of main-effect QTL pairs in the USI 
The results of scanone and scantwo indicated main effect QTLs on Chr 2, 5, 16 17 
with the possibility of second QTLs on Chr 5 (Mrip3), 16 (Mrip4) and six possible 
interactions as indicated in Table 3-1.  We investigated the possibility of epistasis by 
fitting a six-QTL model using the ‘fitqtl’ function taking the positions from scantwo 
to create QTL object 1 as outlined in Table 3-2. 
Table 3-2 ANOVA table for modelling epistasis of main effects QTLs in QTL-object 1.  
Type III SS= sum of squares, %var=estimated proportion of the phenotype variance 
explained by the terms in the model.  F statistic=the ratio of the mean squares (the 
sum of squares divided by the df to the error mean square, p values are based on the 
F statistic. 
QTL object 1 df 
Type III 
SS 
LOD %var F statistic 
p values (F) 
significance 
Chr 2 Mrip1 (60.0cM) 3 1846.01 2.69 4.98 3.92 0.0104 * 
Chr 5 Mrip2 (39.5cM) 3 1527.61 2.24 4.12 3.24 0.0240 * 
Chr 5 Mrip3 (64.22cM) 4 1964.69 2.85 5.30 3.13 0.0169 * 
Chr 16 Mrip4 (25.4cM) 2 1784.50 2.60 4.81 5.69 0.0042 ** 
Chr 16 Mrip5 (46.8cM) 3 1594.85 2.34 4.30 3.39 0.0200 * 
Chr 17 D17Mit180 (26.7cM) 3 3108.04 4.40 8.39 6.61 0.0003 *** 
Chr 2:5 (Mrip1:3)  1 998.84 1.48 2.69 6.37 0.0127 * 
Chr 2:16 (Mrip1:5)  1 6.66 0.01 0.01 0.04 0.8369  
Chr 5:5 (Mrip2:3)  1 164.87 0.25 0.44 1.05 0.3069  
Chr 5:16 (Mrip2:5)  1 618.49 0.92 1.66 3.94 0.0490 * 
Chr 5:17 (Mrip3) 1 120.54 0.18 0.32 0.76 0.3820  
Chr 16:17 (Mrip4)  1 1732.36 2.53 4.67 11.0 0.0011 ** 
Error 129 20215.21     
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Total 141 37035.75     
Significance codes: ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 
The overall fit of the full model (six-QTL) is relative to the null and includes all the 
terms of the model with 12 degrees of freedom (df) and a LOD score of 18.68.  This 
model explains a substantial proportion of the phenotypic variance (45.4%).  
Reducing the model by dropping one of the specified QTLs at a time and comparing 
the LOD score relative to this ‘reduced’ model (and not the null model) using ANOVA 
indicated strong evidence for all main effects loci included in this model: Chr 2 
(Mrip1), Chr 5 (Mrip2 and Mrip3) and Chr 16 (Mrip5) (p ≤ 0.05), Chr 16 (Mrip4) (p ≤ 
0.01) and Chr 17 (D17Mit280) (p ≤ 0.001), significant interactions between; Mrip1:3 
(Chr 2:5), Mrip2:5 (Chr 5:16) (p ≤ 0.05) and 6 Mrip4:D17Mit280 (Chr 16:17) (p ≤ 
0.001), in total accounted for ~9% of the phenotypic variance.  No evidence was 
detected for the other interactions within this model.  The refined position and LOD 
values of the QTL model showed a 0.07 LOD increase after 2 increments with very 
minor positional changes of each loci.   
QTL pairs, which were shown to have significant interaction determined by ANOVA, 
were investigated for interactions using effect plots (Figure 3-5).  Additively acting 
QTL pairs are not shown.  According to our BC, (AxB) xA, heterozygous AB from the 
Apcmin/+ mouse carrying the Mom1R, (resistant strain) are expected to have lower 
polyp numbers than homozygous AA alleles and this was observed by effect plots.  
The QTL pairs of Object 1 show that Chr 5 (D5Mit139/Mrip3) AA allele has an effect 
in the presence of heterozygous alleles (AB) at Chr 2 D2Mit395/Mrip1).  Similarly, 
Chr 2 has an effect only in the presence of the (AA) at Chr 5.  Therefore, only 
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individuals that are AA at Chr 5 and AB at Chr 2 show high polyps multiplicity in the 
USI.  The other 3 genotypes have similar effects on polyp numbers.   
Similar findings were observed for QTL pair between Prkdc (AA) and heterozygote 
(AB) at Chr 17 (D17Mit280).  Finally, individuals that are AA at Chr 5 
(D5Mit201/Mrip2) and AA at Chr 16 (D16Mit189/Mrip5) have higher polyp 
numbers and so the QTL favours the homozygosity at both loci.   
Interaction plots concerning main-effect QTL pairs 
 
Figure 3-5 Phenotype averages against two-locus genotypes as effect plots for QTL-
object 1 of the upper small intestine trait, p value (p val) statistical significance 
based on F statistic for the six-QTL model as analysed using ANOVA (Table 3-2).  
A=BALB/c allele (homozygous) and B=ApcMin/+ allele (heterozygous).   
3.3.7 QTL object 2 pairs central to Mrip2 
 We next investigated a four-QTL model involving Mrip2 on Chr 5.  The initial full 
model with LOD score of 9.10 (7df) accounts for 25.5% estimated proportion of the 
phenotypic variance explained by all terms.  The drop one analysis (Table 3-3) 
 166 
indicated evidence for only one of the four loci, the Mrip2 locus, but found significant 
interactions with the marginal effect QTLs on Chr 9, 10 and 14. 
Table 3-3 ANOVA for multiple QTL pair modelling and testing significance of 
epistasis involving Mrip2.  Type III SS= sum of squares, %var=estimated proportion 
of the phenotype variance explained by the terms in the model.  F statistic=the ratio 
of the mean squares (the sum of squares divided by the df to the error mean square, 
p values are based on the F statistic. 
QTL object 2 df 
Type III 
SS 
LOD %var 
F 
statistic 
P value(F) 
significance 
Chr 5 Mrip2 
(39.5cM) 
4 9014.3 8.72 24.33 10.95 1.03e-07  *** 
Chr 9–D9Mit90 (17.8cM) 2 1171.2 1.28 3.16 2.84 0.0616  
Chr 10–D10Mit103 (11.7cM) 2 949.3 1.04 2.56 2.30 0.1035  
Chr 14 – D14Mit102 (34.4cM) 2 1175.3 1.28 3.17 2.85 0.0610  
Chr 5: 9 1 833.2 0.91 2.25 4.05 0.0462  * 
Chr 5: 10 1 887.5 0.97 2.396 4.31 0.0397  * 
Chr 5: 14 1 1088.2 1.19 2.93 5.28 0.0230  * 
Error 134 27569.53     
Total 141 37035.74     
Significance codes: ‘***’ 0.001 ‘*’ 0.05 
QTL pairs were investigated for interaction using effect plots to confirm interactions 
involving Mrip2 (D5Mit201) between markers on Chr 9, 10 and 14 (Figure 3-6).  It 
was confirmed that the heterozygote (AB) at Mrip2 locus has lowest effect on polyp 
numbers and homozygous (AA) for Mrip2 in each QTL pair results in higher polyps: 
with homozygote individuals at D9Mit90; either AA or AB genotype at D10Mit106 
and heterozygote (AB) at D14Mit102.   
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Interaction plots of QTL pairs central to D5Mit201 (Mrip2) 
 
Figure 3-6 Phenotype averages against two-locus genotypes are shown as effect 
plots for QTL object 2 of the upper small intestine trait.  A=BALB/c alleles and 
B=ApcMin/+ allele.  P value (p val) statistical significance based on F statistic for the 
six-QTL model as analysed using ANOVA (Table 3-3). 
3.3.8 QTL object 3 pairs central to Mrip3 
A seven-QTL model involving Chr 5 (D5Mit139/Mrip3) of QTL object 3 was 
investigated.  The initial full model with LOD score of 17.02 (13df) accounts for 
42.3% estimated proportion of the phenotypic variance explained by all terms; all 
loci were significant except Chr 12 and four out of six interactions tested significant 
under ANOVA (Table 3-4) and shown in effect plots (Figure 3-7).   
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Table 3-4 ANOVA table for multiple QTL modelling and testing significance of 
epistasis involving Mrip3.  Type III sum of squares (SS), estimated proportion of the 
phenotype variance explained by the terms in the model (%var) F statistic and p 
values are based on the F statistic, model (M) and interaction (int) as denoted to the 
QTL pairs. 
QTL objects 3 df 
Type III 
SS 
LOD %var 
F 
statistic 
P value(F) 
significance 
Chr 5 Mrip3 (39.5cM) 7 13147.2 14.8 35.4 11.26 4.56E-11 *** 
Chr 1 D1Mit132 (39.5cM) 2 2981.1 4.03 8.04 8.94 0.00023 *** 
Chr 4 D4Mit308 (57.7cM) 2 1078.8 1.52 2.91 3.23 0.04254 * 
Chr 12 D12Mit91 (30.1cM) 2 635.2 0.90 1.71 1.90 0.15292  
Chr 13 D13Mit78  (67.2cM) 2 1358.6 1.90 3.66 4.07 0.01923 * 
Chr 15 D15Mit100 (19.3cM) 2 1419.6 1.98 3.83 4.25 0.01619 * 
Chr 18 D18Mit222 (8.1cM) 2 2411.3 3.30 6.51 7.23 0.00105 ** 
Chr 5:1 1 2226.9 3.06 6.01 13.3 0.00037 *** 
Chr5:4 1 622.5 0.88 1.68 3.73 0.05549 . 
Chr 5:12 1 540.7 0.77 1.46 3.24 0.07403 . 
Chr 5:13 1 985.9 1.39 2.66 5.91 0.01639 * 
Chr 5:15 1 1403.6 1.96 3.79 8.42 0.00436 ** 
Chr 5:18 1 2011.1 2.77 5.43 12.0 0.00070 *** 
Error 128 21334.40     
Total 141 37035.8     
Significance codes: ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 
QTL pairs were investigated for interactions using effect plots for evidence of 
interactions between these loci (Figure 3-7).  Additively acting QTL pairs are not 
shown.  The heterozygote (AB) alleles at Mrip2 locus confirmed that the B allele 
from B6Min/+ yields lower polyps than the A allele from the BALB/c strain.  Evidence 
of epistasis causing higher polyp numbers is observed in homozygote individuals 
(AA) at Chr 5 (D5Mit139/Mrip3) and heterozygotes (AB) at Chr 1 (D1Mit132) and 
Chr 13 (D13Mit178).  In the case of epistasis between Chr 15 (D15Mit100); the 
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genotype information AA or AB have similar effects on polyp numbers for 
individuals which are AA for Chr 5 (D5Mit139/Mrip3).   
Interaction plots of QTL pairs central to D5Mit139 (Mrip3) 
 
Figure 3-7 Phenotype averages against two-locus genotypes are shown as effect 
plots for QTL object 3 of the USI trait.  A=BALB/c alleles and B=ApcMin/+ allele.  P 
value (p val) statistical significance based on F statistic for the six-QTL model as 
analysed using ANOVA.   
Finally, the inference of a QTL interaction between Mrip3 and Chr 18 (at D18Mit222, 
8.08cM) is located close to the modifier of Min (Mom7) (3cM), an existing novel 
modifier of the Apcmin/+ mouse model.  Heterozygous individuals carrying the B allele 
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for D18Mit222 were expected to have lower polyp numbers due to the Mom7 
modifier effect to suppress polyp multiplicity in B6Min/+ and this is confirmed in our 
data.  A dot plot (Figure 3-8) of this interaction further shows that the 2 
recombinant classes differed in the number of polyps between homozygote (AA) or 
heterozygote (AB) at D5Mit139 (Mrip3).  That is homozygote AA at Mrip3 and 
D18Mit222 have higher numbers polyp.  The inference of the second QTL, 
D18Mit222, depends approximately on equal numbers of individuals genotyped at 
AA and AB and shows further reliability of results.  However, there is considerably 
more missing data in the AB genotyped group.   
The effect of D5Mit139 and D18Mit222 linked QTLs 
 
Figure 3-8 The effect of two-linked QTL on Chr5:18 against the upper small 
intestine polyp phenotype assessed using the 2Gy data.  The dot plot of the 
phenotype as a function of marker genotypes confirms the difference between two 
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recombinant classes of Mrip3 AA over AB and D18Mit222 AA over AB for increased 
polyp severity.  Black circles correspond to observed genotypes and red for imputed 
data where genotype information is missing.   
3.3.9 Exploration of additive and additive-interactive models of multiple 
interacting QTLs  
The automated model selection process was applied to identify a subset of loci that 
influence polyp burden and how these may contribute together to produce the 
phenotype were evaluated using MQM and a penalized LOD score with penalties 
fixed for main effects and interactions (Figures 3-9 and 3-10).  Starting with a single 
QTL scan, Mrip4 (Chr 5) was selected followed by scan for additional additive QTL 
and any additional interacting QTLs.  At each step the location of the QTLs in the 
current model are refined and repeated until a six-loci model was achieved.   
Mrip1, 2, 5 were identified within the first 3 steps of the forward selection process 
supported by genotype-phenotype data in the USI trait.  Additional additive QTLs; 
Q4 on Chr 6 at 62.9cM (D6Mit194), Q5 on Chr 6 at 53.1cM (D6Mit287) and Q6 on 
Chr 16 at 55cM (D16Mit106) were selected under the additive model (Figure 3-9) 
but as these were previously discounted during earlier cis-epistasis analysis as 
linked QTLs not much weight was given to them.  Stepwise search for interactive 
QTLs to add to the model first searched for an additive QTL and then tested for 
interaction assigning pLODs at each process according to the mains effect or 
interaction QTL detected.   
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Figure 3-9 The sequence of model selection visited by forward (A) and backward 
(B) search for additional quantitative trait loci of additive and interaction effects in 
the upper small intestine using the 2Gy data.  The penalised LOD (pLOD) value for 
adding a QTL (Q) the model as shown in the formula (y) indicating the structure of 
the additive and/or interactive (connected) QTLs during model selection.  The 
forward selection process is followed by backward elimination set to a maximum of 
6 QTLs 
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A second QTL model was developed while searching for interacting QTLs and 
involved Mrip2 and 5 and the suggestive QTL on Chr 17 (Figure 3-10).  To this, 
additional QTLs were added involving Chr 16 (which was previously discounted as 
linked QTLs) and Chr 3.  Chr 3 QTL is a possible overlapping loci between the USI of 
the 0Gy and 2Gy data, however, caution was applied to the interpretation of these 
results due to the missing genotype data and redundancy of D3Mit320 and 
D3Mit352 markers which was detected from Map Manager QTX.  R-qtl handled the 
missing data differently and did not hide these markers from analysis which 
probably accounts for the difference in analysis.  This also indicates that slightly 
different and dynamic patterns emerge with the use of different software programs 
all which greatly depend on the statistical inference of missing genotype data.   
The model showed an interaction between Chr 5:16 and Chr 17:16 (D16Mit106).  
The latter interaction differs from the output of the 2D scan and ANOVA analysis 
which showed a Chr 17:16 interaction to involve Prkdc (at 20cM) and not 
D16Mit106 at 52.6cM.  However, in the context of MQM it appears to favour analysis 
involving peaks distal to the second QTL peak on Chr 16 (D16Mit189/Mrip5) based 
on LOD score evaluation and would seem that the difference in 2D scan and MQM 
may concern the treatment of missing genotypes.  No great difference was noted 
between the forward or backward elimination approaches.   
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Figure 3-10 The sequence of model selection visited by forward (A) and backward 
(B) search for additional quantitative trait loci of interaction effects in the upper 
small intestine using the 2Gy data.  The penalised LOD (pLOD) value for adding a 
QTL (Q) to the model as shown in the formula (y) indicating the structure of the 
additive and/or interactive (connected) QTLs during model selection.  The forward 
selection process is followed by backward elimination set to a maximum of 6 QTLs.   
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3.4 DISCUSSION 
The findings presented here indicate that statistical epistasis as a property of 
specific genotypes at two loci whose interaction has an impact on irradiation-
induced adenoma multiplicity does exist.  The aim of this analysis was to test for the 
genome-wide effects of interactions based on main-effect QTLs within a statistical 
framework.  The permutation testing which performs 1000 genome scans on 
permuted dataset to obtain a stable distribution of the model under the null 
hypothesis of no QTLs existing in the data gave a threshold from 2.53 -2.60 LOD and 
we were confident that this would not lead to potentially greater numbers of type I 
errors.  We calculated a range of ~8-18% total phenotypic variance overall 
accounted for by the three QTL-object models of epistasis in that determine 
adenoma multiplicity.  The phenotypic variance of 18% is central to Mrip2, 8% 
central to Mrip3 and 9% involving two main-effect QTLs. 
We used R-qtl to perform an exhaustive search to work through all possible 
combinations of epistatic QTL pairs using a two-QTL hypothesis testing approach 
and interactions to test the interdependence between two locus models using 
ANOVA.  The drop one analysis was particularly valuable for studying the support 
for the individual terms in each model.  For the USI trait 10 significant interactions 
were detected each involved at least one previously detected main-effect QTL.  
Seven additional markers on Chr9, 10, 14 and Chr1, 13, 15 and 18 were detected by 
virtue of their interaction with either Mrip2 or Mrip3, respectively and were 
previously undetected as single locus QTLS.  As expected, homozygosity of the 
BALB/c allele at Mrip2 and Mrip3 increased the average polyp numbers for the USI 
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with respect to the corresponding heterozygous state and was detected in the 
background of either homozygous or heterozygous states of the second inferred QTL 
markers.  In addition, Chr6 (D6Mit194) which was previously detected in the LSI 
trait and not in the USI, showed evidence as a second QTL (LODf of 7.23, LODa of 6.01 
and LODi of 1.32 following a 2D scan) and was also selected as an additive QTL from 
the automatic model selection approach (Figure 3-9) of the USI trait.  This would 
suggest epistatic pleiotropy where the co-variation observed between the USI and 
LSI may be caused by this single QTL on Chr 6 (D6Mit194).  D6Mit194 was therefore 
involved in significant interactions between Mrip5 (Chr 16) of the USI (p =0.032) 
and Chr 3 (D3Mit320) of the LSI (p = 0.011).  No other significant interactions were 
observed in LSI or LI our data.   
In summary, we applied exploratory functions within MQM mapping to select subset 
of loci models that are best supported by a 2-dimensional scan of our 2Gy data.  The 
selection of the appropriate model criterion is important for analysing MQM.  
Furthermore, the outcome of MQM varies depending on statistical approaches and 
key difficulties in establishing evidence for linked QTLs or interacting QTLs in the 
context of multiple QTL models is controlling for large effect QTLs and therefore the 
selection of suitable markers as covariates is a crucial process.  We explored MQM 
while controlling for major QTL loci to identify QTL pairs that are not artefacts 
resulting from strong associations at QTLs with strong LOD scores and thus creating 
an interaction effect between other loci.  Higher order epistasis modelling of up to a 
three-way interaction was not tested as population size requirements of >500 are 
needed to reliably estimate higher order interactions.  A further consideration was 
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that permutation testing of at least 1,000 replicates would involve multidimensional 
analyses and suffers from computational burden.   
Next, we plan to map these interactions to genomic regions and to evaluate genes 
involved in the control of irradiation-induced intestinal polyposis.  We hope to show 
that by using in silico methodology combined with literature search to begin the 
process of refining QTLs and the identification of candidate genes of interest.   
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4. CHAPTER 4 IN SILICO SEQUENCE MODELLING OF 
FUNCTIONAL SNPS AS A RATIONAL TO SELECT 
CANDIDATE GENES WITHIN MRIP 1-5.  
4.1 INTRODUCTION 
4.1.1 In silico modelling 
Using unannotated sequences from databases and computational biology tools it is 
possible to gain further insights into the functions of proteins based on their 
sequence, structure, evolutionary history and the interactions between proteins.  I 
aim to provide a framework to screen the Mrip regions for functional coding region 
SNP changes and predict using bioinformatics tools the deleterious effects.  I also 
aim to design an initial draft of target genes which will be refined to detect more 
specific pathways.  This will begin the exploratory search of candidate genes as 
opposed to cherry-picking ones that I consider are important within the identified 
QTL regions and that may play a role in irradiation induced intestinal polyposis.  
This will contribute towards our understanding of CRC and irradiation biology, but 
more specifically to understanding polyposis in the mouse model than can then be 
extrapolated to humans through comparative mapping.  
The aim here, is, to investigate the biological context behind Mrip and QTL pairs 
identified from epistasis using the application of an ‘in silico’ sequence search (Grupe 
et al., 2001, Darvasi et al., 2001) and literature search based on the epistatic QTL 
pairs detected in chapter 3.  The target genes then serve as the basis to further 
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explore susceptibility loci and their involvement towards irradiation and CRC 
progression based on literature mining.   
Sequence based selection of target genes is based on polymorphisms and the use of 
algorithms to predict deleterious effects on protein function.  In this section the aim 
is to look more specifically at underlying SNPs which are likely to represent 
modifiers of inherited susceptibility.  SNPs are partly responsible for individual 
differences observed in populations affecting disease severity, effectiveness, side-
effects and tolerability to drugs and treatments and have become an important 
process in medical research (Stoneking et al., 2001; Chakravarti 2001; Stenson et al., 
2009).  The availability of SNP information from NCBI dbSNP 
(http://www.ncbi.nlm.nih/gov/SNP/) (Sherry et al., 2001) can be used to predict 
the detrimental effects of amino acid changes in peptide sequence (Chasman and 
Adams, 2001; Sunyaev et al., 2000; Sunyaev et al., 2001).   
90% of all human genetic variation are made up of SNPs which are randomly 
distributed every 100-300 bases along human genome and there are ~11 million in 
the human genome, yet only a small proportion of these SNPs is known to alter the 
gene function to influence measurable differences in the phenotype (Sachidanandam 
et al., 2001).  SNPs within coding regions, non-synonymous SNPs (nsSNPs) 
(Ramensky et al., 2002) and regulatory SNPs (rSNPs) of genes, are most likely to 
cause an amino acid change in the peptide sequence or influence the overall activity 
of the protein or the gene expression.  Approximately 10–15% of nsSNPs are 
projected by predictive software to be damaging and, hence, likely to influence 
phenotype (Ng and Henikoff, 2002).  Such SNPS are believed to predispose 
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individuals to diseases and impact an individual’s response to environmental factors 
such as bacteria, toxins, chemicals and drug and other therapies including, 
radiotherapy and chemotherapy (Sunyaev et al., 2001).  SNPs that do not result in a 
protein change are called synonymous SNPs (sSNPs), the majority of which are 
intronic, at 3'-UTRs or between genes.  Most sSNPs are deemed neutral on the basis 
of their location and are unlikely to modify proteins and, as a consequence, do not 
contribute to a phenotype (Zhao et al., 2003).   
By using the mouse strain data to select nsSNPs that are polymorphic between 
parental BALB/c and B6 strains within Mrip, the functional effect changes of these 
SNPs using prediction algorithms will be investigated using an in silico approach.  
The high density of single genetic variants provides a convincing rationale to predict 
the deleterious effects in genes in this manner, furthermore, the large volume of SNP 
data is a demonstrable platform for comparing human and mouse genomes and is 
valuable for identifying conserved genes and regulatory elements between the two 
species.   
Several methods use sequence conservation of particular amino acids within a 
family of sequences or look for particular features of a protein structure to predict 
whether a substitution affects protein function.  Prediction effects of nsSNPs are 
based on the biochemistry involving the amino acid substitution and its context 
within the protein sequence, taking into account factors such as hydrophobicity, 
helical-breaking residue, 3D structure and general rules of protein chemistry 
(Grantham, 1974) which can complement in silico modelling.   
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I am interested in making use of these features and using empirical prediction rules 
based on the protein sequence, structural information and homologies in amino acid 
sequences between species using Polymorphism Phenotyping v1 (PolyPhen) 
(Ramensky et al., 2002) and Sorts Intolerant From Tolerant (SIFT) prediction tools 
(SIFT) (Kumar et al., 2009).  Xi et al. found that that PolyPhen and SIFT predicted 
correctly the effect of 96% of amino acid substitutions on protein activity in APEX1 
(Xi et al., 2004).  In validation studies, PolyPhen and SIFT have been shown to 
predict successfully the effect of over 80% of amino acid substitutions, 
benchmarking studies based on the analysis of “known” deleterious substitutions 
(Ng and Henikoff, 2002; Sunyaev et al., 2000).  Therefore, in silico screening, 
prediction algorithms and the use of comparative mouse-human genomics forms the 
basis for further refining the selection of disease loci involved in intestinal polyp 
multiplicity.   
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4.2 MATERIAL AND METHODS 
4.2.1 In silico  
A search of the Mouse Phenome Database MPD for loci that are potentially 
regulatory such as nsSNPs and splice site ssSNPS was conducted within the 
candidate regions.  The MPD holds ~1400 phenotypic ‘phenomics’ measurements 
for 600 strains of mice covering approximately 740 million SNP alleles and is a 
useful repository for complex trait analysis (Grubb et al., 2009).  Polymorphic 
nsSNPs were selected within the same genomic window as used previously for PA 
and based predominantly on QTL mapping (±15cM) and epistasis analysis using 
http://phenome.jax.org/db/q?rtn=strains%2 Fcompare2_menu&strains=50,7 using 
Sangar1 dataset/  The SNPs and the related protein sequence for the selected genes 
were obtained from dbSNP (NCBI; http://www.ncbi.nlm.nih.gov/SNP/).   
Next, the fasta format and the amino acid position and SNP-associated change were 
submitted to computer algorithms to predict the functional effect of amino acid 
changes by considering conservation over evolution, the physiochemical differences, 
and the proximity of the substitution to predicted functional domains (Figure 4-1).  
The protein sequence together with sequence position and the two amino acid 
variants is submitted to Polyphen server (which was available at 
http://coot.embl.de/PolyPhen/ and currently replaced by PolyPhen version 2.2.2 of 
the software).  The analysis was initially set to the original PolyPhen criteria and 
then assessed using SIFT at http://sift.bii.a-star.edu.sg/ which uses a modified 
version of PSI-BLAST and Dirichlet mixture regularisation to construct multiple 
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sequence alignment of proteins that can be globally aligned to a query sequence 
which belongs to the same clade (Sjolander et al., 1996; Altschul et al., 1997).  This 
procedure was adopted because of the 90% coverage and 9% rate of false positives 
rate using PolyPhen compared to 60% coverage and 20% false positives using SIFT 
(Ng et al., 2006).  In addition, SIFT predicts the functional importance of amino acid 
substitutions based the phylogenetic information with the alignment of orthologous 
and or paralogous protein sequences. This distinguishes residues that are 
conserved, and thus intolerant to most sequence changes, from those residues that 
are poorly conserved and tolerant to sequence changes.  Sequences within the 
database, which show between 90-99% sequence similarities to the query are 
removed from the alignment process in order to exclude proteins containing the 
substitution of interest and to avoid matching to pseudogenes.   
 
Figure 4-1 A simplified diagram of the in silico workflow process.  Starting with a 
gene list derived from MPD of nsSNPs polymorphic between the strains, the fasta 
format of the genes are submitted to PolyPhen. This combines information on 
sequence features, multiple alignments of 45 vertebrate genomes using NCBI human 
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genome, homologous proteins sequences from UniProtKB/UniRef100 and structural 
parameters based on 3D mapping from PDB/DSSP Snapshot to make a prediction of 
the amino acid (AA) variant effect on protein function.  SIFT predictions are based 
on orthologues and homologous sequences from UniProt and Swiss-Prot and 
TrEMBL 
Sequence-based characterisation of the substitution site, profile analysis of 
homologous sequences, and mapping of substitution site to a known protein 3D 
structure are the parameters taken into account by PolyPhen to calculate a PSIC 
score for each of the two variants and then computes the PSIC score difference 
between them.  The higher the PSIC score difference the higher the functional impact 
a particular amino acid substitution is likely to have.  PolyPhen scores were 
designated as probably damaging with a z-score of 2.00, possibly damaging (z = 
1.50-1.9), potentially damaging (z = 1.25- 1.49), borderline (z = 1.00-1.24), or benign 
(z = 0.00-0.99; Xi et al., 2004).  The SNPs predicted as ‘probably or possibly 
damaging’ were selected for SIFT analysis.  Similarly, protein sequences were 
obtained, data was entered and predictions were based on the comparisons of 
sequences of related proteins which are sourced from UniProt (Universal Protein 
Resource) consisting of 2,392,904 proteins with 91,269 human proteins from Swiss-
Prot and TrEMBL compared to POLYPHEN which uses 70,627 human proteins from 
Uniprot July 7, 2005 Release 5.0.  SIFT scores were classified as intolerant (0.00-
0.05), potentially intolerant (0.051-0.10), borderline (0.101-0.20), or tolerant 
(0.201-1.00) according to the classification proposed by Ng et al (2003) and Xi et al 
(2004).   
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The criteria for selecting target genes was based on the cM position within the QTL 
interval (±15cM).  Target genes must have contained nsSNPs in the regulatory and 
or functional domains that are predicted to be ‘damaging’ and be confirmed as 
variants in our strains of mice and/or linked by citation to other genes for possible 
genetic epistasis.  The suitability of target genes will be based on literature evidence 
and data mining and the findings presented here.   
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4.3 RESULTS  
4.3.1 In silico results 
This in silico results section details the large-scale homology and sequence based 
predictions of 419 fully annotated genes that were selected within the 5 Mrips. Also 
presented are the subsequent analyses of 1,248 nsSNPs to ascertain functional 
candidate genes involved in irradiation induced intestinal polyposis (detailed below 
and in Figure 4-2).  The goal of the analysis is to predict mutations (or a subset of 
mutations) which are likely to affect the structure or function of the gene, and thus 
to identify which of these mutations may have a role in the progression or 
development of irradiation-induced CRC and related disease.  A total of 652 genes 
(1,870 nsSNPs) (Table 4-1) were highlighted initially on the basis of polymorphism 
between the two strains within the 5 Mrip regions from MPD.  The first filter applied 
to these genes excluded any poorly annotated and hypothetical genes, such as 
locations (LOCs), variants (GM) or Riken (Rik) (the three major types) and various 
transcripts or predicted proteins (BOC, ENS, Vnmr). This resulted in omission of 80 
genes (12.2% of the total) accounting for 267 nsSNPs (Figure 4-2 and Table 4-1).  
Similarly, 134 (293 nsSNPs) and 19 genes (63 nsSNPs) were selected within the 
Mrip1 (Chr 2) and Mrip5 (Chr 16) respectively which belonged to the olfactory 
receptor (Olfr) and accounted for 20.5% of the total genes.  For Chr 2, these genes 
are closely located between regions 85.4 – 112.6cM (genes Olfr996-Olfr1314) with 
280 nsSNPs found clustered within 85.4Mbp and 89.4Mbps of these regions.  Chr 16 
Olfr172 – 209 spanned from 58.7Mbps – 59.3 Mbp region of Mrip5 (Figure 4-2).  
These are the largest olfactory receptor gene cluster, with over 400 genes expressed 
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in BALB/c and B6 genome alone.  Olfactory genes were not considered to have any 
important function in adenoma multiplicity and tended to inflate the actual number 
of genes.  As a result, these genes were discarded from predicting functional 
polymorphisms.  In addition, pseudogenes that have lost their protein coding 
function and are regarded as defective were excluded from further analysis.   
Next, 419 genes (fully annotated genes) carrying 1248 nsSNPs were subjected to a 
second filtering process: a sequence-based prediction method using physical and 
comparative analysis tools involving PolyPhen v1.12 (based on March 2006 releases 
of UniProt, NCBI, PDB) and SIFT programs. These softwares were used to 
understand which sequence changes are likely to either disrupt the structure or 
function of the protein.  This resulted in 156 genes (37%) predicted deleterious and 
or damaging nsSNPs and 263 genes (63%) predicted to have benign effects and 
were excluded (Figure 4-2 and Table 4-1).  The damaging and or deleterious genes 
were subjected to a third filter; exclusions were based on genes not involved in 
tumourigenesis from literature analysis and therefore regarded as not likely 
candidates.  This process eliminated a further 129 genes.  The resulting 27 likely 
candidates were subjected to numerous searches including literature reviews based 
on genes involved in CRC, IR and polyps, followed by a search for functional 
domains, conservations of the nsSNPs across species and pathway assocations were 
all taken into account before final gene targets were selected.   This resulted in a 
final reduction to 12 QTL targets and 21 subsequent nsSNPs as outlined in Table 4-2 
as potentially deleterious by PolyPhen and SIFT, and the functional domains 
associated with some of these polymorphisms were identified.  From these 12 genes 
a subset of 7 genes were identified within Mrip1, 2 and 1 genes within Mrip2 and 3 
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and 1 and 1 for Mrip4 and 5 respectively (including Prkdc), were selected for further 
investigation), details of in silico predictions are found in Table 4-2 and literature 
supporting target gene selection in Table 4-3 
Table 4-1 Selection of genes based on BALB/c specific nsSNPs (in parenthesis) 
obtained from the MPD.  The data presented for each Mrip region as defined.  A total 
of 419 genes and 1248 nsSNPS (column 4) were filtered from MPD (excluding 
hypothetical genes (column 3).  Resulting nsSNPs were investigated for predicted 
affects by PolyPhen and SIFT and deleterious and or damaging nsSNPs (column 5) 
were subjected to subsequent analysis outlined in column 6.  The final number of 
genes and corresponding nsSNPs were selected as potential candidates relevant to 
trait of interest.   
Mrip         
Chr 
Region 
MPD 
genes 
selected : 
polymorphic 
nsSNPs 
Poorly 
annotated 
genes 
(excluded 
(Filter 1) 
Fully 
annotated 
genes 
(included 
for 
prediction 
analysis) 
Predicted 
damaging 
and or 
deleterious; 
(Filter 2) 
Filters 3 & 4 
Final target 
genes 
selected  
Mrip1- 
Chr2 
(69.2Mbp - 
131.6Mbp) 
330 (1003) 159 (386) 171 (617) 52 Functional 
domains, 
(literature 
based) 
involveme
nt in 
tumourige
nesis, CRC, 
IR and 
polyps 
-- 
Structure 
and 
function of 
SNPs 
-- 
Amino acid 
conservati
on (EMBL-
EBI) 
7 
(14) 
Mrip2- 
Chr5 
(21.3Mbp - 
85.1Mbp) 
69 (186) 16 (61) 53 (125) 20 
2 
(2) 
Mrip3-
Chr5 
(90.4Mbp - 
138.3Mbp) 
167 (435) 28 (98) 139 (338) 60 
1 
(1) 
Mrip4-
Chr16 
(3.8Mbp - 
37.3Mbp) 
29 (108) 2 (5) 27 (103) 9 
1 
(2) 
Mrip5-
Chr16 
(37.3Mbp - 
84.7Mbp) 
57 (138) 28 (73) 29 (65) 15 
1 
(2) 
Total  652 233 419 156 12 
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Figure 4-2  Flow diagrams of the processes involved in the selection of target genes 
for Mrip1-Mrip5.  Eliminated genes are shown in red boxes and candidate genes in 
blue. 
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Table 4-2 Predictive assessment of BALB specific amino acid polymorphisms for 
potentially damaging alterations.  Polymorphisms within known functional domains 
were identified. Polyphen and SIFT analysis was carried out to identify potentially 
damaging alterations. Polyphen predictions by position specific independent count 
(PSIC). PSIC ≥1.5 is potentially damaging and are in bold (except in the case of * 
where PolyPhen v2,2 was applied which uses a scale of 1-1.0)  SIFT predicts the 
change to be tolerated (T) or not tolerated (N), if intolerant then the substitution 
effect is stated.  The conservation of sequence alignment at and around the amino 
acid substitution is compared between different species using Polyphen.  The 
polymorphisms were located within some functional domains and determined using 
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) (Jensen et al., 
2009) available at; http://string-db.org/ 
 Gene 
Variation 
polymorphism 
Functional 
domain 
PolyPh
en 
(PSIC) 
SIFT 
Conservation 
(%) 
Mrip1 
Duox2 
H[His] ⇒R[Arg]627 
rs27453362 Animal 
heam 
peroxidise 
(aa 60-562) 
1.524 T 36% (9/25) 
G[Gly] ⇒S[Ser]553 
rs27453360 
0.114 T 44% (11/25) 
S[Ser] ⇒N[Asn] 378 
rs27453345 
0.299 T 36% (9/25) 
Bub1b 
S[Ser] ⇒G[Gly] 240 
rs3144766 CDC20 
binding to 
BUBR1 
(Mad2 
dependent) 
Casc5 by 
sequence 
similarity 
1.32 T 75% (6/8) 
P[Pro] ⇒T[Thr] 278 
rs3149979 
0.549 T 44% (4/9) 
V[Val] ⇒A[Ala]312 
rs3149980 
0.072 T 63% (5/8) 
D[Asp] ⇒E[Glu]664 
rs27423851 
1.241 N (Acidic to acidic) 67% (5/8 
N[Asn] ⇒D[Asp]705 
rs27423850 
0.345 N- Acidic to 
uncharged polar) 
67% (5/8) 
Dll4 
Q[Gln] ⇒L[Leu]419 
rs27423750 
EGF like 6 
0.431 T 25% (15/59) 
G[Gly] ⇒S[Ser]627 
rs27423747 
1.516 N- Uncharged 
polar to non-polar 
38% (6/16) 
Casc5 I[Ile] ⇒T[Thr]1286  1.643 T 60% (3/5) 
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rs27471474 
Bub1 
P[Pro] ⇒S[Ser]153 
rs28269039 
 
1.569 T 57% (4/7) 
Mertk 
A[Ala] ⇒T[Thr]441 
rs27446346 
Extracellula
r domain 
0.833* N 75% (6/8) 
Thbs1 
Q[Gln] ⇒R[Arg]960 
rs27502423 
TSP C-
terminal 
0.99* T 74% (8/11) 
Mrip2 
Arap2 
P[Pro] ⇒R[Arg]278 
rs31438432 
 
2.271 N (Basic to non-
polar) 
100% (7/7) 
Rcf1 
Y[Tyr] ⇒N[Asn]66 
rs31457275 
 
2.440 T 79% (8/11) 
Mrip3 Cxcl5 
R[Arg] ⇒H[His]10 
rs31723268 
 
1.582 N/A 100% (2/2) 
Mrip4 Prkdc 
R[Arg] 
⇒C[Cys]2140 
rs4164952 
Pfam 
domain 
Nuc194 
entry 
2.495 N (basic to 
uncharged polar) 
100% (9/9)  
M[Met] 
⇒V[Val]3844 
rs48580935 
Pi3K/Pi4K 
domain 
0.208 T 50% (4/8) 
Mrip5 Itgb2l 
N[Asn] ⇒D[Asp]509 
rs316615 
 
2.193 T 100% 
(45/45) 
G[Gly] ⇒S[Ser]539 
rs3164214 
1.662 T 56% (25/45) 
Table 4-3 The function of candidate genes and their role in mediated radiation 
response and tumourigenesis selected using in silico.  
Symbol Gene Functional/expression 
Duox2 dual oxidase 2 Generate ROS species; Innate immune response; 
expressed in mucosal surfaces including gut (Bedard 
and Krause, 2007); hypermethylated in lung cancer 
(Luxen et al., 2008). 
Bub1b budding uninhibited by 
benzimidazoles 1 homolog, beta 
Mitotic checkpoint gene involved in chromosomal 
instability. Upregulation in CRC (Abal et al., 2007; Hanks 
et al., 2004)). 
DLL4 delta-like 1 Notch signalling, regulates tumor angiogenesis and 
tumour growth, expressed in the gut (Katoh and Katoh, 
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2006). 
Casc5 cancer susceptibility candidate 
5, AF15q14 
A member of the Spc105/Spc7/KNL-1 family, directly 
links spindle checkpoint proteins BubR1 and Bub1 to 
kinetochores and is required for chromosome 
alignment (Kiyomitsu et al., 2007) 
Bub1 budding uninhibited by 
benzimidazoles 1 homolog 
Regulates exit from cell cycle checkpoint, genetic and 
epigenetic alterations in CRC (Grady, 2004) 
Arap2 ArfGAP with rhoGAP domain 
ankyrin repeat and PH domain 
Human homologue involved in focal adhesion and 
mediates effects of RhoA (Yoon et al., 2006) 
Rcf11 replication factor C (activator 1) 
1 
A multi-subunit protein complex needed for 
proliferating cell nuclear antigen (PCNA)-dependent 
DNA replication and repair synthesis (Hashiguchi et al., 
2007). 
Cxcl5 chemokine (C-X-C motif) ligand 
5 
Chemokines as regulators of angiogenesis (Baier et al., 
2005).  Expressed in the colon and variants associated 
with CRC (Dimberg et al., 2007). 
Prkdc protein kinase, DNA activated, 
catalytic polpeptide 
DNA double strand break repair mechanism (Wetering 
and Chen, 2007).  
Itgb2l integrin beta 2-like During an inflammatory response, Itg2l help retain 
CXCL13-expressing cells (Hojgaard et al., 2006) 
4.3.2 Profile of all SNPs within Mrip regions 
At the time of writing the profile of all SNPs within the Mrip was extracted from MPD 
using Sanger dataset (ftp://ftpmouse.sanger.ac.uk/ current_snps) as of November 
2011 and the consequence was according to NCBI dbSNP mouse build 132 
(ftp://ftp.ncbi.nih.gov/snp/ organisms/mouse_10090 as of December 2010).  
44,417 SNPs were located within 1,560 genes (including predicted genes and 
locations) of the Mrip regions and briefly summarised in Table 4-4.   
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Table 4-4 SNP variant profile in 1560 genes within the Mrip regions, extracted from 
MGI build 37.  ns= non synonymous, s= synonymous, i=intronic, l=location of 
unknown consequence, stopL=stop codon loss,U3 and U5=3 and 5 prime 
untranslated region, ess=essential splice site, ss=splice site, %=percentage of SNPs 
expressed as a total of 44,417 SNPS ( -=percentage value is low) 
SNP 
Coding 
genes 
Olfactory 
genes 
Hypothetical 
genes 
Total 
genes 
% 
i 33926 77 6,854 40857 1.1 
U3 818 7 78 903 2.1 
s 732 144 68 944 92 
ns 331 101 67 499 0.7 
U5 102 14 25 141 - 
l 55 37 240 332 2 
ss 3   1 4 0.3 
stopL 1 - - 1 - 
ess 1   2 3 - 
multiple        733 1.6 
 
It was discovered during data cleansing of this list that 16.6% of all SNPs comprised 
of hypothetical genes, with locations (LOCs), variants (GM) or Riken (Rik) genes as 
the major three types.  Others included expressed sequences (AI*), cDNA (BC*) 
sequences, DNA segments (D*Ertd*), and various transcripts or predicted proteins 
(EG, ENS, OTT, RP-23) and this inflated the number of polymorphisms.  Rikens, GM 
and LOC constituted the major proportion of predicted protein genes and or 
locations, of which 6,854 were intronic and a more equal ratio of sSNPs and nsSNPs 
was observed (68 and 67 respectively).  A total of 147 olfactory genes, with 380 
SNPs; 101 non-synonymous (nsSNPs), 144 synonymous SNPs (sSNPs) and 77 
intronic SNPs (iSNPs) were observed.  Data validation showed that 733 SNPs were 
assigned more than one consequence which is most likely due to the multiple 
transcripts used which determined the different consequence.   
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The total occurrence of mouse SNPs was the highest within introns (40,857 SNPs 
91.9%), then 2.1% were sSNPs (944), 1.1% nsSNPs, (499) and 0.7% were found 
within a locus with an unidentified consequence (332).  Some 2% and 0.3% SNPs 
were detected in the 3’ prime UTR (903) and 5’ prime UTR (141), respectively.  UTR-
SNPs, albeit a small fraction, may have functional consequences on mRNA stability 
and or expression.  However, it is less straightforward to predict the functional 
importance of SNPs within regulatory regions.  As expected low numbers of rarer 
and infrequent SNPs such as essSNPS (3) and ssSNPs (1) were detected mainly in 
Riken genes.  In addition, 1 stop codon gain (olfactory gene) and 1 stop codon loss in 
leucine carboxyl methyltransferase 2 (Lcmt2) were also observed.   
The higher rate of iSNPs may be explained on the assumption that these SNPs are 
not under selective pressure and or due to the length of intronic regions that are in 
the 100s of kilobases and are generally poorly conserved.  Furthermore, the high 
numbers of polymorphisms suggests that these could be in LD with other variants 
and leaves the open question of whether a proportion of these are actually gene-
associated SNPs.  Increasing evidence shows that introns exert a control of genes 
and are involved in high-level gene expression (Choi et al., 1991; Palmiter et al., 
1991; Millar et al., 2010) and so are no longer regarded as ‘junk’ DNA and, instead, 
are involved in complex processes during mRNA transcription.  In comparing actual 
genes (excluding all ambiguously annotated or hypothetical genes), a ratio of 2.2 
sSNP (732) to every nsSNP (331), was noted and, overall, SNPs were the lowest in 
exons and highest in introns (33,926 iSNPs) (Table 4-4).   
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4.3.3 Target genes selected through literature search 
Literature analysis was used to investigate the epistatic potential of both Mrip2 and 
Mrip5, which have the strongest association between adenoma numbers in the USI. 
Additional gene targets: Ras-related C3 botulinum toxin (Rac1) and T lymphoma 
invasion and metastasis 1 (Tiam1) were selected based on the Chr5:Chr16 
interaction between Mrip2:Mrip5. Tiam1 is a metastasis-related gene of T lymphoma 
that is also involved in the metastasis of CRC. In the presence of the Wnt3a 
stimulation Rac1 is proposed to interact with Tiam1, which is known to be involved 
in metastatic potential in CRC (Liu et al., 2005).  The model suggested that Tiam1 
activates the GTP-bound state of Rac1 via a GDP-GTP exchange, which mediates 
Wnt-induced transcription via β-catenin/TCF4 complexes (Esufali et al., 2004; 
Buongiorno et al., 2008).  Tiam1 is also thought to activate selectively the Rac1 
GTPase gene, which is expressed in the base of intestinal crypts and involved in the 
Wnt pathway.  Tiam1 deficiency is also reported to significantly reduce the 
formation and growth of polyps in Min mice (Carter et al., 2004, Malliri et al., 2006).  
Further to this, action of Asef and Asef2, which are guanine-nucleotide exchange 
factors specific to Rac1, are important for adenoma formation in ApcMin/+ mice 
(Kawasaki et al., 2009).   
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4.4 DISCUSSION  
The potential biological relevance of the QTL results was investigated using the joint 
effects of two prediction tools, PolyPhen and SIFT.  The in silico approach provided 
an overview of the extent of functional coding sequence variation between mouse 
inbred strains and has helped to speed the identification of candidate genetic 
variations that underlie between the two strains and within irradiation induced CRC 
QTLs.  The selection of target genes was narrowed based on a literature review and 
an known associations with irradiation, tumourigenesis and epistasis from the 
previous chapter (Chapter 3).    
The model built in the work presented here are appropriate for candidate gene 
selection based on the examination of nsSNPs, which could potentially influence 
proteins. The SNP search was constrained to coding regions within Mrips and only 
polymorphisms, which were strain-specific were selected.  The relevant information 
was taken from the different integrative biomedical databases and literature to 
improve data quality and extraction to define subsets of genes that are 
physiologically important.  In silico tools further demonstrates a useful approach in 
providing information about the nature of mutations and functions as a first pass 
filter to determine the deleterious amino acid substitutions worth pursuing for 
further validation between the gene variation and trait association.  Therefore, the 
study presented by this chapter demonstrated that by utilising the huge wealth of 
data already available it is possible to cut the use of animal breeding, selecting 
targets according to literature based evidence.  In the next chapter, the aim is to 
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confirm and extend these results using sequencing analysis and mRNA gene 
expression of the selected targets. 
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5. CHAPTER 5 SINGLE NUCLETIDE POLYMORPHISMS 
MUTATION ANALYSIS AND MRNA EXPRESSION OF 
TARGET GENES. 
5.1 INTRODUCTION 
DNA sequence polymorphisms affecting either expression and or gene function form 
the underlying molecular basis for QTLs.  Therefore, identifying the sequence 
variation between strains is an important process to detect the causal gene (Abiola, 
2003).  Here, QTLs have been associated with adenoma multiplicity using traditional 
IM analysis and putative target genes within the QTLs have been identified using an 
in silico based sequenced based scan.   
To summarise, target gene selection was based on 2 criteria: first, SNPs were 
selected from sequenced data which may confer partial functional activity (in silico) 
and this was followed with computer-based algorithms to predict functional effects 
and distinguish disease-associated missense mutations from common variants; 
second, a selection genes was prioritised on literature search to minimise bias in 
selection.  The outcome revealed 14 target genes (including Rac1 and Tiam1), which 
may confer potentially susceptible alleles involved in adenoma multiplicity.  This 
chapter aims to characterise the target genes by verifying polymorphisms using 
sequencing and to distinguish mRNA expression differences in the USI and LSI 
between BALB/c and B6Min/+ in the intestinal mucosal expression of genes that may 
influence susceptibility to radiation-induced polyposis in BALB/c and B6Min/+ mice.   
 199 
5.2. MATERIALS AND METHODS 
5.2.1 Inter-strain sequencing  
Genomic DNA was prepared from healthy intestines of BALB/c, B6Min/+ and N2 
ApcMin/+ mice using snap-frozen tissue (~25mg) as mentioned in section 2.2.2.  PCR 
conditions were 95ºC for 15 minutes, followed by 24 cycles (95ºC for 1 minute, 55ºC 
for 1 minute 72ºC for 1 minute) and elongation at 72ºC for 10 minutes.   
Primer sets were designed using Primer3 v. 0.4.0 (available from 
http://frodo.wi.mit.edu/).  The PCR reaction products were cleaned to remove 
residual contaminants such as Taq enzyme, nucleotides (dNTPs) and primers using 
ExoSAP-IT® (USB Corporation, Cleveland, Ohio).  ExoSAP-IT treats PCR products 
ranging in size from less than 100 bp to over 20 kb while conserving the full 
recovery of the PCR product.  A 5 μl sample of the PCR reaction product was mixed 
with 2 μl of ExoSAP-IT® for a combined 7 μl reaction volume. The sample was 
incubated at 37ºC for 15 minutes to degrade remaining primers and nucleotides and 
then incubated at 80ºC for 15 minutes to inactivate ExoSAP-IT®, resulting in a 
purified PCR product.   
The purified product was prepared for the sequence reaction before running on the 
ABI 3100 genetic sequencer (Applied Biosystems, Warrington, UK).  A stock solution 
of Big Dye Terminator v3.1 (containing buffer, polymerase, and labeled dNTPs) 
containing 800 μl was diluted with 800 μl 5x Big Dye Terminator v3.1 sequencing 
buffer (ABI) and 800 μl PCR water. A typical sequencing reaction included 8 μl 
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diluted Big Dye Terminator v3.1, 1 μl of a 20 μM working solution primer (either the 
forward or the reverse primer), 1 μl PCR water and 10 μl purified PCR product, 
giving a total volume of 20 μl. PCRs were performed on an MJ Research Tetrad 
Thermal Cycler. PCR cycling conditions were 5 minute denaturation at 95°C, 
followed with denaturation at 96°C for 30 seconds, annealing at 50°C for 45 seconds 
and extension at 60°C for 4 minutes repeated 34 times, after which samples are kept 
at 4°C.  The annealing temperature varied according to the primer data in the range 
of 61-64°C, but typically the primers annealed at 60°C.   
Unincorporated dye terminators are removed from sequencing reactions before 
loading onto the ABI 3100 genetic analyzer using a DyeEx 96 well plate kit 
(QIAGEN).  The plate was placed on top of the sample collection plate provided and 
centrifuged for 3 minutes at 2,000 rpm. After discarding the flow-through, the plate 
was placed on a 96 well elution plate with a suitable adaptor. 10 μl of the purified 
sequencing reaction was carefully applied to the gel bed of each well. This was 
centrifuged for 3 minutes at 2,000 rpm, the dye bound dNTPs bind to the column 
which consisted of pre-hydrated gel-filtration resin and the eluent contained the 
purified sequencing reactions.   
The spatial calibration for the ABI-Prism 3100 Genetic Analyser was performed 
using Hi-Di Formamide.  Samples run through the machine must be suspended in Hi-
Di Formamide in order to produce an accurate sequence reading. Hence, following 
DyeEx clean up, 1 μl of sequencing product was added to 9 μl of Hi-Di Formamide 
and then denatured by heating at 95°C for 5 minutes in a MJ Research Tetrad 
Thermal Cycler. This was immediately placed on wet ice for 5 minutes before 
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loading into the ABI-Prism 3100 Genetic Analyser.  Data analysis was performed 
using Sequencer version 4.7 for Windows (Gene Codes Corporation, Michigan, USA).   
Any identified polymorphisms were checked against the SNP database, (NCBI, Build 
36.1) to distinguish between known and novel SNPs. As noted above, SNPs are 
categorised as synonymous and non-synonymous based on alterations at the amino 
acid level and nsSNPs investigated for potential effects on protein function.   
5.2.2 Reverse transcription 
Intestinal musosal scrapings from the USI and LSI were taken from wild type (WT) 
8-9 weeks old BALB/c and B6Min/+ mice (n=3), and each sample was processed 
separately and in duplicate.  Total RNA was extracted using micro RNAeasy kits 
(Sigma) and contaminating DNA was removed using RNAse-free DNAse1.  RNA 
samples were checked on 1% agarose gels and concentration determined using 
NanoDrop®, ND-1000 UV-Vis Spectrophotometer.  Total RNA was used to synthesise 
cDNA using the First-Strand cDNA Synthesis Kit, purchased from Amersham 
Biosciences.  To 5 µg of RNA sample was added 1 µl 50mM Oligo(dT)18 primers and 
denatured in 70°C for 5 min and cooled on ice rapidly.  The RNA/primer reaction 
volume was made up to 20 µl with RNase-free water and a cDNA synthesis mix 
consisting of 4 µl of RT reaction Buffer (5X), 1 µl [10mM each] dNTPs, 0.25 µl 
Ribonuclease inhibitor [40U/µl] and 2 µl DTT, 0.5 µl M-MLV reverse Transcriptase 
[200U/µl].  The solution is gently mixed and incubated for 1hr at 42°C before the 
reaction was terminated at 70°C for 15 minutes and cooled on ice.  cDNA was 
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cleaned up with the QIAquick PCR purification kit and the purity of cDNA was 
checked on 1% agarose gel electrophoresis and quantified using nanodrop.   
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis 
was performed using the ABI 7900 Sequence Detection System instrument (PE 
Applied Biosystems).  TaqMan polymerase chain reaction primers were purchased 
from the Applied Biosystems to amplify 13 candidate genes selected from our QTL 
regions.  qRT-PCR was performed and the difference between the cycle thresholds 
(Ct) of these genes from the reference house keeping gene, glyceraldehydes 
triphosphate dehydrogenase (Gapdh) was calculated for each sample.  The results 
were analysed using the Ct (cycle threshold) value given the cycle number (out of 
40) at which the level of fluorescence crossed the threshold value.  The threshold 
value was ‘set to above the baseline and sufficiently low to be within the exponential 
growth region of the amplification curve.   
To calculate the relative fold change value, the Ct values were normalised to the 
endogenous control Gapdh using the following: ΔCt = Ct target gene – Ct Gapdh and 
squared to give 2-∆∆Ct.  Standard error value of the means (SEM) were calculated 
using the following equation SE = SD/√n where SD is the standard deviation and n 
the sample size (Livak and Schmittgen, 2001).  The 2-∆∆CT was used to statistically 
measure the expression profiles of the target genes and the fold difference in the 
intestinal sections between BALB/c and B6Min/+. 
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5.3 RESULTS 
5.3.1 Sequencing of BALB/C, B6 and N2 offspring identifies single nucleotide 
polymorphism 
No mutations were detected from the complete gene sequencing done on: Rac1 and 
Tiam1 (selected on the basis of Chr5:Chr16 epistasis), including the coding regions 
and splice sites, upstream and downstream of the 5’ and 3’ UTRs for polymorphisms 
in BALB/c, B6Min/+ and N2 ApcMin/+ offspring.  The targets selected from in silico 
showed a more constructive approach towards detecting polymorphisms and 
facilitating the possibility to filter out SNPs and omitting the need to sequence entire 
genes.  This conserved analysis has shown, that from 44 nsSNPs 23 (52.3%) 
polymorphisms were confirmed in our mouse model as presented in Table 5-1 and 
representative sequencing chromatograms for Dll4 and Duox2 are shown in Figure 
5-1 and 5-2) 
Table 5-1 Sequencing of selected nsSNPs identified 23 polymorphisms present 
between BALB/c and B6Min/+within in silico targets.  Data extracted from MPD or 
NCBI Build 37.1(*).   
Gene 
ID 
Chr:bps refSNP Residue change and position 
BALB
/c 
B6Min/+ 
Bub1b 
  2:118438465 rs3144766 G[Gly] ⇒S[Ser] 240 A G 
  2:118440768 rs3149979 P[Pro] ⇒T[Thr] 278 C A 
  2:118440871 rs3149980 A[Ala] ⇒V[Val] 312 T C 
  2:118456696 rs27423851 D[Asp] ⇒E[Glu] 664 C G 
  2:118457497 rs27423850 D[Asp] ⇒N[Asn] 705 A G 
* 2:118639687 rs13474781 L[Leu] ⇒F[Phe] 959 A T 
Thbs1   2:117948718 rs27502453 R[Arg] ⇒Q[Gln] 960 G A 
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* 2:118117486 rs8251599 ^S[Ser] ⇒A[Ala] 376 or /-  
⇒R[Arg]     
* 2:118113119 rs27502496 D[Asp] ⇒N[Asn] 73 G A 
* 2:118113233 rs27502494 D[Asp] ⇒Y[Tyr] 111     
* 2:118117487 rs8251600 S[Ser] ⇒I[Ile] 376 or /- ⇒T[Thr]     
* 2:118117488 rs8251601 S[Ser] ⇒R[Arg] 376     
* 2:118117592 rs8251605 N[Asn] ⇒T[Thr] 411 or /- ⇒I[Ile]     
* 2:118117612 rs8251606 S[Ser] ⇒P[Pro] 418     
Casc5 
  2:118894273 rs27471494 G[Gly] ⇒S[Ser] 240     
  2:118894395 rs50321001  K[Lys] ⇒N[Asn] 280     
  2:118894607 rs27471489 F[Phe] ⇒Y[Tyr] 351     
  2:118894963 rs27471486 F[Phe] ⇒I[Ile] 470     
  2:118895680 rs3684717 I[Ile] ⇒V[Val] 709     
  2:118897412 rs27471474 I[Ile] ⇒T[Thr] 1286 C T 
  2:118897436 rs29812960 A[Ala] ⇒V[Val] 1294     
  2:118897454 rs29669827 E[Glu] ⇒G[Gly] 1300     
  2:118897832 rs27471471 Y[Tyr] ⇒C[Cys] 1426     
  2:118907258 rs52269307 T[Thr] ⇒P[Pro] 1707     
Dll4 
  2:119157891 rs27423750 Q[Gln] ⇒L[Leu] 419 T A 
  2:119158514 rs27423747 G[Gly] ⇒S[Ser] 627 A G 
Duox2 
  2:122117242 rs27453362 H[His] ⇒R[Arg] 627 C T 
  2:122118031 rs27453360 S[Ser] ⇒G[Gly] 553 C T 
  2:122119828 rs27453345 S[Ser] ⇒N[Asn] 378 C T 
  2:122122077 rs48311667 Q[Gln] ⇒R[Arg] 231     
  2:122122455 rs27453333 H[His] ⇒R[Arg] 159 C T 
* 2:122292682 rs32841329 V[Val] ⇒D[Asp] 495     
Bub1 
  2:127649702 rs28269040 K[Lys] ⇒R[Arg] 187     
* 2:127823966 rs28269039 S[Ser] ⇒P[Pro] 153 T C 
Mertk 
  2:128562357 rs27446565 N[Asn] ⇒D[Asp] 176 G A 
  2:128597122 rs27446346 T[Thr] ⇒A[Ala] 441 A G 
  2:128627269 rs27431508 I[Ile] ⇒V[Val] 951 A G 
Arap2 
  5:63021396 rs48756961 I[Ile] ⇒L[Leu] 1419 or /-  ⇒F [Phe]     
* 5:62748842 rs31438432 R [Arg] ⇒ P [Pro] 278 G C 
Rfc1   5:65704206 rs31457275 N [Asn] ⇒ Y [Tyr] 66 A T 
Cxcl5 
  5:91188497 rs31723268  R [Arg] ⇒ H [His] 10 A G 
  5:91188515 rs31723269 I [Ile] ⇒ S [Ser] 16     
Itgb2l 
  16:96647834 rs3164214 G [Gly] ⇒ S [Ser] 539     
  16:96648384 rs3166158 N [Asn] ⇒ D [Asp] 509 G A 
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Figure 5-1 Representative DNA sequencing chromatograph for DLL4 mutation 
determined by fluorescent DNA sequence analysis.  PCR products of genomic DNA 
were obtained with forward and reverse primers and sequenced to illustrate the G 
to A transversion resulting in the protein coding sequence change of glycine to 
serine.  Blue highlight indicates the base call marking the nsSNP against the known 
NCBI dbSNP sequence (Build 36) 
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Figure 5-2 Representative DNA sequencing chromatograph for Duox2 mutation 
determined by fluorescent DNA sequence analysis.  PCR products of genomic DNA 
were obtained with forward and reverse primers and sequenced to illustrate the C 
to T transversion resulting in the protein coding sequence change of serine to 
asparganine.  Blue highlight indicates the base call marking the nsSNP compared 
with known NCBI dbSNP sequence (Build 36) 
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5.3.2 Analysis of expression by quantitative reverse transcriptase PCR reveals 
differential gene expression 
Based on the study outcome so far; Duox2 (Mrip1 on Chr 2)  Rac1 Chr5 (Mrip2) and 
Tiam1 from Chr16 (Mrip5) were selected  to test the expression in the USI fragments 
between BALB/c and B6Min/+ (Table 5-2).  The expression of these target genes was 
tested in parental unirradiated strains (due to radiation based experimental 
constraints at this time animal irradiation facilities were not available) to investigate 
the difference between the 2 strains in their corresponding segments of the 
intestine.  Our initial target gene expression profiling provides, in part, some 
understanding of any apparent differences between our strains and segments 
information on expression levels in normal un-irradiated intestine of BALB/c and 
B6Min/+, allowing comparison between the two strains to assist in linking target 
genes to risk processes and possible pathways as modifiers.   
Total RNA extracted from BALB/c (n=3) and B6Min/+ (n=3) mice showed no evidence 
of degradation on visualisation by agarose gel electrophoresis.  The efficiency of 
amplification was validated using the house keeping probe, Gapdh, which gave 
consistent measurements with little variability.  The mRNA expression levels of 
target genes were determined and the expression in the same intestinal fragment 
compared (either USI or LSI) between BALB/c and B6Min/+ (Table 5-2).  All results 
were validated with repeats and each assay (n=3) was carried out in triplicates 
(n=9) in separate 96 well plates. 
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Table 5-2 Summary statistics of Duox2, Rac1 and Tiam1 expression in the upper 
small intestine (USI) and lower small intestine (LSI) of BALB/c (B) or B6Min/+ (M).  
The data include the average gene expression signal (Mean), standard error of the 
mean (SEM), fold change in expression compared to the highest gene expression 
value and p values as analysed by ANOVA,  
 
USI LSI 
B6Min/+ BALB/c B6Min/+ BALB/c 
Duox2 
Mean 60.54 11308.89 7.12 44.69 
SEM 26.49 4672.02 1.42 9.22 
p value B vs M p=<0.0001 B vs M p=<0.0001 
Fold 186.8 6.3 
Rac1 
Mean 11.45 8.89 6.49 3.26 
SEM 2.16 1.55 1.8 0.74 
p value N/A M vs B p=0.001 
Fold 1.3 2.0 
Tiam1 
Mean 21097.05 6440.46 2709.09 1459.69 
SEM 10920.74 2300.48 1116.7 292.12 
p value M vs B p=1.17 E-03 N/A 
Fold 3.3 1.9 
Duox2 is expressed preferentially with higher expression in the USI of BALB/c over 
the LSI from the same mouse and almost 187 times higher expression in the USI of 
BALB/c compared to the USI of B6Min/+ (Table 5-2 and Figure 5-3).  These data show 
highly specific Duox2 expression in the USI of BALB/c strain.   
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Figure 5-3 Duox2 shows a significant increase in expression between BALB/c 
compared to corresponding segments of the B6Min/+  A 187-fold increase of Duox2 
was observed.  Standard error of the mean (SEM) indicated by error bars. 
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5.4 DISCUSSION 
Following a genome wide scan and faced with a critical challenge of identifying 
target genes from over 1,000 within our Mrip regions made thorough candidate gene 
selection a near impossible task.  We ameliorated this process by combining 
multiple techniques, namely in silico and literature search to present a final analysis 
that incorporated aspects to provide a summary outcome of high priority target 
genes.   
5.4.1 Chromosome 5 targets 
Two main-effect QTLs were identified using IM on chromosome 5.  Both showed 
highly significant associations between adenoma numbers in the USI associated with 
marker intervals at D5Mit201 and D5Mit139.  Arap2, Rcf1, Cxcl5 were selected from 
in silico.  The involvement of Rac1 (Chr5) and Tiam1 (Chr16) in radiation-induced 
multiplicity would be supported by the significant chr5:16 QTL pair interaction 
(Table 3-2) and the synergy in risk mechanism may be important for the candidate 
assessment of these genes.  In review of our study outcome, no mutations were 
found in either Rac1 or Tiam1 in the N2 ApcMin/+ or parental strains.  However, Rac1 
(Chr5) which was expressed in the both BALB/c and B6Min/+ mice plays a role in the 
Wnt pathway.  Higher Tiam1 expression was observed in the USI of B6Min/+ (p = 1.1 
E-03) when compared with BALB/c (Table 5-2) with a 3 fold increase in mRNA 
compared to USI BALB/c and a 7.8 fold increase when compared to the LSI of the 
same strain (B6Min/+).  No significant expression difference was noted for the LSI 
segment between BALB/c and B6Min/+. These data would suggest there is sufficient 
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evidence to test the hypothesis that under irradiation Tiam1 expression is up 
regulated in B6Min/+ (of the USI) which possibly correlates with the levels of Rac1, to 
act as a modifier of IR induced polyp formation.  Further support for the 
involvement of Rac1 also comes from a study that shows an inhibitory effect on 
Nox1/Nox3 both of which are abundantly expressed in the colon, (Krause et al., 
2007).  These enzymes share the capacity to transport electrons across the plasma 
membrane and to generate superoxide and other ROS in response to multiple 
processes including, hypoxia, wound healing, microbial entry, inflammation, and the 
various forms of abiotic stress similar to DUOX2.   
Sequence analysis of Arap2 confirmed 1 nsSNP change with predicted ‘possible 
damaging’ effects to the protein function and was selected as a high priority 
candidate gene.  A recent microarray analysis showed ARAP2 to be strongly up-
regulated under conditions of hydrogen peroxide (H2O2) production in SOD1 mutant 
cultured cells (Boutahar et al., 2011).  This suggests that Arap2 could be involved in 
IR-induced tumourigenesis in our model.  H2O2 formation depends greatly on the 
cellular PH level and ARAP2 contains five PH-domains which suggests a possible 
physiochemical link between Duox2 and Arap2 based on the epistasis detected 
between main effect QTL pairs; Chr2:5 (Table 3-2).  ARAP2 is involved in regulating 
cell shape and adhesion and in the presence of H2O2 and SOD1 mutation it is up-
regulated which leads to the increased microbial uptake (Gavicherla et al., 2010).  
DUOX2 plays a role in gut innate immunity by generating an oxidation-mediated 
antimicrobial response in the epithelial mucosal cell which may be impaired due to 
the mutated Arap2 and possible interactions with Duox2 leading to anti 
inflammatory response.   
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5.4.2 Chromosome 2 targets 
A single main-effects QTL was detected on chromosome 2.  QTL mapping identified a 
significant association with adenoma numbers in the USI and the D2Mit395.  The 
target genes investigated within these regions are shown in Figure 5-4.   
 
Figure 5-4 Target genes located within Mrip1 of chromosome 2.  The black 
horizontal bars represent the genetic markers with the highest LRS values against 
adenoma numbers (QTL).  Markers and target genes are displayed in red and blue, 
respectively.  Positions extracted from MPD.   
Thbs1 is reported to have some connectivity in the inflammatory response and is 
thought to be involved in the regulation of adenoma formation in the Min mouse 
model (Gutierrez et al., 2003).  Our sequencing data reveals two nsSNPS changes 
between BALB/c and B6Min/+ which are predicted to influence protein function 
 213 
(Table 5-2).  Thbs1 is strongly expressed in normal colonic epithelial cells and 
involved in the activation of the Wnt signalling pathway in intestinal epithelial cells 
(Jo et al., 2005).  Recently, Thbs1 was shown to play a role as a negative regulator in 
IBD associated angiogenesis, (Danese, 2008) and is already established as a low-
penetrance susceptibility allele in CRC (Webb et al., 2006).   
BUB1B plays a critical role in spindle checkpoint activation and deficiencies lead to a 
compromised response to DNA damage via its interaction with PARP1, mediating 
DNA damage responses via TP53 activity (Wang et al., 2004).  Bulb1b also 
demonstrates genomic instability in Min mice, and, therefore, plays a role in the 
development of adenomatous tumours (Rao et al., 2005).  A total of 6 nsSNPs were 
confirmed in our mouse model suggesting possible markers for irradiation-induced 
damage via cell cycle arrest (Table 5-2).   
Dll4 is involved in the Notch signalling pathway. In this study 2 nsSNP changes were 
confirmed, one of which was predicted to have damaging effects on the protein.  A 
recent study revealed that Dll4 is up regulated in conditions of hypoxia and 
intestinal injury and was expressed in the endothelium of colon cancers (Jubb et al., 
2009; Fox et al., 2009).   
Duox2 is a high priority candidate gene and will be discussed in more detail in the 
next chapter.  Here, we discuss some general features and ‘gene to promoter’ 
analysis in order to understand how it may be regulated.  We used the Frameworker 
utility from Genomatix; (http://www.genomatix.de/products/index.html) Genomatix 
Software GmbH, Munich, Germany) (Quandt et al., 1995) to apply comparative 
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analysis to identify gene-gene interactions and investigate alternative transcription 
elements and promoters linked to the Duox2.  Based on DNA similarities 
Frameworker analysis revealed 5 transcription factor binding sites (TFBS) elements 
to be in common by being on the same strand.   
FrameWorker was set to analyse oligo similarities based on different quorum 
constraint parameters and 66% of the input sequences had to contain the 
framework.  This showed a two promoter element model V$HEAT and V$ETSF 
where 66.5% of vertebrates have V$HEAT and 99% have V$ETSF.  ModelInspector 
used this 2 element model to detect the number of genes and or loci that share this 
complex framework and showed 88 genes/promoters from a 51,000 promoter 
sequence library scanned for DNA matches.  These genes were added to the 
bibliosphere analysis (literature datawarehouse) and the analysis was repeated 
showing only one gene Mediator complex subunit 15 (Med15) with high specificity 
to share a co-regulatory sequence in the mouse genome with Duox2.   
Med15 is located on Chr16, 9.9cM.  This is located 0.7cM distally from chromosome 
16 QTL at Prkdc (9.2cM).  The function of this gene is not so well defined in the 
intestine, but appears to play a crucial role in the regulation of transcription.  It is 
also involved in gene ‘silencing’ by promoter hypermethylation and is associated 
with nasopharyngeal carcinoma (Kwong et al., 2005).  Duox2 is also silenced by 
promoter methylated in lung cancer (Luxen et al., 2008).   Mouse Phenome Database 
(MPD) showed 5 nsSNPs in Med15 but neither were polymorphic between the 
BALB/c and B6 strains, which could suggests epigenetic mechanisms affecting the 
dysregulation of cell expression in Med15.   
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As briefly mentioned previously, Duox2 is involved in the oxidase system and plays a 
role in generation of ROS.  The DUOX2 protein is located at the apical membrane of 
the enterocytes in the brush border villa and acts as an immune barrier against 
pathogenic microbes and is believed to play a potential host defence role in IBD and 
mucosal inflammation (Rokutan et al., 2006).  It is a transmembrane glycoprotein 
with a unique N-terminal heme peroxidase-like domain which protrudes inside the 
cell as well as a membrane-spanning NADPH oxidase domain with an additional 
cytosolic segment containing two calcium-binding domains.  DUOX2 is a member of 
the NADPH oxidase (NOX) family of proteins; NOX1, 2, 3, 4 and NOX5, along with 
DUOX1 and are membrane bound proteins that generate ROS (Fischer et al., 2009).  
DUOX2 is expressed in the human colon, small intestine and duodenum, (El Hassani 
et al., 2005) and we also report significant difference in expression in BALB/c over 
B6 (Figure 5-3).  The expression of dual oxidase maturation factor 2 (DuoxA2) is 
mandatory for the translocation of Duox2 to the plasma membrane to initiate 
functional enzymatic activity (Grasberger and Refetoff, 2006) with more recent 
observations of DuoxA2 mutations affecting the type and amount of ROS response 
(Hoste et al., 2012).  Duox2 as a modifier of CRC will be discussed in the next section.   
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6. CHAPTER 6 SUMMARY AND FURTHER WORK  
In this study genotype-phenotype associations were investigated to allow detection 
of QTLs, which may harbour modifiers of IR induced polyposis in the Min mouse.  
This involved assessing the polyp multiplicity in 143 mice in response to 2Gys of 
irradiation and using numerous bioinformatics tools to identify candidate genes.   
My studies found that the majority of genes involved were linked to several 
missense polymorphisms shown to be associated with susceptibility via their 
influence on the inflammatory processes.  Bub1b and Casc5, which are involved in 
known IR response pathways such as cell cycle arrest, proliferation DNA repair 
pathways should also be followed up. In addition, I propose developing an 
understanding of the genes involved in transcriptional changes of genes involved in 
cellular shape and adhesion (Arap2), Wnt signalling targets (Rac1 and Tiam1), and 
an inflammatory associated gene (Duox2).  Expression analysis of Duox2 in BALB/c 
and B6Min/+ alongside the detection of nsSNPs by sequence analysis, identified Duox2 
as by far the ‘most likely’ candidate gene within Mrip1.  This finding will be 
discussed further here. 
I hypothesise that Duox2 is a modifier of polyp formation in the Min mouse following 
irradiation induced oxidative stress, which results in cytokine and ROS release.  As 
mentioned previously, DUOX2 is expressed throughout the colon and recently 
observed to be overexpressed in human pancreatic cell lines (Wu et al., 2011).  In 
the respiratory tract, it has been demonstrated that DUOX2-generated H2O2 kills 
bacteria in conjunction with lactoperoxidase and thiocyanate (synthesised to 
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hypothiocyanite, a bactericide). In this process, DUOX2 is induced by interferon 
gamma (IFNγ) and the killing effect is important for host defence.  More recently, a 
linkage study conducted by Esworthy and colleagues defined a region glutathione 
peroxidase (Gpx)-deficiency-associated colitis 1 (Gdac1) (Esworthy et al., 2012), 
which overlaps with Mrip1 detected by us in the USI and LI (Figure 2-8) and the QTL 
Cdcs3 detected in inbred mice treated to develop IBD (Farmer et al., 2001).  This 
places significant weight on my findings indicating a link between colitis and 
irradiation induced polyposis.  Esworthy and colleagues used a colitis mouse model 
involving resistant B6 and susceptible 129S1/SvlmJ (129) strain with double knock 
out technology to produce mice deficient in Gpx1 and Gpx2.  Using similar in silico 
techniques for gene selection and elimination they studied the gut microflora in 
ileocolitis and reported Duox2 as the most worthy of the 10 colitis associated 
candidate genes involved in the promotion of inflammation.  
DUOX2 produces H2O2 as part of the innate immune system and H2O2 is a well-
known mutagen. It appears to be associated with ROS species in the promotion of 
inflammation, which is a well-known consequence of gastrointestinal inflammation 
in IBD patients, leading to dysplasia and CRC and a common adverse reaction to IR 
exposure.  The implications of my findings and those of others suggest a connection 
between DUOX2 and inflammation, and GI toxicity caused by IR and subsequent UC-
associated dysplasia and adenoma formation.  This study of Duox2 makes it 
especially relevant for cancers induced by chronic inflammation and also IR induced 
GI damage.  Targeting DUOX2 and or DUOXA2 expression and their downstream 
targets in humans could improve the treatment phase of IBD lessening inflammatory 
symptoms, while reducing the risk of progression to cancer.  This study urges a 
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better understanding of the role of DUOX2 and the need to investigate the possibility 
of missense mutations in human populations at risk of IBD.  I propose that DUOX2 
might also be involved in the regulation of Wnt signaling in intestinal cells involving 
the B6Min/+ BC, possibly via the NOD pathway which forms part of innate immunity to 
sense microbial components derived from bacterial peptidoglycan.  NOD1 has also 
been shown to participate in host defence and mutations occur in patients of Crohn’s 
disease.  Irradiation of mouse intestinal cells carrying IR susceptibility genes 
possibly from BALB/c has allowed me to link the generation of ROS through Duox2, 
and speculate on possible cross talk between ROS and Wnt β-catenin signaling 
pathway, which is known to be responsive for polyp formation. This will require 
experimental verification. 
I also propose that oxidative DNA damage has, in part, led to the cellular 
transformation and development of adenomas in our mouse model due to the 
defective DNA repair mechanism, introduced by Prkdc of BALB/c strain.  It can be 
suggested therefore that ROS and oxidative damage induced by IR may possibly lead 
to tumour progression via enhanced Duox2 expression in BALB/c, which is 
confirmed by the high mRNA expression observed in wild type BALB/c.   
Since the completion of the present study’s experiments in 2009, advancements in 
next generation sequencing (NGS) technologies have propelled genomic medicine 
and research into a new era.  Targeted sequencing of protein coding regions (the 
functional exome) combined with the predictive power of bioinformatics tools now 
provide high resolution analysis of nsSNPs in cancer genomes.  Timmerman and 
colleagues provided the first whole exome NGS of primary colon cancers and 
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identified over 50,000 small nucleotide variations (Timmermann et al., 2010).  
Therefore, exome sequencing of specific DNA tracts will play a bigger part in 
candidate gene identification in the future (Biesecker et al., 2010).  With proof of 
concept to localise causative genes behind rare and complex disorders it is believed 
that NSG techniques will help improve the success rate of QTL to gene identification 
and the discovery of the underlying pathogenic mutation and with this information 
novel treatments can then be developed. 
6.1 Concluding remarks  
The data presented in this thesis supports the hypothesis that additional Mrip 
detected on chromosome 2 and 5 for the USI and 2 and 8 for the LI influence 
increased polyp multiplicity following IR.  The search for candidate genes has 
provided insights into the importance of oxidative stress caused by Duox2 as a 
modifier of Apcmin/+ mice and the importance of the Wnt pathway in the 
pathogenesis of IR induced adenoma progression.  Additionally, further 
interpretation of the model used here present mechanistic links between IR-induced 
GI inflammation and IBD associated CRC.   Whilst Duox2 has emerged as the most 
prominent candidate gene, other genes are worthy of further investigation.  In 
addition, it is also likely that genes underlying the Mrip QTLs are representative of 
novel loci which when mutated may cause disruption to normal development and or 
the symbiosis of the intestinal system, and may lead to tumour formation.  My study 
presents opportunities for new discoveries with the application of NGS techniques 
targeted to the regions identified by QTL mapping and epistasis analysis followed by 
appropriate functional studies. 
 220 
REFERENCE LIST 
Aaltonen, L. A., Peltomäki, P., Leach, F. S., Sistonen, P., Pylkkänen, L., Mecklin, J. P, 
Järvinen, H., Powell, S. M., Jen, J., and Hamilton, S. R. (1993). Clues to the 
pathogenesis of familial colorectal cancer. Science 260, 812-6. 
Abal, M., Obrador-Hevia, A., Janssen, K. P., Casadome, L., Menendez, M., Carpentier, S., 
Barillot, E., Wagner, M., Ansorge, W., Moeslein, G., Fsihi, H., Bezrookove, V., Reventos, 
J., Louvard, D., Capella, G., Robine, S. (2007) APC inactivation associates with 
abnormal mitosiscompletion and concomitant BUB1B/MAD2L1 up-regulation. 
Gastroenterology. 132, 2448–58. 
Abiola, O. (2003). The nature and identification of quantitative trait loci: a 
community’s view. Nat. Rev. Genet, 4, 911-916. 
Ahmadi, A., Polyak, S. and Draganov, P.V. (2009) Colorectal cancer surveillance in 
inflammatory bowel disease: the search continues. World J Gastroenterol. 15, 61-6. 
Alberici, P., de Pater, E., Cardoso, J., Bevelander, M., Molenaar, L., Jonkers, J. and 
Fodde, R. (2007). Aneuploidy arises at early stages of Apc-driven intestinal 
tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance 
between mouse and human. Am J Pathol. 170, 377-87. 
Albuquerque, C., Breukel, C., van der Luijt, R., Fidalgo, P., Lage, P., Slors, F.J., Leitão, 
C.N., Fodde, R. and Smits, R. (2002). The 'just-right' signaling model: APC somatic 
mutations are selected based on a specific level of activation of the beta-catenin 
signaling cascade. Hum Mol Genet. 11, 1549-60. 
Alexander, D. D., Weed, D. L., Cushing, C. A. and Lowe K. A. (2011). Meta-analysis of 
prospective studies of red meat consumption and colorectal cancer. Eur J Cancer 
Prev. 4, 293-307 
Al-Tassan N., Chmiel N. H., Maynard J., Fleming N., Livingston A. L., Williams G. T., 
Hodges A. K., Davies D. R., David S. S., Sampson J. R. and Cheadle J. P. (2002). 
 221 
Inherited variants of MYH associated with somatic G:C>T:A mutations in colorectal 
tumors. Nat. Genet. 30, 227–232. 
Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W. and Lipman, 
D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database 
search programs. Nucleic Acids Res. 25, 3389-402. 
Andreyev, H. J., Vlavianos, P., Blake, P., Dearnaley, D., Norman, A. R., Tait, D. (2005). 
Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist? 
Int J Radiat Oncol Biol Phys. 62, 1464-71. 
Andreyev, H. J. ( 2007). Gastrointestinal problems after pelvic radiotherapy: the past, 
the present and the future. Clin Oncol. 19, 790-9. 
Aretz, S., Uhlhaas, S., Goergens, H., Siberg, K., Vogel, M., Pagenstecher, C., Mangold, E., 
Caspari, R., Propping, P., Friedl, W. (2006). MUTYH-associated polyposis: 70 of 71 
patients with biallelic mutations present with an attenuated or atypical phenotype. 
Int J Cancer. 119, 807-14. 
Bailey, S. M., Meyne, J., Chen, D. J., Kurimasa, A., Li, G. C., Lehnert, B. E., Goodwin, E. H. 
(1999). DNA double-strand break repair proteins are required to cap the ends of 
mammalian chromosomes. Proc Natl Acad Sci U S A. 21, 14899-904. 
Balkwill, F. and Mantovani, A. (2001). Inflammation and cancer: back to Virchow? 
Lancet. 17, 539-45. 
Balmain, A. (2002). Cancer as a complex genetic trait: tumor susceptibility in 
humans and mouse models. Cell. 108, 145–152. 
Baran, A., Silverman, K., Zeskand, J., Koratkar, R., Palmer, A., McCullen, K., Curran, J. 
C., Bocker, T., Siracusa, L. and Buchberg, A. M. (2007). The modifier of Min 2 (Mom2) 
locus: Embryonic lethality of a mutation in the Atp5a1 gene suggests a novel 
mechanism of polyp suppression. Genome Res. 17, 566-576. 
Barker, N., van Es J, Kuipers, J., Kujalam P, van den Born M., Cozijnsen, M, et al.  
(2007).  Identification of stem cells in small intestine and colon by marker gene Lgr5.  
Nature. 449, 1003-07. 
 222 
Barker, N., Clevers, H. (2012). Leucine-Rich Repeat-Containing G-Protein-Coupled 
Receptors as Markers of Adult Stem Cells. Gastroenterology. 138, 1681–96. 
Barton, N. H. and Keightley, P. D. (2002). Understanding quantitative genetic 
variation. Nat Rev Genet. 1, 11-21. 
Bassaganya-Riera, J., Viladomiu, M., Pedragosa, M., De Simone, C. and Hontecillas, R. 
(2012). Immunoregulatory mechanisms underlying prevention of colitis-associated 
colorectal cancer by probiotic bacteria. PLoS One.7(4). 
Basten ,C. J., Weir, B. S., Zeng, Z. B., (1994). Zmap–a QTL cartographer. In Proceedings 
of the 5th World Congress on Genetics Applied to Livestock Production: Computing 
Strategies and Software, edited by C. Smith, J. S. Gavora, B. Benkel, J. Chesnais, W. 
Fairfull, J. P. Gibson, B. W. Kennedy and E. B. Burnside. 22, 65-66. Published by the 
Organizing Committee, 5th World Congress on Genetics Applied to Livestock 
Production, Guelph, Ontario, Canada. 
Basten, C. J., Weir, B. S. and Zeng, Z. B. (2004). QTL Cartographer, Version 1.17. 
Departmentof Statistics, North Carolina State University, Raleigh, NC. 
Bateson, W., Saunders, E. R. and Punnett, R. C. (1906). Experimental studies in the 
physiology of heredity. Reports to the Evolution Committee, Royal Society of 
London. 3. 
Baum, L. E., Petrie, T., Soules, G. and Weiss, N. (1970). A maximization technique 
occurring in the statistical analysis of probabilistic functions of Markov chains. Ann. 
Math. Statist.. 41, 164–171. 
Baxter, N. N., Tepper, J. E., Durham, S. B., Rothenberger, D. A., Virnig, B. A. (2005). 
Increased risk of rectal cancer after prostate radiation: a population-based study. 
Gastroenterology. 128, 819-24. 
Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., Issa, J. P. (1998). Alterations in 
DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 72, 141–196. 
 223 
Beazer-Barclay, Y., Levy, D. B., Moser, A. R., Dove, W. F., Hamilton, S. R., Vogelstein, B., 
Kinzler, K. W. (1996). Sulindac suppresses tumorigenesis in the Min mouse. 
Carcinogenesis. 17, 1757-60. 
Bedard, K., and Krause, K. H. (2007) The NOX family of ROS-generating NADPH 
oxidases: physiology and pathophysiology. Physiol Rev 87: 245–313. 
Bedell, M. A., Jenkins, N. A. and Copeland, N. G. (1997). Mouse models of human 
disease. Part I: techniques and resources for genetic analysis in mice. Genes Dev. 11, 
1-10. 
Behrens, J. (2005). The role of the Wnt signalling pathway in colorectal 
tumorigenesis. Biochem. Soc. Trans. 33, 672-675. 
BEIR V, Biological Effects of Ionising Radiation. (1990). Health Effects of Exposure to 
low levels if ionizing radiation.  National Academy Press, ISBN-13: 978-0-309-
07358-5 
Béroud, C. and Soussi, T. (1996). APC gene: database of germline and somatic 
mutations in human tumors and cell lines. Nucleic Acids Res. 24, 121-4. 
Bertario, L., Russo, A., Sala, P., Varesco, L., Giarola, M., Mondini, P., Pierotti, M., 
Spinelli, P. and Radice, P. (2003). Multiple approach to the exploration of genotype-
phenotype correlations in familial adenomatous polyposis. J Clin Oncol. 21, 1698–
707. 
Bhandari, S., Sinha, A. and Clark, S. A. (2011). Evaluation of management of desmoids 
tumours associated with familial adenomatous polyposis in Dutch patients. Br J 
Cancer. 104, 1236. 
Bienz, M. and Clevers, H. (2000). Linking colorectal cancer to Wnt signaling. Cell 103, 
311-320. 
Biesecker, L. G. (2010). Exome sequencing makes medical genomics a reality. Nat 
Genet. 42, 13–14. 
 224 
Bodmer, W. F., Bailey, C. J., Bodmer, J., Bussey, H. J., Ellis, A., Gorman, P., Lucibello, F. 
C., Murday, V. A., Rider, S. H. and Scambler, P. (1987). Localization of the gene for 
familial adenomatous polyposis on chromosome 5. Nature. 328, 614-616. 
Boer, M. P., Ter Braak, C. J., Jansen, R. C. (2002). A penalized likelihood method for 
mapping epistatic quantitative trait loci with one-dimensional genome searches. 
Genetics. 162, 951-60. 
Boone, C., Bussey, H. and Andrews, B. J. (2007). Exploring genetic interactions and 
networks with yeast. Nat Rev Genet. 8, 437-49. 
Bourne, R. G., Kearsley, J. H., Grove, W. D., Roberts, S. J. (1983). The relationship 
between early and late gastrointestinal complications of radiation therapy for 
carcinoma of the cervix. International Journal of Radiation Oncology * Biology * 
Physics. 10, 1445-50 
Boutahar, N., Wierinckx, A., Camdessanche, J. P., Antoine, J. C., Reynaud, E., 
Lassabliere, F., Lachuer, J. and Borg, J. (2011). Differential effect of oxidative or 
excitotoxic stress on the transcriptional profile of amyotrophic lateral sclerosis-
linked mutant SOD1 cultured neurons. J Neurosci Res. 89, 1439-50. 
Brenner , D. J. (2010) Should we be concerned about the rapid increase in CT usage? 
Rev Environ Health. 25, 63-8. 
Brenner, D. J., Doll, R., Goodhead, D. T., Hall, E. J., Land, C. E., Little, J. B., Lubin, J. H., 
Preston, D. L., Preston, R. J., Puskin, J. S., Ron, E., Sachs, R. K., Samet, J. M., Setlow, R. B. 
and Zaider, M. (2003). Cancer risks attributable to low doses of ionizing radiation: 
assessing what we really know. Proc Natl Acad Sci U S A. 100, 13761-6. 
Broman, K. W., Wu, H., Sen, Ś. and Churchill, G. A. (2003). R/qtl: QTL mapping in 
experimental crosses. Bioinformatics. 19, 889-890. 
Bujanda, L., Cosme, A., Gil, I. and Arenas-Mirave, J. I. (2010). Malignant colorectal 
polyps. World J. Gastroenterol. 16, 3103-3111. 
Buongiorno, P., Pethe, V. V., Charames, G. S., Esufali, S. and Bapat, B. (2008). Rac1 
GTPase and the Rac1 exchange factor Tiam1 associate with Wnt-responsive 
 225 
promoters to enhance beta-catenin/TCF-dependent transcription in colorectal 
cancer cells. Mol Cancer. 7, 73. 
Burgess-Herbert, S. L., Cox, A., Tsaih, S. W. and Paigen, B. (2008). Practical 
applications of the bioinformatics toolbox for narrowing quantitative trait loci.  
Genetics. 180, 2227-35. 
Butcher, D. T. and Rodenhiser, D. I. (2007). Epigenetic inactivation of BRCA1 is 
associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) 
in some sporadic breast tumours. Eur. J. Cancer 43, 210-219. 
Caldwell, C. M., Green, R. A., Kaplan, K. B. (2007). APC mutations lead to cytokinetic 
failures in vitro and tetraploid genotypes in Min mice. J Cell Biol. 178, 1109-20. 
Calvanese, V., Lara, E., Kahn, A., Fraga,M. F. (2009). The role of epigenetics in aging 
and age-related diseases. Ageing Res. Rev. 8, 268-276. 
Cancer Research UK CancerStats Incidence 2008 – UK April (2011). 
Carlborg, Ö., Andersson, L. and Kinghorn,B. (2000). The use of a genetic algorithm 
for simultaneous mapping of multiple interacting quantitative trait loci. Genetics, 
155, 2003–2010. 
Carter, J. H., Douglass, L. E., Deddens, J. A., Colligan, B. M., Bhatt, T. R., Pemberton, J. 
O., Konicek, S., Hom, J., Marshall, M. and Graff, J. R. (2004). Pak-1 expression 
increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res. 
10, 3448–3456. 
Cerrotta, A., Gardani, G., Lozza, L., Kenda, R., Tana, S., Valvo, F. and Zucali, R. (1995). 
Ileal obstruction following radiosurgical treatment for rectosigmoid neoplasm. 
Radiol Med. 89,643-6. 
Chakravarti, A. (2001). Single nucleotide polymorphisms: to a future of genetic 
medicine. Nature 409, 822-823. 
 226 
Chasman, D. and Adams, R. M. (2001). Predicting the functional consequences of 
non-synonymous single nucleotide polymorphisms: Structure-based assessment of 
amino acid variation. J Mol Biol 307, 683–706. 
Chell, S., Patsos, H. A., Qualtrough, D., Zadeh, A. M., Hicks, D. J., Kaidi, A., Witherden, 
I.R., Williams, A. C., Paraskeva, C. (2005). Prospects in NSAID-derived 
chemoprevention of colorectal cancer. Biochem. Soc. Trans. 33, 667-671. 
Chen, H. M., Fang, J. Y. (2009). Genetics of the hamartomatous polyposis syndromes: 
a molecular review. Int J Colorectal Dis. 8,865-74. 
Chiu, C. H, McEntee, M. F, Whelan, J. (1997). Sulindac causes rapid regression of 
preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. 
Cancer Res. 57, 4267–4273. 
Cho, K. H., Lee, C. K., Levitt, S. H. (1995). Proctitis after conventional external 
radiation therapy for prostate cancer: importance of minimizing posterior rectal 
dose. Radiology. 3, 699-703. 
Churchill, G. A., and Doerge, R. W. (1994). Empirical threshold values for quantitative 
trait mapping.  Genetics 138, 963-971. 
Clark, A., and Wang, L. (1997). Epistasis in measured genotypes: Drosophila P-
element insertions. Genetics, 147, 157–63. 
Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127, 
469-480. 
Colnot, S., Niwa-Kawakita, M., Hamard, G., Godard, C., Le Plenier, S., Houbron, C., 
Romagnolo, B., Berrebi, D., Giovannini, M., Perret, C. (2004). Colorectal cancers in a 
new mouse model of familial adenomatous polyposis: influence of genetic and 
environmental modifiers, Lab. Invest. 84, 1619–1630. 
Cordell, H. J. (2002). Epistasis: what it means, what it doesn't mean, and statistical 
methods to detect it in humans.  Hum Mol Genet. 11, 2463-8. 
 227 
Cordell, H. J. (2009). Detecting gene-gene interactions that underlie human diseases. 
Nat Rev Genet. 6, 392-404. 
Cormier, T., Bilger, A., Lillich, A., Halberg, R., Hong, K., Gould, K., Borenstein, N., 
Lander, E., Dove, W. (2000). The Mom1AKR intestinal tumor resistance region 
consists of Pla2g2a and a locus distal to D4Mit64. Oncogene 19, 3182-3192. 
Danese, S. (2008). Negative regulators of angiogenesis in inflammatory bowel 
disease: thrombospondin in the spotlight. Pathobiology. 75, 22-4. 
Darvasi, A. (2001). In Silico Mapping of Mouse Quantitative Trait Loci, Science, . 
294,.2424– 2426. 
Dean, M,. Fojo, T., Batesman S. (2005). Tumour stem cells and drug resistance. Nat 
Rev Cancer. 5, 275-84. 
De Belle, J. S. and Heisenberg, M. (1996). Expression of Drosophila mushroom body 
mutations in alternative genetic backgrounds: a case study of the mushroom body 
miniature gene (mbm). Proc. Natl. Acad. Sci. U S A. 93, 9875–9880. 
de la Chapelle, A. (2004). Genetic predisposition to colorectal cancer.  Nat Rev 
Cancer. 4; 769-80 
De Filippo, C., Luceri, C., Caderni, G., Pacini, M., Messerini, L., Biggeri, A., Mini, E., 
Tonelli, F., Cianchi, F. and Dolara, P. (2002). Mutations of the APC gene in human 
sporadic colorectal cancers. Scand. J. Gastroenterol. 37, 1048–1053. 
Debinski, H. S., Love, S., Spigelman, A. D. and Phillips, R. K. (1996). Colorectal polyp 
counts and cancer risk in familial adenomatous polyposis. Gastroenterology 110, 
1028-30. 
DeBry, R. W. and Seldin, M. F. (1996). Human/mouse homology relationships. 
Genomics. 33, 337-51. 
Degg, N. L., Weil, M. M., Edwards, A., Haines, J., Coster, M., Moody, J., Ellender, M., Cox, 
R. and Silver, A. (2003). Adenoma multiplicity in irradiated ApcMin mice is modified 
by chromosome 16 segments from Balb/c. Cancer Res. 63, 2361-2363. 
 228 
Demant, P. (2003). Cancer susceptibility in the mouse: genetics biology and 
implications for human cancer.  Nat Rev Genet. 4, 721-734. 
Dermitzakis, E. T., Reymond, A., Lyle, R., Scamuffa. N., Ucla, C., Deutsch, S., Stevenson, 
B. J., Flegel, V., Bucher, P., Jongeneel, C. V. and Antonarakis, S. E. (2002). Numerous 
potentially functional but non-genic conserved sequences on human chromosome 
21. Nature. 420, 578–582. 
Dietrich, W. F., Lander, E. S., Smith, J. S., Moser, A. R., Gould, K. A., Luongo, C., 
Borenstein, N. and Dove, W. F. (1993). Genetic identification of Mom-1, a major 
modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell, 75, 631-
639. 
Dietrich, W. F., Miller, J., Steen, R., Merchant, M. A., Damron-Boles, D., Husain, Z., 
Dredge ,R., Daly, M. J., Ingalls, K. A and O’Connor, T. J. (1996). A  comprehensive 
genetic map of the mouse genome. Nature (Lond) 380, 149–152. 
Dimberg, J., Dienus, O., Lofgren, S., Hugander, A., Wagsater, D. (2007). Expression and 
gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients. Int J 
Oncol. 31, 97–102. 
DiPetrillo, K., Wang, X., Stylianou, I. M. and Paigen, B. (2005). Bioinformatics toolbox 
for narrowing rodent quantitative trait loci. Trends Genet. 12, 683-92. 
Dirisina, R., Katzman, R. B., Goretsky, T., Managlia, E., Mittal, N., Williams, D. B., Qiu, 
W., Yu, J., Chandel, N. S., Zhang, L. and Barrett, T. A. (2011). p53 and PUMA 
independently regulate apoptosis of intestinal epithelial cells in patients and mice 
with colitis. Gastroenterology. 141, 1036-45. 
Dobbie, Z., Heinimann, K., Bishop, D. T., Muller, H. and Scott, R. J. (1997). 
Identification of a modifier gene locus on chromosome 1p35-36 in familial 
adenomatous polyposis. Hum. Genet. 99, 653-657. 
Dragani, T. A. (2003). 10 years of mouse cancer modifier loci: human relevance. 
Cancer Res. 63, 3011–3018. 
 229 
Drayton, M. and Noben-Trauth, K. (2006). Mapping quantitative trait loci for hearing 
loss in Black Swiss mice. Hear Res. 212, 128-39. 
Dryja, T. P., Friend, S. and Weinberg, R. A. (1986). Genetic sequences that predispose 
to retinoblastoma and osteosarcoma. Symp Fundam Cancer Res. 39, 115-9. 
Duff, E. K. and Clarke, A. R. (1998). Smad4 (DPC4)-a potent tumour suppressor? Br J 
Cancer. 78, 1615-9. 
Dunlop, M. G., Dobbins, S. E., Farrington, S. M., Jones, A. M., Palles, C., Whiffin, N., 
Tenesa, A., Spain, S., Broderick, P., Ooi, L. Y., Domingo, E., Smillie, C., Henrion, M., 
Frampton, M., Martin, L., Grimes, G., Gorman, M., Semple, C., Ma, Y. P., Barclay, E., 
Prendergast, J., Cazier, J. B., Olver, B., Penegar, S., Lubbe, S., Chander, I., Carvajal-
Carmona, L. G., Ballereau, S., Lloyd, A., Vijayakrishnan, J., Zgaga, L., Rudan, I., 
Theodoratou, E.; Colorectal Tumour Gene Identification (CORGI) Consortium, Starr, 
J. M., Deary, I., Kirac, I., Kovacević, D., Aaltonen, L. A., Renkonen-Sinisalo, L., Mecklin, 
J. P., Matsuda, K., Nakamura, Y., Okada, Y., Gallinger, S., Duggan, D. J., Conti, D., 
Newcomb, P., Hopper, J., Jenkins, M. A., Schumacher, F., Casey, G., Easton, D., Shah, M., 
Pharoah, P., Lindblom, A., Liu, T.; Swedish Low-Risk Colorectal Cancer Study Group, 
Smith, C. G., West, H., Cheadle, J. P.; COIN Collaborative Group, Midgley, R., Kerr, D. J., 
Campbell, H., Tomlinson, I. P., Houlston, R. S. (2012). Common variation near 
CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet. 44, 
770-6. 
Dupuis, J., Brown, P. O. and Siegmund, D. (1995). Statistical methods for linkage 
analysis of complex traits from high-resolution maps of identity by descent. Genetics 
140, 843-56. 
East, E. M. (1910). A Mendelian interpretation of variation that is apparently 
continuous. Am. Nat. 44, 65–82. 
Efron, B. and Tibshirani, R. J. (1993). An introduction to the bootstrap. Monographs 
on Statistics and Applied Probability, 57. Chapman and Hall, New York. ISBN: 0-412-
04231-2. 
 230 
El Hassani, R. A., Benfares, N., Caillou, B., Talbot, M., Sabourin, J. C., Belotte, V., 
Morand, S., Gnidehou, S., Agnandji, D., Ohayon, R., Kaniewski, J., Noël-Hudson, M. S., 
Bidart, J. M., Schlumberger, M., Virion, A. and Dupuy, C. (2005). Dual oxidase2 is 
expressed all along the digestive tract. Am J Physiol Gastrointest Liver Physiol. 288, 
933-42. 
Esufali, S. and Bapat, B. (2004). Cross-talk between Rac1 GTPase and dysregulated 
Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-
mediated transcriptional activation. Oncogene. 23, 8260-71. 
Esworthy, R. S., Kim, B. W., Rivas, G. E., Leto, T. L., Doroshow, J. H., Chu, F. F. (2012). 
Analysis of candidate colitis genes in the Gdac1 locus of mice deficient in glutathione 
peroxidase-1 and -2. PLoS One. 7, e44262.  
Farmer, M. A., Sundberg, J. P., Bristol, I. J., Churchill, G. A., Li, R., Elson, C. O. and Leiter, 
E. H. (2001). A major quantitative trait locus on chromosome 3 controls colitis 
severity in IL-10- deficient mice. Proc Natl Acad Sci U S A. 98, 13820–13825. 
Farrington, S. M., Tenesa, A., Barnetson, R., Wiltshire, A., Pren-dergast, J., Porteous, 
M., Campbell, H. and Dunlop, M. G. (2005). Germline susceptibility to colorectal 
cancer due to base-excision repair gene defects. Am. J. Hum. Genet. 77, 112–119. 
Fearnhead, N. S., Britton, M. P. and Bodmer, W. F. (2001). The ABC of APC. Hum. Mol. 
Genet. 10, 721-733. 
Fearon, E. R. and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. 
Cell. 61, 759-767. 
Fearon, E. R., Hamilton, S. R. and Vogelstein, B. (1987). Clonal analysis of human 
colorectal tumors. Science. 238, 193-197. 
Feldser, D. M., Hackett, J. A., Greider, C. W. (2003). Telomere dysfunction and the 
initiation of genome instability. Nat. Rev. Cancer. 3, 623-627. 
Fijneman, R.J. de Vries. S. S., Jansen, R.C. and Demant P. (1996). Complex interactions 
of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the 
susceptibility to lung cancer in the mouse. Nat. Genet. 14, 465–467. 
 231 
Fischer, H. (2009). Mechanisms and Functions of Duox in Epithelia of the lung. 
Antioxid. Redox Signal. 11, 2453–2465. 
Fisher, R., Pusztai, L., Swanton, C. (2013).  Cancer heterogeneity: implications for 
targeted therapeutics. Br J Cancer. 108, 479-85. 
Flint, J., Valdar, W., Shifman, S. and Mott, R. (2005). Strategies for mapping and 
cloning quantitative trait genes in rodents. Nature Reviews Genetics. 6, 271-286. 
Flint, J.and Mackay, T. F. (2009). Genetic architecture of quantitative traits in mice, 
flies, and humans. Genome Res. 19, 723-33. 
Fodde, R., Edelmann, W., Yang, K., van Leeuwen, C., Carlson, C., Renault, B., Breukel, 
C., Alt, E., Lipkin, M. and Khan,P. M. (1994). A targeted chain termination mutation in 
the mouse Apc gene results in multiple intestinal tumors, Proc. Natl. Acad. Sci. U S A 
91, 8969–8973. 
Fodde, R.and Smits, R. (2002). Cancer biology: A matter of dosage. Science 298, 761–
763. 
Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Semin 
Oncol. 29, 15–18. 
Followill, D. S., Kester, D. and Travis, E. L. (1993). Histological changes in mouse 
colon after single- and split-dose irradiation. Radiat Res. 136, 280-8. 
Fox, S. B.and Harris, A. L. (2009) Expression of delta-like ligand 4 (Dll4) and markers 
of hypoxia in colon cancer. Br J Cancer. 101, 1749-57. 
French, J. E., Lacks, G. D., Trempus, C., Dunnick, J. K., Foley, J., Mahler, J., Tice, R. R., 
Tennant, R. W. (2001). Loss of heterozygosity frequency at the Trp53 locus in p53-
deficient (+/−) mouse tumors is carcinogen-and tissue-dependent. Carcinogenesis. 
22, 99–106 
Fridrichova, I. (2006). New aspects in molecular diagnosis of Lynch syndrome 
(HNPCC). Cancer Biomark. 2, 37-49. 
 232 
Friedl, W., Caspari, R., Sengteller, M., Uhlhaas, S. L. C., Jungck, M., Kadmon, M., Wolf, 
M., Fahnenstich, J., Gebert, J., Möslein, G., Mangold, E. and Propping, P. (2001). Can 
APC mutation analysis contribute to therapeutic decisions in familial adenomatous 
polyposis? Experience from 680 FAP families. Gut. 48, 515-21. 
Friend, S. H., Bernards, R., Rogelj, S., Weinberg,.R. A., Rapaport, J. M., Albert, D. M., 
Dryja, T. P. (1986). A human DNA segment with properties of the gene that 
predisposes to retinoblastoma and osteosarcoma. Nature. 323, 643-646. 
Frush, D. P., Goske, M. J. and Hernanz-Schulman, M. (2008). Computed tomography 
and radiation exposure. N Engl J Med. 358,851. 
Fuchs, C. S., Giovannucci, E. L., Colditz, G. A., Hunter, D. J., Speizer, F. E. and Willett, W. 
C. (1994). A prospective study of family history and the risk of colorectal cancer. N 
Engl J Med. 331, 1669-74. 
Fulker, D. W., Cherny, S. S., Cardon, L. R. (1995). Multipoint interval mapping of 
quantitative trait loci, using sib pairs. Am J Hum Genet. 5, 1224–1233. 
Galton, F. (1869). Hereditary Genius. London. Macmillan. 
Galton, F. (1889). Natural Inheritance London. Macmillan & Co 
Galvan, A., Colombo, F., Noci, S., Pazzaglia, S., Mancuso, M., Manenti, G., Broman, K. 
W., Saran, A., Dragani, T. A. (2012). The Lsktm1 locus modulates lung and skin 
tumorigenesis in the mouse. G3 (Bethesda).  2, 1041-6.  
Gavicherla, B., Ritchey, L., Gianfelice, A., Kolokoltsov, A. A., Davey, R. A. and Ireton, K. 
(2010). Critical role for the host GTPase-activating protein ARAP2 in InlB-mediated 
entry of Listeria monocytogenes.Infect Immun. 78, 4532-41. 
Gerlai, R. (1996). Gene-targeting studies of mammalian behaviour: is it the mutation 
or the background genotype? Trends Neurosci. 19, 177–181. 
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, 
Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, 
Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-
 233 
Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, 
Swanton C. (2012). Intratumor heterogeneity and branched evolution revealed by 
multiregion sequencing.Engl J Med. 366, 883-92. 
Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G. M., 
Booker, S. V., Cruz-Correa, M. and Offerhaus, J. A. (2000). Very high risk of cancer in 
familial Peutz-Jeghers syndrome. Gastroenterology. 119, 1447-53. 
Giles, R. H., Van Es, J. H. and Clevers, H. (2003). Caught up in a Wnt storm: Wnt 
signaling in cancer. Biochim. Biophys. Acta. 1653, 1-24. 
Gillen, C. D., Walmsley, R. S., Prior, P., Andrews, H. A. and Allan, R. N. (1994). 
Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in 
extensive colitis. Gut. 35, 1590-2. 
Gitton, Y., Dahmane, N., Baik, S., Ruiz, I., Altaba, A., Neidhardt, L., Scholze, M., 
Herrmann, B. G., Kahlem, P., Benkahla, A., Schrinner, S., Yildirimman, R., Herwig, R., 
Lehrach, H., Yaspo, M. L. (2002). HSA21 expression map initiative. A gene expression 
map of human chromosome 21 orthologues in the mouse. Nature. 420, 586-90. 
Goffinet, B. and Gerber, S. (2000). Quantitative trait loci: a meta-analysis. Genetics. 
155, 463-73. 
Good, P. (2005). Permutation, Parametric, and Bootstrap Tests of Hypotheses 
(Springer Series in Statistics). Springer ISBN 0-387-20279-X 
Gould, K. A., Dietrich, W. F., Borenstein, N., Lander, E. S. and Dove, W. F. (1996a). 
Mom1 is a semi-dominant modifier of intestinal adenoma size and multiplicity in 
Min/+ mice. Genetics. 144, 1769-76. 
Gould, K. A., Luongo, C., Moser, A. R., McNeley, M. K., Borenstein, N., Shedlovsky, A., 
Dove, W. F., Hong, K., Dietrich, W. F. and Lander, E. S. (1996b). Genetic evaluation of 
candidate genes for the Mom1 modifier of intestinal neoplasia in mice. Genetics. 144, 
1777-85. 
Grady, W. M. and Carethers, J. M. (2008). Genomic and epigenetic instability in 
colorectal cancer pathogenesis. Gastroenterology. 135, 1079-99. 
 234 
Grady, W. M. (2004). Genomic instability and colon cancer. Cancer Metastasis Rev. 
23, 11-27. 
Grady, W. M., Rajput, A., Myeroff, L., Liu, D. F., Kwon, K., Willis, J. and Markowitz, S. 
(1998). Cancer Res. 58, 3101-3104. 
Grady, W. M., Willis, J., Guilford, P. J., Dunbier, A. K., Toro, T. T., Lynch, H., Wiesner, G., 
Ferguson, K., Eng, C., Park, J. G., Kim, S. J., Markowitz, S. (2000). Methylation of the 
CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat. 
Genet. 26, 16-17. 
Grantham, R. (1974). Amino acid difference formula to help explain protein 
evolution. Science. 185, 862–864. 
Grasberger, H. and Refetoff, S. (2006). Identification of a maturation factor for dual 
oxidase. J. Biol. Chem. 281, 18269–18272. 
Groden, J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L., Albertsen, H., Joslyn, G., 
Stevens, J., Spirio, L., Robertson, M., Sargeant, L., Krapcho, K., Wolff, E., Burt, R., 
Hughes, J.P., Warrington, J., McPherson, J., Wasmuth, J., Le Paslier, D., Abderrahim, H., 
Cohen, D., Leppert, M.  and White R. (1991). Identification and characterization of 
the familial adenomatous polyposis coli gene. Cell. 66, 589-600. 
Grohmann, A., Tanneberger, K., Alzner, A., Schneikert, J. and Behrens, J. (2007). 
AMER1 regulates the distribution of the tumor suppressor APC between 
microtubules and the plasma membrane. J. Cell Sci. 120, 3738-3747. 
Groves, C., Lamlum, H., Crabtree, M., Williamson, J., Taylor, C., Bass, S., Cuthbert-
Heavens, D., Hodgson, S., Phillips, R. and Tomlinson, I. (2002). Mutation cluster 
region, association between germline and somatic mutations and genotype-
phenotype correlation in upper gastrointestinal familial adenomatous polyposis. Am 
J Pathol. 160, 2055-61. 
Grubb, S. C., Maddatu, T. P., Bult, C. J. and Bogue, M. A. (2009). Mouse phenome 
database. Nucleic Acids Res. 37(Database). D720-30. 
 235 
Grupe, A., Germer, S., Usuka, J., Aud, D., Belknap, J. K., Klein, R. F., Ahluwalia, M. K., 
Higuchi, R. and Peltz, G. (2001). In silico mapping of complex disease-related traits in 
mice. Science. 292, 1915-8. 
Guarner, F. (1998).  Prebiotics in inflammatory bowel diseases. Br J Nutr. 98, 85-9. 
Gurganus, M.C., Nuzhdin, S.V., Leips, J.W. and Mackay, T.F. (1999). High-resolution 
mapping of quantitative trait loci for sternopleural bristle number in Drosophila 
melanogaster. Genetics. 152, 1585–1604 
Gutierrez, L. S., Suckow, M., Lawler, J., Ploplis, V. A. and Castellino, F, J. (2003). 
Thrombospondin 1-A regulator of adenoma growth and carcinoma progression in 
the APC(Min/+) mouse model. Carcinogenesis. 24, 199-207 
Hackett, J.A., Feldser,D.M., and Greider,C.W. (2001). Telomere dysfunction increases 
mutation rate and genomic instability. Cell. 106, 275-286. 
Haines, J., Dunford, R., Moody, J., Ellender, M., Cox, R. and Silver, A. (2000). Loss of 
Heterozygosity in Spontaneous and X-Ray–Induced Intestinal Tumors Arising in F1 
Hybrid Min Mice: Evidence for Sequential Loss of Apc1 and Dpc4 in Tumor 
Development. Genes Chromosomes Cancer. 28, 387–394 
Haines, J., Johnson, V., Pack, K., Suraweera, N., Slijepcevic, P., Cabuy, E., Coster M., 
Ilyas, M., Wilding, J., Sieber, O., Bodmer, W., Tomlinson, I., and Silver A. (2005). 
Genetic basis of variation in adenoma multiplicity in ApcMin/+ Mom1s mice. PNAS, 
102: 2868-2873, 
Halberg, R. B., Katzung, D. S., Hoff, P. D., Moser, A. R., Cole, C. E., Lubet, R. A., 
Donehower, L. A., Jacoby, R. F. and Dove, W. F. (2000). Tumorigenesis in the multiple 
intestinal neoplasia mouse: redundancy of negative regulators and specificity of 
modifiers. Proc Natl Acad Sci U S A. 97, 3461-6. 
Halfvarson, J., Bodin, L., Tysk, C., Lindberg, E. and Järnerot G. (2003). Inflammatory 
bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and 
clinical characteristics. Gastroenterology. 124, 1767-73. 
 236 
Hall, E.J. and Wu, C.S. (2003). Radiation-induced second cancers: the impact of 3D-
CRT and IMRT. Int J Radiat Oncol Biol Phys. 56,83-8. 
Hall, E.J. (2006). Intensity-modulated radiation therapy, protons and the risk of 
second cancers. Int. J. Radiation Oncology Biol. Phys. 65, 1–7. 
Halperin, E.C. (2009). Randomized prospective trials of innovative radiotherapy 
technology are necessary. J Am Coll Radiol. 6, 33-7. 
Hamada, H., Petrino, M. G., Kakunaga, T., Seidman, M. and Stollar, B. D. (1984). 
Characterization of genomic poly(dT-dG) l poly(dC-dA) sequences: ‘structure, 
organization and conformation. Mol. Cell. Biol. 4, 2610-21. 
Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Hanauer, S. B. (1996). Inflammatory bowel disease. N Engl J Med. 334, 841-8. 
Hanks, S., Coleman, K., Reid, S., Plaja, A., Firth, H., Fitzpatrick, D., Kidd, A., Méhes, K., 
Nash, R., Robin, N., Shannon, N., Tolmie, J., Swansbury, J., Irrthum, A., Douglas, J. and 
Rahman, N. (2004).  Constitutional aneuploidy and cancer predisposition caused by 
biallelic mutations in BUB1B.  Nat Genet. 36, 1159-61. 
Harper, J. W. and Elledge, S. J. (2007) The DNA damage response: ten years after. Mol 
Cell. 28, 739-45. 
Harvey, J. J. (1964). An unidentified virus which causes the rapid production of 
tumours in mice. Nature. 204, 1104–5. 
Hashiguchi, K., Matsumoto, Y., Yasui, A. (2007) Recruitment of DNA repair synthesis 
machinery to sites of DNA damage/repair in living human cells. Nucleic Acids Res. 
35, 2913–23. 
Haston, C.K., Zhou, X., Gumbiner-Russo, L., Irani, R., Dejournett, R., Gu, X., Weil, M., 
Amos, C.I. and Travis, E.L.  (2002). Universal and Radiation-specific Loci Influence 
Murine Susceptibility to Radiation-induced Pulmonary Fibrosis Cancer Res. 
62:3782-3788. 
 237 
He, X. C., Zhang, J., Tong, W. G., Tawfik, O., Ross, J., Scoville, D. H., Tian, Q., Zeng, X.,  He, 
X., Wiedemann, L. M., Mishina Y. and Li, L. (2004). BMP signaling inhibits intestinal 
stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet. 
36, 1117-21. 
Hedrick, L., Cho, K.R., Fearon, E.R., Wu,T.C., Kinzler, K.W. and Vogelstein, B. (1994). 
The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes 
Dev. 8, 1174-83. 
Heldin, C.H., Miyazono, K. and Dijke, P. (1997). TGF-beta signalling from cell 
membrane to nucleus through SMAD proteins. Nature. 390, 465-71. 
Helentjaris, T., Weber, D. F., Wright, S. (1986). Use of monosomics to map cloned 
DNA fragments in maize.  Proc Natl Acad Sci U S A. 83, 6035–6039. 
Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell, G., 
Warren, W., Aminoff, M., Höglund P., Järvinen, H., Kristo, P., Pelin, K., Ridanpää, M., 
Salovaara, R., Toro, T., Bodmer, W., Olschwang, S., Olsen, A.S., Stratton, M.R., de la 
Chapelle, A. and Aaltonen, L.A. (1998). A serine/threonine kinase gene defective in 
Peutz-Jeghers syndrome.Nature. 391, 184-7. 
Herman, J. G. and Baylin, S. B. (2003). Gene silencing in cancer in association with 
promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054. 
Hernandez-Flores, G., Gomez-Contreras, P. C., Dominguez-Rodriguez, J.R., Lerma-
Diaz, J.M., Ortiz-Lazareno P.C., Cervantes-Munguia, R., Sahagun-Flores, J.E., Orbach-
Arbouys, S., Scott-Algara, D. and Bravo-Cuellar, A. (2005). Gamma-irradiation 
induced apoptosis in peritoneal macrophages by oxidative stress. Implications of 
antioxidants in caspase mitochondrial pathway. Anticancer Res. 25, 4091–4100. 
Herrera, L., Kakati, S., Gibas, L., Pietrzak, E. and Sandberg, A.A. (1986). Gardner 
syndrome in a man with an interstitial deletion of 5q. Am J Med Genet. 25, 473–476 
Herszényi L and Tulassay Z. (2010). Epidemiology of gastrointestinal and liver 
tumors. Eur Rev Med Pharmacol Sci. 14, 249-58. 
 238 
Herszényi, L., Miheller, P. and Tulassay, Z. (2007). Carcinogenesis in inflammatory 
bowel disease. Dig Dis. 25, 267-9. 
Heyen, D. W., Weller, J. I., Ron, M., Band, M., Beever, J. E., Feldmesser, E., Da, Y., 
Wiggans, G. R., VanRaden, P. M., and Lewin, H, A. (1999). A genome scan for QTL 
influencing milk production and health traits in dairy cattle. Physiol Genomics 11, 
165-75. 
Hirschhorn, J. N. and Daly, M. J. (2005). Genome-wide association studies for 
common diseases and complex traits. Nat. Rev. Genet. 6, 95–108. 
Hoeijmakers, J.H. (2001). Genome maintenance mechanisms for preventing cancer. 
Nature. 411, 366-74. 
Hoffmeister, M., Raum, E., Winter, J., Chang-Claude, J. and Brenner, H. (2007). 
Hormone replacement therapy, body mass, and the risk of colorectal cancer among 
postmenopausal women from Germany. Br J Cancer. 97, 1486–1492. 
Hojgaard. A., et al. (2006). Altered localization of CXCL13 expressing cells in mice 
deficient in Pactolus following an inflammatory stimulus. Immunology. 119, 212–
223. 
Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. (1991). p53 mutations in 
human cancers. Science 253, 49-53. 
Hoste, C., Dumont, J. E., Miot, F. and De Deken, X. (2012). The type of DUOX-
dependent ROS production is dictated by defined sequences in DUOXA Exp Cell Res. 
318, 2353-64. 
Houlston, R. S, Cheadle. J, Dobbins. S. E., Tenesa, A., Jones, A. M., Howarth, K., Spain, S. 
L., Broderick, P., Domingo, E., Farrington,S., Prendergast, J. G, Pittman, A. M., 
Theodoratou, E., Smith, C. G., Olver, B., Walther, A., Barnetson, R. A., Churchman, M, 
Jaeger, E. E., Penegar, S., Barclay, E., Martin, L., Gorman, M., Mager, R., Johnstone, E., 
Midgley, R., Niittymäki. I., Tuupanen, S., Colley, J., Idziaszczyk, S., COGENT 
Consortium, Thomas, H. J., Lucassen, A. M., Evans, D. G., Maher, E. R., CORGI 
Consortium, COIN Collaborative Group, Maughan. T., Dimas. A., Dermitzakis. E., 
 239 
Cazier, J. B., Aaltonen, L. A., Pharoah, P., Kerr, D. J, Carvajal-Carmona, L. G., Campbell, 
H., Dunlop, M. G., Tomlinson, I. P. (2010). Meta-analysis of three genome-wide 
association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 
12q13.13 and 20q13.33. Nat Genet.42, 973-7. 
Houlston, R. S., Webb, E., Broderick, P., Pittman, A. M., Di Bernardo, M. C., Lubbe, S., 
Chandler, I., Vijayakrishnan, J., Sullivan, K., Penegar, S.; Colorectal Cancer Association 
Study Consortium, Carvajal-Carmona L., Howarth, K., Jaeger, E., Spain, S. L., Walther, 
A., Barclay, E., Martin, L., Gorman, M., Domingo, E., Teixeira, A. S.; CoRGI Consortium, 
Kerr, D., Cazier, J. B., Niittymäki, I., Tuupanen, S., Karhu, A., Aaltonen, L. A., 
Tomlinson, I. P., Farrington, S. M., Tenesa, A., Prendergast, J. G., Barnetson, R. A., 
Cetnarskyj, R., Porteous, M. E., Pharoah, P. D., Koessler, T., Hampe, J., Buch, S., 
Schafmayer, C., Tepel, J., Schreiber, S., Völzke, H., Chang-Claude, J., Hoffmeister, M., 
Brenner, H., Zanke, B. W., Montpetit, A., Hudson, T. J., Gallinger, S.; International 
Colorectal Cancer Genetic Association Consortium, Campbell, H., Dunlop, M. G., 
(2008). Meta-analysis of genome-wide association data identifies four new 
susceptibility loci for colorectal cancer. Nat Genet. 40, 1426-35. 
Houlston, R. S. and Tomlinson, I. P. (2001). Polymorphisms and colorectal tumor 
risk. Gastroenterology. 121, 282-301. 
Howe, J. R., Roth, S., Ringold, J. C., Summers, R. W., Järvinen, H. J., Sistonen, P., 
Tomlinson, I. P., Houlston, R. S., Bevan, S., Mitros, F. A., Stone, E.M. and Aaltonen, L. A. 
(1998). Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 280, 
1086-8. 
Howe, J. R., Sayed, M. G., Ahmed, A. F., Ringold, J., Larsen-Haidle, J., Merg, A., Mitros, F. 
A., Vaccaro, C.A., Petersen, G. M., Giardiello, F. M., Tinley, S. T., Aaltonen, L. A. and 
Lynch, H. T. (2004). The prevalence of MADH4 and BMPR1A mutations in juvenile 
polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet. 41, 
484-91. 
Howlader, N., Ries, L. A., Stinchcomb, D. G. and Edwards, B. K. (2009). The impact of 
underreported Veterans Affairs data on national cancer statistics: analysis using 
population-based SEER registries. J Natl Cancer Inst. 101, 533-6. 
 240 
Hua, G., Thin, T. H., Feldman, R., Haimovitz-Friedman, A., Clevers, H., Fuks, Z.and 
Kolesnick, R. (2012). Crypt base columnar stem cells in small intestines of mice are 
radioresistant. Gastroenterology 143, 1266-76 
Hubner, R. A. and Houlston, R. S. (2007). MTHFR C677T and colorectal cancer risk: A 
meta-analysis of 25 populations. Int J Cancer. 120, 1027-35. 
Hugh, T. J., Dillon, S. A., O'Dowd, G., Getty, B., Pignatelli, M., Poston, G. J. and Kinsella, 
A. R. (1999). beta-catenin expression in primary and metastatic colorectal 
carcinoma. Int. J. Cancer 82, 504-511. 
Itzkowitz, S. H. and Harpaz N. (2004) Diagnosis and management of dysplasia in 
patients with inflammatory bowel diseases. Gastroenterology. 126, 1634-48. 
Jannink, J. L., and Jansen, R. (2001). Mapping epistatic quantitative trait loci with 
one-dimensional genome searches. Genetics. 2001 157, 445-54. 
Jass, J. R. (2007). Hereditary and DNA methylation in colorectal cancer.  Gut. 56, 154-
155. 
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J.and Thun, M. J. (2009). Cancer statistics. CA 
Cancer J Clin. 59,225-49. 
Jenne, D.E., Reimann, H., Nezu, J., Friedel, W., Loff, S., Jeschke, R., Müller, O., Back, W. 
and Zimmer, M. (1998). Peutz-Jeghers syndrome is caused by mutations in a novel 
serine threonine kinase. Nat Genet. 18, 38-43. 
Jensen, L. J., Kuhn, M., Stark, M., Chaffron, S., Creevey, C., Muller, J., Doerks, T., Julien, 
P., Roth, A., Simonovic, M., Bork, P., von Mering, C. (2009). STRING 8--a global view 
on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37 
(Database issue), D412-6. . 
Jiang, C. and Zeng, Z. B. (1995). Multiple trait analysis of genetic mapping for 
quantitative trait loci. Genetics. 140, 1111-27. 
 241 
Jo, W. S., Mizukami, Y., Duerr, E. M., Zukerberg, L. R., Chung, D. C. (2005). Wnt 
signaling can repress thrombospondin-1 expression in colonic tumorigenesis. 
Cancer Biol Ther. 4, 1361-6. 
Johns, L. E. and Houlston, R. S. (2001) A systematic review and meta-analysis of 
familial colorectal cancer risk. Am J Gastroenterol 96, 2992-3003, 
Johnson, G. C., and J. A. Todd. (2000). Strategies in complex disease mapping. Curr 
Opin Genet Dev 10, 330. 
Johnson, V., Volikos, E., Halford, S. E., Eftekhar Sadat, E. T., Popat, S., Talbot, I., 
Truninger, K., Martin, J., Jass, J., Houlston, R., Atkin, W., Tomlinson, I. P. and Silver, 
A.R. (2005). Exon 3 beta-catenin mutations are specifically associated with 
colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut. 
54, 264–267. 
Jones, D., Perttunen, C. and Stuckman, B. (1993) Lipschitzian optimization without 
the Lipschitz constant. J. Optim. Theory App., 79, 157–181. 
Jones, P. A. and Baylin, S. B. (2007). The Epigenomics of Cancer. Cell, 128, 683-692. 
Jubb, A. M., Turley, H., Moeller, H. C., Steers, G., Han, C., Li, J. L., Leek, R., Tan, E.Y., 
Singh, B., Mortensen, N. J., Noguera-Troise, I., Pezzella, F., Gatter, K. C., Thurston, G., 
Fox, J., Harris, A. L. (2009). Expression of delta-like ligand 4 (Dll4) and markers of 
hypoxia in colon cancer. Br J Cancer. 101, 1749–57.  
Julié, C., Trésallet, C., Brouquet, A., Vallot, C., Zimmermann, U., Mitry, E., Radvanyi, F., 
Rouleau, E., Lidereau, R., Coulet, F., Olschwang, S., Frébourg, T., Rougier, P., 
Nordlinger, B., Laurent-Puig, P., Penna, C., Boileau, C., Franc, B., Muti, C. and 
Hofmann-Radvanyi, H. (2008). Identification in daily practice of patients with Lynch 
syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-
based approach versus molecular screening. Am J Gastroenterol. 103, 2825-35. 
Kaklamani, V.G., Hou, N., Bian, Y., Reich, J., Offit, K., Michel, L. S., Rubinstein, W. S., 
Rademaker, A., Pasche, B. (2003). TGFBR1*6A and cancer risk: a meta-analysis of 
seven case-control studies. J Clin Oncol. 21, 3236-43. 
 242 
Kao, C. H., Zeng, Z. B. and Teasdale, R. D. (1999). Multiple interval mapping for 
quantitative trait loci. Genetics, 152, 1203–1216. 
Kao, C. H., Zeng, Z. B. (2002). Modelling epistasis of quantitative trait loci using 
Cockerham’s model. Genetics. 160, 1243-61. 
Katoh, M. and Katoh, M., (2006) Notch ligand, JAG1, is evolutionarily conserved 
target of canonical WNT signaling pathway in progenitor cells.Int J Mol Med. 17, 
681-5. 
Kawasaki, Y., Tsuji, S., Muroya, K., Furukawa, S., Shibata, Y., Okuno, M., Ohwada, S. 
and Akiyama, T. (2009). The adenomatous polyposis coli-associated exchange 
factors Asef and Asef2 are required for adenoma formation in Apc(Min/+)mice. 
EMBO Rep. 10, 1355-62. 
Kendal, W. S. and Nicholas, G. A, (2007). Population-based analysis of second 
primary cancers after irradiation for rectal cancer. Am J Clin Oncol. 30, 333-9. 
Kennedy, B. P., Payette, P., Mudgett, J., Vadas, P., Pruzanski, W., Kwan, M., Tang, C., 
Rancourt, D. E.and Cromlish W. A. (1995). A natural disruption of the secretory 
group II phospholipase A2 gene in inbred mouse strains. J Biol Chem. 270, 22378-85. 
Kennedy, D., and Heise, CP. (2007). Radiation Colitis and Proctitis Clin Colon Rectal 
Surg. 20, 64–72. 
Kerber, R. A., Amos, C. I., Yeap, B. W., Finkelstein, D. F., Thomas, D. C. (2008). Design 
considerations in a sib-pair study of linkage for susceptibility loci in cancer. BMC 
Med Genet, 9, 64 
Kim, Y. I. and Mason, J. B. (1996). Nutrition chemoprevention of gastrointestinal 
cancers: a critical review.Nutr Rev. 54, 259-79. 
Kinzler, K. and Vogelstein, B. (1996). Lessons from hereditary colorectal cancer. Cell 
87, 159-170. 
Kinzler, K. W. and Vogelstein, B. (1997) Cancer-susceptibility genes. Gatekeepers 
and caretakers. Nature. 24, 761, 763. 
 243 
Kinzler, K. W., Nilbert, M. C., Su, L. K., Vogelstein, B., Bryan, T. M., Levy, D. B., Smith, K. 
J., Preisinger, A. C., Hedge, P., and McKechnie, D. (1991). Identification of FAP locus 
genes from chromosome 5q21. Science. 9, 661-5. 
Kirsten, W. H., Schauf, V. and McCoy, J. (1970). Properties of a murine sarcoma virus. 
Bibl Haematol. 36, 246–9. 
Kleinsmith, L. (2006). Principles of Cancer Biology.  Pearson Benjamin Cummings. 
Knott, S. A. and Haley, C.S. (2000) Multitrait least squares for quantitative trait loci 
detection. Genetics. 156, 899-911. 
Knudson, A. G., Jr. (1971). Mutation and cancer, statistical study of retinoblastoma. 
Proc. Natl. Acad. Sci. U S A. 68, 820-823. 
Knudson, A. G., Jr. (1985). Hereditary cancer, oncogenes, and antioncogenes. Cancer 
Res. 45, 1437-43 
Kondo, Y. and Issa, J., P. (2004). Epigenetic changes in colorectal cancer. Cancer 
Metastasis Rev. 23, 29-39. 
Korol, A. B., Ronin, Y. I., Nevo, E. and Hayes, P. (1998). Multi-interval mapping of 
correlated trait complexes, simulation analysis and evidence from barley. Heredity 
80, 273–284. 
Korstanje, R. and Paigen, B. (2002). From QTL to gene, The harvest begins. Nature 
Genet. 31, 235–236. 
Kosambi, D.D. (1944). The estimation of map distance from recombination values, 
Annals of Eugenics, 12, 172–175 
Kosinski C., Li V. S. W., Chan, A. S. Y., Zhang, J., Ho C, Tsui, W. Y., (2007). Gene 
expression patterns of human colon tops and basal crypts and BMP antagonists as 
intestinal stem cell niche factors. Proceedings of the National Academy of Sciences. 
104, 15418-23. 
Koyama, M., Ito, M., Nagai, H., Emi, M., Moriyama, Y. (1999). Inactivation of both 
alleles of the DPC4/SMAD4 gene in advanced colorectal cancers, Identification of 
 244 
seven novel somatic mutations in tumors from Japanese patients. Mutat Res. 406, 
71–77. 
Kruglyak, L. and Lander, E. S. (1995). Complete multipoint sib-pair analysis of 
qualitative and quantitative traits. Am J Hum Genet. 57, 439–454. 
Ku, J.L., Park, S. H., Yoon, K. A., Shin, Y. K., Kim, K. H., Choi, J. S., Kang, H. C., Kim, I. J., 
Han, I.O.and Park, J., G. (2007). Genetic alterations of the TGFbeta signaling pathway 
in colorectal cancer cell lines, a novel mutation in Smad3 associated with the 
inactivation of TGFbeta- induced transcriptional activation. Cancer Lett. 247, 283-
292 
Kumar, P., Henikoff, S.and Ng, P. C. (2009) Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 4, 
1073-81 
Kuraguchi, ,M., Wang, X. P., Bronson, R. T., Rothenberg, R., Ohene-Baah, N. Y., Lund, J. 
J., Kucherlapati, M., Maas, R. L., Kucherlapati, R. (2006). Adenomatous polyposis coli 
(APC) is required for normal development of skin and thymus, PLoS Genet. 2 
Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., 
Ittmann, M. (2001). Haploinsufficiency of the Pten tumor suppressor gene promotes 
prostate cancer progression. Proc Natl Acad Sci U S A. 98, 11563-8. 
Kwong, L. N., Shedlovsky, A., Biehl, B. S., Clipson, L., Pasch, C. A. and Dove, W. F. 
(2007). Identification of Mom7, a novel modifier of Apc(Min/ +) on mouse 
chromosome 18. Genetics. 176, 1237–1244. 
Kwong, J., Lo, K. W., Chow, L. S., Chan, F. L., To, K. F. and Huang, D. P. (2005). Silencing 
of the retinoid response gene TIG1 by promoter hypermethylation in 
nasopharyngeal carcinoma. Int J Cancer. 113, 386-92. 
Lai, C., Robinson, J., Clark, S., Stamp, G., Poulsom, R., and Silver, A. (2011). Elevation 
of WNT5A expression in polyp formation in Lkb1+/- mice and Peutz-Jeghers 
syndrome. J. Pathol. 223, 584-592. 
 245 
Laken, S. J., Petersen, G. M., Gruber, S. B., Oddoux, C., Ostrer, H., Giardiello, F. M., 
Hamilton, S. R., Hampel, H., Markowitz, A., Klimstra, D., Jhanwar, S., Winawer, S., Offit, 
K., Luce, M.C., Kinzler, K. W., Vogelstein, B. (1997). Familial colorectal cancer in 
Ashkenazim due to a hypermutable tract in APC. Nat Genet. 17, 79-83. 
Lamlum, H., Ilyas, M., Rowan, A., Clark, S., Johnson, V., Bell, J., Frayling, I., Efstathiou, 
J., Pack, K., Payne, S., Roylance, R., Gorman, P., Sheer, D., Neale, K., Phillips, R., Talbot, 
I., Bodmer, W., and Tomlinson, I. (1999). The type of somatic mutation at APC in 
familial adenomatous polyposis is determined by the site of the germline mutation, a 
new facet to Knudson's 'two-hit' hypothesis. Nat Med. 5, 1071-5. 
Lander, E. S, and Botstein, D. (1989) Mapping mendelian factors underlying 
quantitative traits using RFLP linkage maps. Genetics. 121, 185-199 
Lander, E. S., Linton, L. M. et al (254 co-authors). Initial sequencing and analysis of 
the human genome. Nature 409, 860-921 (2001). 
Lander, E., Kruglyak, L. (1995). Genetic dissection of complex traits, Guidelines for 
interpreting and reporting linkage results. Nat Genet. 11, 241–247 
Lashner, B. A. (1994). Genetic heterogeneity in ulcerative colitis. Am J Gastroenterol. 
89, 1927-8. 
Leach, F.S., Nicolaides, N.C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., Peltomäki, P., 
Sistonen, P., Aaltonen, L. A., Nyström-Lahti, M. (1993). Mutations of a mutS homolog 
in hereditary nonpolyposis colorectal cancer. Cell. 75, 1215-25. 
Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1997). Genetic instability in 
colorectal cancers. Nature 386, 623–627. 
Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1998). Genetic instabilities in human 
cancers. Nature 396, 643-649. 
Leppert, M., Burt, R., Hughes, J. P., Samowitz, W., Nakamura, Y., Woodward, S., 
Gardner, E., Lalouel, J. M., White, R. (1990). Genetic analysis of an inherited 
predisposition to colon cancer in a family with a variable number of adenomatous 
polyps. N Engl J Med. 29, 904-8. 
 246 
Leslie, A., Pratt, N. R., Gillespie, K., Sales, M., Kernohan, N. M., Smith, G., Wolf, C. R., 
Carey, F. A., Steele, R. J. (2003). Mutations of APC, K-ras, and p53 are associated with 
specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res. 63, 
4656–61 
Levitt, N.C., Hickson, I.D. (2002). Caretaker tumour suppressor genes that defend 
genome integrity. Trends Mol Med. 8,179-86. 
Li, Q., Ishikawa, T. O., Oshima, M., Taketo, M. M. (2005). The threshold level of 
adenomatous polyposis coli protein for mouse intestinal tumorigenesis, Cancer Res. 
65, 8622–8627. 
Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., 
Pukkala, E., Skytthe, A., Hemminki, K. (2000). Environmental and heritable factors in 
the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and 
Finland. N Engl J Med, 343, 78-85 
Lipton L., Tomlinson I. (2004). The multiple colorectal adenoma phenotype and 
MYH, a base excision repair gene. Clin. Gastroenterol. Hepatol. 2, 633–638 
Lipton, L., and Tomlinson, I. (2006). The genetics of FAP and FAP-like syndromes. 
Fam Cancer 5, 221-6. 
Liu, L., Wu, D. H., Ding, Y. Q. (2005). Tiam1 gene expression and its significance in 
colorectal carcinoma.. World J Gastroenterol.  7, 705-7. 
Livak, K., and Schmittgen, T. D. (2001). Analysis of Relative Gene Expression Data 
Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods. 25, 402-08. 
Ljungberg, K., Holmgren, S., Carlborg, O. (2004). Simultaneous search for multiple 
QTL using the global optimization algorithm DIRECT. Bioinformatics, 20, 1887–
1895. 
Lockhart-Mummery, J. P. (1934). The causation and treatment of multiple 
adenomatosis of the colon. Ann. Surg. 99, 178-184. 
 247 
Logan, C. Y., Nusse, R. (2004). The Wnt signaling pathway in development and 
disease. Annu. Rev. Cell Dev. Biol. 20, 781–810. 
Logan, C., Y., and Nusse, R. (2004). The Wnt signalling pathway in development and 
disease.  Annu Rev Cell Dev Biol 20, 7812-810. 
Loo, L. W., Cheng, I., Tiirikainen, M., Lum-Jonesm A., Seifried, A., Dunklee, L. M., 
Church, J. M., Gryfe, R., Weisenberger, D. J., Haile, R. W., Gallinger, S., Duggan, D. J., 
Thibodeau, S. N., Casey, G., Le Marchand, L. (2012). cis-Expression QTL analysis of 
established colorectal cancer risk variants in colon tumors and adjacent normal 
tissue. PLoS One. 7(2), e30477. 
Lu, S., Shen, K., Wang, Y., Santner, S. J., Chen, J., Brooks, S. C., Wang, Y. A. (2006). Atm-
haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors. 
Carcinogenesis. 2006 27(4),848-55. 
Lugli, A., Iezzi, G., Hostettler, I., Muraro, M., G., Mele, V., Tornillo, L., (2010). 
Prognostic impact of the expression of putative cancer stem cell markers CD133, 
CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. British Journal of Cancer. 
103, 382-90. 
Luongo, C., Moser, A. R., Gledhill, S., Dove, W. F., (1994). Loss of Apc in intestinal 
adenomas from Min mice. Cancer Res 54, 5947–5952. 
Luxen, S., Belinsky, S., A, Knaus, U.,G. (2008). Silencing of DUOX NADPH Oxidases by 
Promoter Hypermethylation in Lung Cancer. Cancer Research. 68, 1037-45 
Lynch, H. T., de la Chapelle. (2003). A. Hereditary colorectal cancer. N Engl J Med. 6, 
919-32.  
Lynch, H. T., Krush, A., J., (1971). Cancer family "G" revisited, 1895-1970. Cancer. 27, 
1505-11. 
Lynch, H. T., Smyrk, T., McGinn, T., Lanspa, S., Cavalieri, J., Lynch, J., Slominski-Castor, 
S., Cayouette, M. C., Priluck, I., Luce, M. C. (1995). Attenuated familial adenomatous 
polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. 
Cancer. 15, 2427-33. 
 248 
MacPhee, M., Chepenik, K. P., Liddell, R. A., Nelson, K. K., Siracusa, L. D., Buchberg, A. 
M. (1995). The secretory phospholipase A2 gene is a candidate for the Mom1 locus a 
major modifier of ApcMin-induced intestinal neoplasia, Cell 81, 957–966. 
Maddams, J., Brewster, D., Gavin, A., Steward, J., Elliott, J., Utley, M., Møller, H. (2009).  
Cancer prevalence in the UK, estimates for 2008. Br J Cancer. 101,541-7 
Maddams, J., Parkin, D., Darby SC. (2011). The cancer burden in the United Kingdom 
in 2007 due to radiotherapy. 129, 2885–2893. 
Maddams, J., Utley, M., Møller, H., (2012). Projections of cancer prevalence in the 
United Kingdom, 2010-2040. Br J Cancer. 25, 1195-202 
Malliri, A., Rygiel, T. P., van der Kammen, R. A., Song, J. Y., Engers, R., Hurlstone, A. F., 
Clevers, H., and Collard, J. G. (2006).  The rac activator Tiam1 is a Wnt-responsive 
gene that modifies intestinal tumor development. J Biol Chem. 281, 543-8 
Manichaikul, A., Moon, J. Y., Sen, S., Yandell, B. S., Broman, K. W. (2009). A model 
selection approach for the identification of quantitative trait loci in experimental 
crosses, allowing epistasis. Genetics. 181, 1077-86. 
Manly, K. F., Cudmore, Jr., R. H., and Meer, J. M. (2001). MapManager QTX, cross-
platform software for genetic mapping. Mamm. Genome, 12, 930-932. 
Mann, B., Gelos, M., Siedow, A., Hanski, M. L., Gratchev, A., Ilyas, M., Bodmer, W. F., 
Moyer, M.P., Riecken, E. O., Buhr, H. J.and Hanski,C. (1999). Target genes of beta-
catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal 
carcinomas. Proc. Natl. Acad. Sci. U S A. 96, 1603-1608. 
Marchini, J., Donnelly, P., Cardon, L. R. (2005). Genome-wide strategies for detecting 
multiple loci that influence complex diseases. Nat Genet. 37, 413–417. 
Margel, D., Baniel, J., Wasserberg, N., Bar-Chana, M., Yossepowitch, O. (2011). 
Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. 
Ann Surg. 254, 947-50 
 249 
Markowitz, S. D. (2007). Aspirin and colon cancer--targeting prevention? N. Engl. J. 
Med. 356, 2195-2198. 
Marlow, A. J., Fisher, S. E., Francks, C., MacPhie, I. L., Cherny, S., S, Richardson, A. J., 
Talcott, J. B., Stein, J. F., Monaco. A. P., Cardon, L. R. (2003). Use of multivariate 
linkage analysis for dissection of a complex cognitive trait. Am J Hum Genet. 72, 561-
70 
Martinez, P., Birkbak, N.J., Gerlinger, M., McGranahan, N., Burrell, R.A., Rowan, A.J., 
Joshi, T., Fisher, R., Larkin, J., Szallasi, Z., Swanton, C. N. (2013). Parallel evolution of 
tumour subclones mimics diversity between tumours. J Pathol. 230, 356-64. 
Matsunami, T., Sato, Y., Hasegawa, Y., Ariga, S., Kashimura, H., Sato, T., Yukawa, M. 
(2011). Enhancement of reactive oxygen species and induction of apoptosis in 
streptozotocin-induced diabetic rats under hyperbaric oxygen exposure.Int J Clin 
Exp Pathol. 4, 255-66. 
May, P., May, E. (1999). Twenty years of p53 research, structural and functional 
aspects of the p53 protein. Oncogene. 18, 7621-36. 
McCart, A. E., Vickaryous, N. K., Silver, A. (2008). Apc mice, models, modifiers and 
mutants. Pathol Res Pract. 204, 479-90. 
McPeek, M. S. (2000). From mouse to human, Fine mapping of quantitative trait loci 
in a model organism Proc Natl Acad Sci U S A. 97, 12389–12390. 
Michor, F. (2004). Dynamics of Cancer progression. Nature Reviews Cancer. 4, 197-
205. 
Midgley, C. A., White, S., Howitt, R., Save, V., Dunlop, M. G., Hall, P. A., Lane, D. P, 
Wyllie, A. H., Bubb, V. J. (1997). APC expression in normal human tissues. J Pathol. 
181,426-33. 
Miyaki, M., Iijima,T., Konishi, M., Sakai, K., Ishii, A., Yasuno, M., Hishima, T., Koike, M., 
Shitara, N., Iwama, T., Utsunomiya, J., Kuroki, T., Mori, T.(1999). Higher frequency of 
Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene. 
18, 3098–3103. 
 250 
Miyaki, M., Konishi, M., Kikuchi-Yanoshita, R., Enomoto, M., Igari, T., Tanaka, K., 
Muraoka, M., Takahashi, H., Amada, Y., Fukayama, M. (1994). Characteristics of 
somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. 
Cancer Res. 54, 3011–3020 
Miyoshi, Y., Ando, H., Nagase, H., (1992). Germ-line mutations of the APC gene in 53 
familial adenomatous polyposis patients. Proc Natl Acad Sci U S A. 89, 4452-6. 
Mohrenweiser, H. W., Wilson, D. M., Jones, I. M., (2003). Challenges and complexities 
in estimating both the functional impact and the disease risk associated with the 
extensive genetic variation in human DNA repair genes. Mutat Res. 15, 93-125. 
Mori, N., Matsumoto, Y., Okumoto, M., Suzuki, N., Yamate, J. (2001). Variations in 
Prkdc encoding the catalytic subunit of DNA-dependent protein kinase (DNAPKcs) 
and susceptibility to radiation-induced apoptosis and lymphomagenesis. Oncogene 
20, 3609–3619. 
Morton, N. M. (1955). Sequential tests for the detection of linkage Am J Hum Genet. 
7, 277–318. 
Moser, A.R., Pitot, H. C. and Dove, W. F. (1990). A dominant mutation that 
predisposes to multiple intestinal neoplasia in the mouse. Science. 247, 322–324 
Mott, R., Talbot, C. J., Turri, M. G., Collins A. C. and Flint J. (2000). A new method for 
fine-mapping quantitative trait loci in outbred animal stocks Proc Natl Acad Sci U S 
A, 97, 12649-12654 
Muleris, M., Chalastanis, A., Meyer, N., Lae, M., Dutrillaux, B., Sastre-Garau, X., 
Hamelin, R., Flejou, J. F. and Duval, A. (2008). Chromosomal instability in near-
diploid colorectal cancer, a link between numbers and structure. PLoS. ONE. 3, 
e1632. 
Munkholm, P. (2003). Review article, the incidence and prevalence of colorectal 
cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 18, 1-5. 
 251 
Murty,V. V., Li, R. G., Houldsworth, J., Bronson, D. L., Reuter, V. E., Bosl, G. J., Chaganti, 
R. S. (1994). Frequent allelic deletions and loss of expression characterize the DCC 
gene in male germ cell tumors. Oncogene. 9, 3227-31. 
Myohanen, S. K., Baylin, S. B. and Herman, J. G. (1998). Hypermethylation can 
selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 58, 591-593. 
Nadeau, J. H. and Frankel, W.N. (2000). The roads from phenotypic variation to gene 
discovery, Mutagenesis versus QTLs. Nat. Genet. 25, 381-384 
Nagase H, Miyoshi Y, Horii A, Aoki T, Ogawa M, Utsunomiya J, Baba S, Sasazuki T, 
Nakamura Y. (1992). Correlation between the location of germ-line mutations in the 
APC gene and the number of colorectal polyps in familial adenomatous polyposis 
patients. Cancer Res. 52,4055–7. 
Nagase, H. and Nakamura, Y. (1993). Mutations of the APC (adenomatous polyposis 
coli) gene. Hum Mutat. 2, 425-34. 
Nagel, R. L. (2001). Pleiotropic and epistatic effects in sickle cell anemia. Curr Opin 
Hematol. 8, 105-10. 
Nagel, R. L. (2005). Epistasis and the genetics of human diseases. C R Biol. 328, 606-
15. 
Nagel, R. L., Steinberg, M. H. (2001). Role of epistatic (modifier) genes in the 
modulation of the phenotypic diversity of sickle cell anemia. Pediatr Pathol Mol Med. 
20, 123-36. 
Nakau, M., Miyoshi, H., Seldin, M. F., Imamura, M., Oshima, M., Taketo, M. M. (2002). 
Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout 
mice. Cancer Res. 15, 4549-53. 
Neklason, D. W., Solomon, C. H., Dalton, A. L., Kuwada, S. K., Burt, R. W. (2004). Intron 
4 mutation in APC gene results in splice defect and attenuated FAP phenotype. Fam 
Cancer. 3, 35-40 
 252 
Newton, K. F., Mallinson, E. K., Bowen, J., Lalloo, F., Clancy, T., Hill, J., Evans, D. G. 
(2012). Genotype-phenotype correlation in colorectal polyposis. Clin Genet. 81, 521-
31. 
Ng, P. C. and Henikoff, S. (2006). Predicting the Effects of Amino Acid Substitutions 
on Protein Function Annu Rev Genomics Hum Genet. 7, 61-80. 
Ng, P. C., 2, S. (2003). SIFT, predicting amino acid changes that affect protein 
function. Nucleic Acids Res.31, 3812-4 
Ng, P. C. and Henikoff, S. (2002). Accounting for human polymorphisms predicted to 
affect protein function. Genome Res. 12, 436–46 
Nica, A. C., Montgomery, S. B., Dimas, A. S., Stranger, B. E., Beazley, C., Barroso, I., 
Dermitzakis, E. T. (2010). Candidate causal regulatory effects by integration of 
expression QTLs with complex trait genetic associations. PLoS Genet. 2010 Apr 
1,6(4), e1000895. 
Niho, N., Takahashi, M., Kitamura, T., Shoji, Y., Itoh, M., Noda, T., Sugimura, T., 
Wakabayashi, K. (2003). Concomitant suppression of hyperlipidemia and intestinal 
polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor 
ligands. Cancer Res. 63, 6090-6095 
Nishisho, I., Nakamura, Y., Miyoshi,Y., Miki, Y., Ando, H., Horii, A., Koyama, K., 
Utsunomiya, J., Baba, S., (1991). Hedge P. Mutations of chromosome 5q21 genes in 
FAP and colorectal cancer patients. Science. 253, 665-9. 
Nugent, K. P., Phillips, R. K., Hodgson, S. V., Cottrell, S., Smith-Ravin, J., Pack, K. and 
Bodmer, W., F. (1994). Phenotypic expression in familial adenomatous polyposis, 
partial prediction by mutation analysis. Gut 35, 1622-3. 
Orholm, M., Binder, V., Sørensen, T. I., Rasmussen, L. P., Kyvik, K. O. (2000). 
Concordance of inflammatory bowel disease among Danish twins. Results of a 
nationwide study. Scand J Gastroenterol. 35, 1075-81. 
Orholm, M., Munkholm, P., Langholz, E., Nielsen, O. H., Sørensen, T. I., Binder, V. 
(1991). Familial occurrence of inflammatory bowel disease. N Engl J Med. 324, 84-8. 
 253 
Oshima, M., Dinchuk, E. J., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., 
Trzaskos, J., Evans, J., Taketo, M. (1996). Suppression of intestinal polyposis in Apc 
(Δ716) knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell. 87, 803-809. 
Ott, J. (1989). Statistical properties of the haplotype relative risk. Genet. Epidemiol. 
6, 127–130. 
Parada, L. F., Tabin, C. J., Shih, C. and Weinberg, R.A. (1982). Human EJ bladder 
carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 10, 
474-8. 
Parkin, D. M., Bray, F., Ferlay, J., Pisani., P (2005). Global Cancer Statistics., CA Cancer 
J Clin. 55, 74-108 
Pasche, B., Kaklamani, V., Hou, N., Young, T., Rademaker, A., Peterlongo, P., Ellis, N., 
Offit, K., Caldes, T., Reiss, M., Zheng, T. (2004). TGFBR1*6A and cancer, a meta-
analysis of 12 case-control studies. J Clin Oncol. 15, 756-8. 
Pasche, B., Luo, Y., Rao, P. H,, Nimer, S. D., Dmitrovsky, E., Caron, P., Luzzatto, L., Offit, 
K., Cordon-Cardo, C., Renault, B., Satagopan, J. M, Murty, V. V., Massagué, J. (1998). 
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a 
polymorphism and a rare variant within a polyalanine tract. Cancer Res. 58, 2727-
32. 
Pataer, A., Nishimura, M., Kamoto, T., Ichioka, K., Sato, M., Hiai H., (1997). Genetic 
resistance to urethan-induced pulmonary adenomas in SMXA recombinant inbred 
mouse strains. Cancer Research; 57, 2904-8 
Payne, S. R. and Kemp, C. J. (2005). Tumor suppressor genetics. Carcinogenesis 26, 
2031-2045. 
Pearce, M. S., Salotti, J. A., Howe, N. L., McHugh, K., Kim, K. P., Lee, C., Craft, A. W., 
Berrington de Gonzaléz, A., Parker, L. (2012). CT Scans in Young People in Great 
Britain, Temporal and Descriptive Patterns, 1993-2002. 
Pearson, K. (1990).The Grammar of science. Cousin London. Adam and Charles Black 
 254 
Peltomäki, P. (2001). DNA mismatch repair and cancer. Mutat Res. 488, 77-85. 
Petitjean, A., Achatz, M. I., Borresen-Dale, A. L., Hainaut, P. and Olivier, M. (2007). 
TP53 mutations in human cancers, functional selection and impact on cancer 
prognosis and outcomes. Oncogene 26, 2157-2165. 
Peto, J., Houlston, R. S. (2001). Genetics and the common cancers. Eur J Cancer. 37, 
88-96. 
Pharoah, P. D., Antoniou, A., Bobrow, M., Zimmern, R. L., Easton, D. F., Ponder, B. A. 
(2002). Polygenic susceptibility to breast cancer and implications for prevention. 
Nat Genet. 31, 33-6. 
Phelps, R. A., Chidester, S., Dehghanizadeh, S., Phelps, J., Sandoval, I. T., Rai, K., 
Broadbent, T., Sarkar, S., Burt, R. W., and Jones, D. A. (2009). A two-step model for 
colon adenoma initiation and progression caused by APC loss. Cell 137, 623-634. 
Pietenpol, J. A. and Vogelstein, B. (1993). Tumour suppressor genes. No room at the 
p53 inn. Nature 365, 17-18. 
Pino, M. S. and Chung, D. C. (2010). Application of molecular diagnostics for the 
detection of Lynch syndrome. Expert Rev Mol Diagn. 10, 651-65. 
Plotz, G., Zeuzem, S., and Raedle, J. (2006). DNA mismatch repair and Lynch 
syndrome. J. Mol. Histol. 37, 271-283. 
Podolsky, D. K. (2002). Inflammatory Bowel Disease. New England Journal of 
Medicine. 347, 417–29 
Polakis, P. (1997). The adenomatous polyposis coli (APC) tumor suppressor. 
Biochim Biophys Acta. 3, 127-47. 
Poli, G., Schaur, R. J., Siems, W. G., Leonarduzzi, G. (2008). 4-Hydroxynonenal: a 
membrane lipid oxidation product of medicinal interest. Medicinal Research 
Reviews. 28, 569–631. 
 255 
Ponder, B. A. and Wilkinson, M. M. (1986). Direct examination of the clonality of 
carcinogen-induced colonic epithelial dysplasia in chimeric mice. J. Natl. Cancer Inst. 
77, 967-976. 
Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. 
N., Vogelstein, B., Kinzler, K. W. (1992). APC mutations occur early during colorectal 
tumorigenesis. Nature. 359, 235-7. 
Praml, C., Savelyeva, L., Le Paslier, D., Siracusa, L. D., Buchberg, A. M., Schwab, M., 
Amler, L. C., (1995). Human homologue of a candidate for the Mom1 locus, the 
secretory type II phospholipase A2 (PLA2S-II), maps to 1p35-36.1/D1S199. Cancer 
Res. 55; 5504-6. 
Preston, S. L., Wong, W. M., Chan, A. O., Poulsom, R., Jeffery, R., Goodlad, R. A., Mandir, 
N., Elia, G., Novelli, M., Bodmer, W. F., Tomlinson, I. P., and Wright, N. A. (2003). 
Bottom-up histogenesis of colorectal adenomas, origin in the monocryptal adenoma 
and initial expansion by crypt fission. Cancer Res. 63, 3819-3825. 
Quan, L., Stassen, A. P., Ruivenkamp, C. A., van Wezel, T., Fijneman, R. J., Hutson, A., 
Kakarlapudi, N., Hart, A, A, Demant, P. (2011). Most lung and colon cancer 
susceptibility genes are pair-wise linked in mice, humans and rats.  PLoS One. 2011 
Feb 24, 6(2), e14727. 
Quandt, K., Frech, K., Karas, H., Wingender, E. and Werner, T. (1995). MatInd and 
MatInspector: new fast and versatile tools for detection of consensus matches in 
nucleotide sequence data. Nucleic Acids Res. 23, 4878-84. 
Radice, G, L. (2000). Committee Reports, Mouse Genome Database (MGD). Bar 
Harbor, Maine, Mouse Genome Informatics, The Jackson Laboratory. Chromosome 
18. 
Ramensky, V., Bork, P., Sunyaev, S. (2002) Human non-synonymous SNPs, server and 
survey. Nucl Acids Res, 30, 3894. 
Rao, C. V., Yang, Y. M., Swamy, M. V., Liu, T., Fang, Y., Mahmood, R., Jhanwar-Uniyal, 
M., and Dai W. (2005). Colonic tumorigenesis in BubR1+/-ApcMin/+ compound 
 256 
mutant mice is linked to premature separation of sister chromatids and enhanced 
genomic instability. Proc Natl Acad Sci U S A. 102, 4365-70. 
Rapiti, E., Fioretta, G., Verkooijen, H. M., Zanetti, R., Schmidlin, F., Shubert, H., 
Merglen, A., Miralbell, R., Bouchardy, C. (2008). Increased risk of colon cancer after 
external radiation therapy for prostate cancer. Int J Cancer. 123, 1141-5. 
Reymond, A., Marigo, V., Murat, B., Yaylaoglu, A., Leoni, C., Scamuffa, N., Caccioppoli, 
C Emmanouil T. Dermitzakis, Robert Lyle, Sandro Banfi, Gregor Eichele, Stylianos E. 
Antonarakis & Andrea Ballabio.  (2000). Human chromosome 21 gene expression 
atlas in the mouse Nature. 420, 582-586. 
Riggins, G. 0. J., Markowitz, S., Wilson, J. K., Vogelstein, B. and Kinzler, K. W. (1995). 
Absence of secretory phospholipase a(2) gene alterations in human colorectal 
cancer. Cancer Res. 55, 5184-5186. 
Risch, N. and Merikangas, K. (1996). The future of genetic studies of complex human 
diseases. Science 273, 1516–1517. 
Ritsert, J. C. (1993). Interval mapping of multiple quantitative trait loci. Genetics. 
135, 205-211. 
Robanus-Maandag, E. C., Koelink, P. J., Breukel, C., Salvatori, D. C., Jagmohan-Changur, 
S. C., Bosch, C. A., Verspaget, H. W., Devilee, P., Fodde, R., Smits, R. (2010). A new 
conditional Apc-mutant mouse model for colorectal cancer. Carcinogenesis. 31, 946-
52. 
Roberts, A. B., Derynck, R. (2001). Meeting report, signaling schemes for TGF-beta. 
Sci STKE. 18, 113 
Roberts, P.J. and Der, C.J. (2007) Targeting the Raf–MEK–ERK mitogen-activated 
protein kinase cascade for the treatment of cancer. Oncogene 26, 3291–3310 
Roderick, T. H. (1963) The response of twenty seven inbred strains of mice to daily 
doses of whole body x-irradiation. Radiat. Res., 20,614-631 
 257 
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., and 
Lane, D. P. (1990). p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 
87, 7555-7559. 
Rodriguez-Bigas, M. A. (1997). Genetic testing is important in families with a history 
suggestive of hereditary non-polyposis colorectal cancer even if the Amsterdam 
criteria are not fulfilled. Br J Surg. 84, 1027-8 
Rogus, J. J., Krolewski, A. S., (1996). Using discordant sib pairs to map loci for 
qualitative traits with high sibling recurrence risk. Am J Hum Genet. 59, 1579–81. 
Rokutan, K., Kawahara, T., Kuwano, Y., Tominaga, K., Sekiyama, A., Teshima-Kondo, S. 
(2006). NADPH oxidases in the gastrointestinal tract, a potential role of Nox1 in 
innate immune response and carcinogenesis.  Antioxid Redox Signal. 8, 1573-82 
Rothkamm K, Kühne M, Jeggo PA, Löbrich M. (2001). Radiation-induced genomic 
rearrangements formed by nonhomologous end-joining of DNA double-strand 
breaks. Cancer Res. 15, 3886-93. 
Rothwell, P. M. (2013). Aspirin in prevention of sporadic colorectal cancer, current 
clinical evidence and overall balance of risks and benefits. Recent Results Cancer 
Res. 191,121-42 
Rubenstein, P., Walker, M., Carpenter, C., Carrier, C., Krassner, J., Falk, C. and 
Ginsberg, F. (1981). Genetics of HLA disease associations, The use of the haplotype 
relative risk (HRR) and the “haplo-delta” (Dh) estimates in juvenile diabetes from 
three racial groups. Hum. Immunol. 3, 384. 
Ruivenkamp, C. A., van Wezel, T., Zanon C. (2002). Ptprj is a candidate for the mouse 
colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. 
Nat. Genet. 31, 295–300 
Rustgi, A. K. (2007). The genetics of hereditary colon cancer. Genes Dev. 21, 2525-38. 
Sachidanandam, R., Weissman, D., Schmidt, S. C., Kakol, J. M., Stein, L. D., Marth, G., 
Sherry, S., Mullikin, J. C., Mortimore, B. J., Willey, D. L., Hunt, S. E., Cole, C. G., Coggill, P. 
C., Rice, C. M., Ning, Z., Rogers, J., Bentley, D. R., Kwok, P. Y., Mardis, E. R., Yeh, R. T., 
 258 
Schultz, B., Cook, L., Davenport, R., Dante, M., Fulton, L., Hillier. L., Waterston, R. H., 
McPherson, J. D., Gilman. B., Schaffner. S., Van Etten, W. J., Reich, D., Higgins, J., Daly, 
M. J., Blumenstiel. B., Baldwin, J., Stange-Thomann, N., Zody, M. C., Linton, L., Lander, 
E. S., Altshuler, D. (2001). International SNP Map Working Group. A map of human 
genome sequence variation containing 1.42 million single nucleotide 
polymorphisms. Nature. 409, 928-33. 
Salhab, N., Jones, D. J., Bos, J. L, Kinsella, A., Schofield, P. F. (1989). Detection of ras 
gene alterations and ras proteins in colorectal cancer. Dis Colon Rectum. 32, 659-64. 
Sanchez-Cespedes, M. (2007). A role for LKB1 gene in human cancer beyond the 
Peutz-Jeghers syndrome. Oncogene. 26, 7825-32. 
Sanchez-Cespedes, M., Parrella, P., Esteller, M., Nomoto, S., Trink, B., Engles, J. M., 
Westra, W. H., Herman, J. G., Sidransky, D. (2002). Inactivation of LKB1/STK11 is a 
common event in adenocarcinomas of the lung. Cancer Res. 62, 3659-62. 
Sanders, M., A., Majumdar A., P. (2011). Colon cancer stem cells: implications in 
carcinogenesis. Front Biosci. 1, 1651-62 
Sansom, O. J., Meniel, V. S., Muncan, V., Phesse, T. J., Wilkins, J. A., Reed, K, R., Vass, J. 
K., Athineos, D., Clevers, J., Clarke, A. R. (2007). Myc deletion rescues Apc deficiency 
in the small intestine, Nature. 446, 676–679. 
Sasai, H., Masaki, M. and Wakitani, K., (2000) Suppression of polypogenesis in a new 
mouse strain with a truncated Apc (Delta474) by a novel COX-2 inhibitor, JTE-522, 
Carcinogenesis. 21, 953–958. 
Sax, K., (1923) The association of size differences with seed coat pattern and 
pigmentation in Phaseolus vulgaris. Genetics. 8, 552–560. 
Schwenter,F., Ratjen,F., Berk,T., Gallinger,S., Gryfe,R., Gradinger,A.B., Md,M.E., and 
Durno,C.A. (2011). Juvenile polyposis syndrome, SMAD4 mutations, and hereditary 
hemorrhagic telangiectasia. J. Pediatr. Gastroenterol. Nutr. 54, 120-2 
 259 
Scott, R. J., McPhillips, M., Meldrum, C. J. (January 2001). Hereditary nonpolyposis 
colorectal cancer in 95 families, differences and similarities between mutation-
positive and mutation-negative kindreds. Am. J. Hum. Genet. 68, 118–127 
Segditsas, S., Rowan, A. J., Howarth, K., Jones, A., Leedham, S., Wright, N. A., Gorman, 
P., Chambers, W., Domingo, E., Roylance, R. R, Sawyer, E. J., Sieber, O. M., Tomlinson, 
I. P. (2008). APC and the three-hit hypothesis. Oncogene. 8,146-55. 
Seksik, P., Nion-Larmurier, I., Sokol, H, Beaugerie, L. (2009). Cosnes. Effects of light 
smoking consumption on the clinical course of Crohn's disease. J. Inflamm Bowel Dis. 
15, 734-41 
Sen. S., and Churchill, G. A. (2001). A statistical framework for quantitative trait 
mapping. Genetics 159, 371-87. 
Senda,T., Iizuka-Kogo, A., Onouchi, T., and Shimomura, A. (2007). Adenomatous 
polyposis coli (APC) plays multiple roles in the intestinal and colorectal epithelia. 
Med. Mol. Morphol. 40, 68-81. 
Seth, R., Keeley, J., Abu,-Ali G., Crook, S., Jackson, D., Ilyas, M. (2009). The putative 
tumour modifier gene ATP5A1 is not mutated in human colorectal cancer cell lines 
but expression levels correlate with TP53 mutations and chromosomal instability. J 
Clin Pathol. 62, 598-603. 
Shen, L., Toyota, M., Kondo, Y., Lin, E., Zhang, L., Guo, Y., Hernandez, N. S., Chen, X., 
Ahmed, S., Konishi, K., Hamilton, S. R., Issa, J. P. (2007). Integrated genetic and 
epigenetic analysis identifies three different subclasses of colon cancer.Proc Natl 
Acad Sci U S A. 104, 18654-9. 
Sherry, S. T., Ward, M. H., Kholodov, M. M., Baker, J., Phan, L., Smigielski, E. M., 
Sirotkin, K. (2001) dbSNP, the NCBI database of genetic variation.  Nucleic Acids 
Research 29, 308-11 
Shibata, H., Toyama, K., Shioya, H., Ito, M., Hirota, M., Hasegawa, S., Matsumoto, H., 
Takano, H., Akiyama, T., Toyoshima, K., Kanamaru, R., Kanegae, Y., Saito, I., 
 260 
Nakamura, Y., Shiba, K. and Noda T. (1997). Rapid colorectal adenoma formation 
initiated by conditional targeting of the Apc gene, Science. 278, 120–123. 
Shih, I. M., Wang, T. L., Traverso, G., Romans, K., Hamilton, S. R., Ben-Sasson, S., 
Kinzler, K. W., Vogelstein, B. (2001). Top-down morphogenesis of colorectal tumors. 
Proc Natl Acad Sci U S A. 98, 2640-5. 
Shiraishi, M., Oates, A. J., and Sekiya, T. (2002). An overview of the analysis of DNA 
methylation in mammalian genomes. Biol. Chem. 383, 893-906. 
Shoemaker, A. R., Moser, A. R. and Dove, W. F. (1995). N-ethyl-N-nitrosourea 
treatment of multiple intestinal neoplasia (Min) mice, age-related effects on the 
formation of intestinal adenomas, cystic crypts, and epidermoid cysts. Cancer Res. 
55, 4479–4485 
Sieber, O. M., Lipton, L., Crabtree, M., Heinimann, K., Fidalgo, P., Phillips, R. K., 
Bisgaard, M. L., Orntoft, T. F., Aaltonen, L. A., Hodgson, S. V., Thomas, H. J., and 
Tomlinson,I. P. (2003). Multiple colorectal adenomas, classic adenomatous 
polyposis, and germ-line mutations in MYH. N. Engl. J. Med. 348, 791-799. 
Sillanpä M., J, Arjas, E. (1998). Bayesian mapping of multiple quantitative trait loci 
from incomplete inbred line cross data. Genetics. 148, 1373–88 
Silverman, K., Korarkor, R., Siracusa, L. D. and Buchberg, A. M. (2002). Identification 
of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced 
intestinal neoplasia.Genome Res. 12, 88-97. 
Sjolander, K., Karplus, K., Brown, M., Hughey, R., Krogh, A., Mian, I. S., Haussler, D. 
(1996) Dirichlet mixtures, a method for improved detection of weak but significant 
protein sequence homology. Comput Appl Biosci. 12, 327 
Slagboom,P. E. and Meulenbelt, I. (2002). Organisation of the human genome and 
our tools for identifying disease genes. Biol. Psychol. 61, 11-31. 
Slattery, M. L., Curtin, K., Anderson, K., Ma, K. N., Ballard, L., Edwards, S., Schaffer, D., 
Potter, J., Leppert, M., Samowitz, W. S. (2000). Associations between cigarette 
 261 
smoking, lifestyle factors, and microsatellite instability in colon tumors.  J Natl 
Cancer Inst. 92, 1831-6 
Slattery, M. L., Kerber, R. A., (1994). Family history of cancer and colon cancer risk, 
the Utah Population Database. J Natl Cancer Inst. 86, 1618-26. 
Smith, G. C. and Jackson, S. P. (1999). The DNA-dependent protein kinase. Genes & 
Dev. 13, 916-934 
Smits, R., van der Houven van Oordt, W., Luz, A., Zurcher, C., Jagmohan-Changur, S., 
Breukel, C., Khan, P. M., Fodde, R., (1998). Apc1638N, a mouse model for familial 
adenomatous polyposis-associated desmoid tumors and cutaneous cysts, 
Gastroenterology. 114, 275–283. 
Smits, R., Kartheuser, A., Jagmohan-Changur, S, Leblanc, V., Breukel, C.,  de Vries, A., 
van Kranen, H., van Krieken, J. H., Williamson, S., Edelmann, W., Kucherlapati, R., 
Khan, P. M., Fodde, R. (1997 ) Loss of Apc and the entire chromosome 18 but 
absence of mutations at the Ras and Tp53 genes in intestinal tumors from 
Apc1638N, a mouse model for Apc-driven carcinogenesis. Carcinogenesis. 18, 321-7 
Soller, M. (1976) On the power of experimental design for the detection of linkage 
between marker loci and quantitative loci in crosses between inbred lines. Theor. 
Appl. Genet. 47, 35–39 
Sountoulides, P., Koletsas, N., Kikidakis, D., Paschalidis, K., and Sofikitis, N. (2010). 
Secondary malignancies following radiotherapy for prostate cancer.  Ther Adv Urol. 
2, 119-125 
Soussi, T. and Wiman, K. G. (2007).  Shaping genetic alterations in human cancer, the 
p53 mutation paradigm. Cancer Cell 12, 303-12. 
Sparks, A. B., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998). Mutational 
analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58, 
1130-1134. 
 262 
Spelman, R., Bovenhuis, H. (1998). Genetic response from marker assisted selection 
in an outbred population for differing marker bracket sizes and with two identified 
quantitative trait loci. Genetics. 148, 1389–1396. 
Spielman, R. S, and Ewens, W. J. (1998). A sibship test for linkage in the presence of 
association, The sib transmission/disequilibrium test. Am. J. Hum. Genet. 62, 450–
458. 
Spielman, R. S., McGinnis, R. E., and Ewens, W. J. (1993). Transmission test for 
linkage disequilibrium, The insulin gene region and insulin-dependent diabetes 
mellitus (IDDM). Am. J. Hum. Genet. 52, 506–516. 
Spirio, L., Otterud, B., Stauffer, D., Lynch, H., Lynch, P., Watson, P., Lanspa, S., Smyrk, 
T., Cavalieri, J., Howard, L (1992). Linkage of a variant or attenuated form of 
adenomatous polyposis coli to the adenomatous polyposis coli (APC) locus. Am J 
Hum Genet. 51, 92-100. 
Srour, M., Rivière, J. B., Pham, J. M., Dubé, M. P., Girard, S., Morin, S., Dion, P. A., 
Asselin, G., Rochefort, D., Hince, P., Diab, S., Sharafaddinzadeh, N., Chouinard, S., 
Théoret, H., Charron, F., Rouleau, G. A. (2010). Mutations in DCC cause congenital 
mirror movements. Science. 328, 592. 
Stehelin, D., Fujita, D. J., Padgett, T., Varmus, H. E., Bishop, J. M. (1977). Detection and 
enumeration of transformation-defective strains of avian sarcoma virus with 
molecular hybridization. Virology. 76, 675-84. 
Steiner, C. C., Weber, J. N., Hoekstra, H. E. (2007). Adaptive variation in beach mice 
produced by two interacting pigmentation genes. Plos Biol.  5, e219. 
Stenson, P. D., Mort, M., Ball, E. V., Howells, K., Phillips, A. D., Thomas, N. S., Cooper, D. 
N. (2009) The human gene mutation database, 2008 update. Genome Medicine 
Stirbu, I., Kunst, A. E., Vlems, F. A., Visser, O., Bos, V., Deville, W., Nijhuis, H. G., 
Coebergh, J. W. (2006). Cancer mortality rates among first and second generation 
migrants in the Netherlands, Convergence toward the rates of the native Dutch 
population. Int J Cancer. 119, 2665-72. 
 263 
Stoneking, M. (2001). Single nucleotide polymorphisms. From the evolutionary past. 
Nature. 15, 821-2. 
Storey, J., Akey, J., and Kruglyak, L., (2005). Multiple locus linkage analysis of 
genomewide expression in yeast. PLOS Biology, 3, 8 
Strohmeyer, D., Langenhof, S., Ackermann, R., Hartmann, M., Strohmeyer, T., Schmidt, 
B. (1997). Analysis of the DCC tumor suppressor gene in testicular germ cell tumors, 
mutations and loss of expression. J Urol. 157, 1973-6. 
Sturt, N. J. H,, Gallagher, M. C., Bassett, P., Philp, C. R., Neale, K. F., Tomlinson, I. P., 
Silver A. R., Phillips, R. K. S.(2004). Evidence for genetic predisposition to desmoid 
tumours in familial adenomatous polyposis independent of the germline APC 
mutation. 53, 1832–1836 
Sturtevant, A. H. (1913). The linear arrangement of six sex-linked factors in 
Drosophila, as shown by their mode of association. Journal of Experimental Zoology, 
14, 43-59. 
Stylianou, I. M., Korstanje, R., Li, R., Sheehan, S., Paigen, B., Churchill, G. A. (2006). 
Quantitative trait loci analysis for obesity reveals multiple networks on interacting 
loci. Mamm Genome. 17, 22-36. 
Su, L. K., Kohlmann, W., Ward, P. A., and Lynch, P. M. (2002). Different familial 
adenomatous polyposis phenotypes resulting from deletions of the entire APC exon 
15. Hum. Genet. 111, 88-95 
Su, L. K., Vogelstein, B., and Kinzler, K. W. (1993). Association of the APC tumor 
suppressor protein with catenins. Science 262, 1734-1737. 
Su, W. L., Sieberts, S. K., Kleinhanz, R. R., Lux, K., Millstein, J., Molony. C, Schadt, E. E. 
(2010). Assessing the prospects of genome-wide association studies performed in 
inbred mice. Mamm Genome. 21, 143-52. 
Sugimura, K., Furukawa, T., Okizuka, H., Yuasa, K., Mihara, Y., Ishida, T. (1990). Post 
radiation changes in the rectum, assessment by MR imaging.  Nihon Gan Chiryo 
Gakkai Shi. 25, 2693-701 
 264 
Sugiyama, F,. Churchill, G., A. Higgens, D., C. Johns, C, Makaritsis, K., P. Gavras, H., 
Paigen, B. (2000). Concordance of murine quantitative trait loci for salt-induced 
hypertension with rat and human loci. Genomics. 171, 70–77 
Suit, H., Goldberg, S., Niemierko, A., Ancukiewicz, M., Hall, E., Goitein, M., Wong, W., 
Paganetti, H. (2007). Secondary carcinogenesis in patients treated with radiation, a 
review of data on radiation-induced cancers in human, non-human primate, canine 
and rodent subjects. Radiat Res. 167, 12-42. 
Sunyaev, S., Ramensky, V., Bork, P. (2000) Towards a structural basis of human non-
synonymous single nucleotide polymorphisms. Trends in Genetics, 16,198-2000. 
Sunyaev, S., Ramensky, V., Koch, I., Lathe, W., Kondrashov, A. and Bork, P. (2001) 
Prediction of deleterious human alleles. Hum Mol Genet 10, 591–597. 
Suraweera, N. ,Haines, J., McCart, A., Rogers, P., Latchford, A., Coster, M., Polanco-
Echeverry, G., Guenther, T., Wang, J., Sieber, O., Tomlinson, I. and Silver, A. (2006). 
Genetic determinants modulate susceptibility to pregnancy-associated 
tumourigenesis in a recombinant line of Min mice, Hum. Mol. Genet. 15, 3429–3435. 
Takagi, Y., Kohmura, H., Futamura, M., Kida, H., Tanemura, H., Shimokawa, K., Saji S. 
(1996) Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. 
Gastroenterology. 111, 1369–1372. 
Takeda, H., Sonoshita, M., Oshima, H., Sugihara, K., Chulada, P.C., Langenbach, R. 
Oshima, M. and Taketo M.M. (2003). Cooperation of cyclooxygenase 1 and 
cyclooxygenase 2 in intestinal polyposis, Cancer Res. 63 4872–4877. 
Tenesa, A., Farrington, S. M., Prendergast, J. G., Porteous, M. E., Walker, M., Haq, N., 
Barnetson, R. A., Theodoratou, E., Cetnarskyj, R., Cartwright, N., Semple, C., Clark, A. 
J., Reid, F. J., Smith, L. A., Kavoussanakis, K., Koessler, T., Pharoah, P. D., Buch, S., 
Schafmayer, C., Tepel, J ., Schreiber, S., Volzke, H., Schmidt, C. O., Hampe, J., Chang-
Claude, J., Hoffmeister, M., Brenner, H., Wilkening, S., Canzian, F., Capella, G., 
Moreno,V., Deary, I. J., Starr, J. M., Tomlinson, I. P., Kemp, Z., Howarth, K., Carvajal-
Carmona, L., Webb, E., Broderick, P., Vijayakrishnan, J., Houlston, R. S., Rennert, G., 
Ballinger, D., Rozek, L., Gruber, S. B., Matsuda, K., Kidokoro, T., Nakamura, Y., Zanke, 
 265 
B. W., Greenwood, C. M., Rangrej, J., Kustra, R., Montpetit, A., Hudson, T. J., Gallinger, 
S., Campbell, H. and Dunlop,M.G. (2008). Genome-wide association scan identifies a 
colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 
18q21. Nat. Genet. 40, 631-637. 
Tetsu,O. and McCormick, F. (1999). Beta-catenin regulates expression of cyclin D1 in 
colon carcinoma cells. Nature 398, 422-426. 
Thoday, J. M. (1961). Location of polygenes. Nature. 191, 368-370 
Timmermann, B., Kerick, M., Roehr, C., Fischer, A., Isau, M. (2010) Somatic Mutation 
Profiles of MSI and MSS Colorectal Cancer Identified by Whole Exome Next 
Generation Sequencing and Bioinformatics Analysis. PLoS ONE 5(12) 
Tomlinson, I. P., Webb, E., Carvajal-Carmona, L., Broderick, P., Howarth, K., Pittman, 
A. M., Spain, S., Lubbe, S., Walther, A., Sullivan, K., Jaeger, E., Fielding, S., Rowan, A., 
Vijayakrishnan, J., Domingo, E., Chandler, I., Kemp, Z., Qureshi, M., Farrington, S. M., 
Tenesa, A., Prendergast, J. G., Barnetson, R. A., Penegar, S., Barclay, E., Wood, W., 
Martin, L., Gorman, M., Thomas, H., Peto, J., Bishop, D. T., Gray, R., Maher, E. R., 
Lucassen, A., Kerr, D., Evans, D. G., Schafmayer, C., Buch, S., Volzke, H., Hampe, J., 
Schreiber, S., John, U., Koessler, T., Pharoah, P., van, W. T., Morreau, H., Wijnen, J. T., 
Hopper, J. L., Southey, M. C., Giles, G. G., Severi, G., Castellvi-Bel, S., Ruiz-Ponte, C., 
Carracedo, A., Castells, A., Forsti, A., Hemminki, K., Vodicka,P., Naccarati,A., Lipton, L., 
Ho, J. W., Cheng, K. K., Sham, P. C., Luk, J., Agundez, J. A., Ladero, J. M., de la Hoya, M., 
Caldes, T., Niittymaki, I., Tuupanen, S., Karhu, A., Aaltonen, L., Cazier, J. B., Campbell, 
H., Dunlop, M. G. and Houlston, R. S. (2008).  A genome-wide association study 
identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. 
Nat. Genet. 40, 623-630. 
Tomlinson, I., Webb, E., Carvajal-Carmona, L., Broderick, P., Kemp, Z., Spain, S., 
Penegar,S., Chandler, I., Gorman, M., Wood, W., Barclay, E., Lubbe, S., Martin, L., 
Sellick, G., Jaeger, E., Hubner, R., Wild, R., Rowan, A., Fielding, S., Howarth, K., Silver, 
A., Atkin, W., Muir, K., Logan, R., Kerr, D., Johnstone, E., Sieber, O., Gray, R., Thomas, 
H., Peto, J., Cazier, J. B. and Houlston, R. (2007b). A genome-wide association scan of 
 266 
tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat. 
Genet. 39, 984-988. 
Tomlinson, I. P., Beck, N. E., Neale, K. and Bodmer, W. F. (1996). Variants at the 
secretory phospholipase A2 (PLA2G2A) locus, analysis of associations with familial 
adenomatous polyposis and sporadic colorectal tumours. Ann. Hum. Genet. 5, 369-
376. 
Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, 
A., Nunes, M., Frost P., Discafani, C. M. (2000). Combinatorial chemoprevention of 
intestinal neoplasia. Nat. Med. 6, 1024–1028 
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., and Issa, J. P. (1999). 
CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 
96, 8681-8686. 
Triantafillidis, J. K., Nasioulas, G., Kosmidis, P. A. (2009) Colorectal cancer and 
inflammatory bowel disease, epidemiology, risk factors, mechanisms of 
carcinogenesis and prevention strategies. Anticancer Res. 29, 2727-37. 
Tysk, C., Lindberg, E., Järnerot, G., Flodérus-Myrhed, B. (1988). Ulcerative colitis and 
Crohn's disease in an unselected population of monozygotic and dizygotic twins. A 
study of heritability and the influence of smoking.Gut. 29, 990-6 
Vagefi, P. A., Longo, W. E. (2005). Colorectal cancer in patients with inflammatory 
bowel disease. Clin Colorectal Cancer. 4, 313-9 
Vallbohmer, D., Brabender, J., Yang, D., Schneider, P. M., Metzger, R., Danenberg, K. D., 
Holscher, A. H.and Danenberg, P. V. (2006). DNA methyltransferases messenger RNA 
expression and aberrant methylation of CpG islands in non-small-cell lung cancer, 
association and prognostic value. Clin. Lung Cancer. 8, 39-44. 
van Es, J. H., Giles, R. H., Clevers, H. C. (2001). The many faces of the tumor 
suppressor gene APC. Exp Cell Res. 1, 126-34. 
Varley, J. (2003) TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol. 
222, 117-29. 
 267 
Vasen, H. F., Watson, P., Mecklin, J. P., Lynch, H. T., (1999). New clinical criteria for 
hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by 
the International Collaborative group on HNPCC. Gastroenterology. 116, 1453–6 
Velmala, R. J., Vilkki, H. J., Elo, K. T, de Koning, D. J., Mäki–Tanila, A. V. (1999). Animal 
Gen. 30, 136-143. 
Vilenchik, M. M., Knudson, A. G. (2003). Endogenous DNA double-strand breaks, 
production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci U S A. 100, 
12871-6. 
Vogelstein, B. (1988) Genetic alterations during colorectal-tumor development. N. 
Engl. J. Med. 319, 525–532 
Vogelstein, B. and Kinzler, K. W. (2004) Cancer genes and the pathways they control, 
Nature Medicine 10, 789-799 
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., 
Nakamura, Y., White, R., Smits, A. M., and Bos, J. L. (1988). Genetic alterations during 
colorectal-tumor development. N. Engl. J. Med. 319, 525-532. 
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., 
Nakamura, Y., White, R., Smits, A. M., Bos, J. L. (1988) Genetic alterations during 
colorectal-tumor development. N Engl J Med. 319, 525-32. 
Vogelstein, B., Kinzler, K. W. (1993) The multistep nature of cancer. Trends Genet. 9, 
138-41. 
Waldman, T., Kinzler, K. W., Vogelstein, B.(1995). p21 is necessary for the p53-
mediated G1 arrest in human cancer cells. Cancer Res. 55, 5187-90. 
Walker, F., Zhang, H., Odorizzi, A., Burgess, A., W. (2012). LGR5 Is a Negative 
Regulator of Tumourigenicity, Antagonizes Wnt Signalling and Regulates Cell 
Adhesion in Colorectal Ca10. Cell Lines. Plos. One 6, 22733 
Walsh, D. (1987) Dead tissue traumatism from roentgen ray exposure, BMJ 3,272-
273, 
 268 
Wang, G. S., Cooper, T. A. (2007). Splicing in disease, disruption of the splicing code 
and the decoding machinery. Nat. Rev. Genet. 8, 749–761 
Wang, Q., Lasset, C., Desseigne, F., Saurin, J. C., Maugard, C., Navarro. C., Ruano, E., 
Descos, L., Trillet-Lenoir, V., Bosset, J.F., Puisieux, A. (1999)  Prevalence of germline 
mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French 
kindreds with nonpolyposis colorectal cancer. Hum Genet. 105, 79-8 
Wang, S., Basten, C. J., and Zeng Z-B. (2007). Windows QTL Cartographer 2.5. 
Department of Statistics, North Carolina State University, Raleigh, NC. Avaliable 
from, (http,//statgen.ncsu.edu/qtlcart/WQTLCart.htm) 
Wang, Z., Jin, H., Xu, R., Mei, Q., Fan, D. (2009). Triptolide downregulates Rac1 and 
the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp 
Mol Med. 41, 717-27. 
Wang, Q., Liu, T., Fang, Y., Xie, S., Huang, X., Mahmood, R., Ramaswamy, G., Sakamoto, 
K. M., Darzynkiewicz, Z., Xu, M., Dai, W. (2004). BUBR1 deficiency results in 
abnormal megakaryopoiesis. Blood. 15, 1278-85.  
Waterston, R. H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J. F. (2002) Initial 
sequencing and comparative analysis of the mouse genome. Nature. 420, 520–562 
Webb, E. L., Houlston, R. S. (2007) Association studies using familial cases, an 
efficient strategy for identifying low-penetrance disease alleles. Methods Mol Biol. 
Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., 
Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., Koh, H., Simms, L., Barker, 
M., Leggett, B., Levine, J., Kim, M., French, A. J., Thibodeau, S. N., Jass, J., Haile, R., and 
Laird, P. W. (2006). CpG island methylator phenotype underlies sporadic 
microsatellite instability and is tightly associated with BRAF mutation in colorectal 
cancer. Nat. Genet. 38, 787-793. 
Westbrook, A. M., Szakmary, A., Schiestl, R. H. (2010). Mechanisms of intestinal 
inflammation and development of associated cancers, lessons learned from mouse 
models.Mutat. Res. 705, 40-59. 
 269 
Weterings, E., Chen, D. J. (2007).  DNA-dependent protein kinase in nonhomologous 
end joining: a lock with multiple keys? J Cell Biol. 179, 183–186. 
Weyden, L., Adams, D. J. (2007). The Ras-association domain family (RASSF) 
members and their role in human tumourigenesis. Biochim Biophys Acta. 1776, 58–
85. 
Wheeler, J. M. (2005). Epigenetics, mismatch repair genes and colorectal cancer. Ann 
R Coll Surg Engl. 87, 15-20. 
Willett, C. G., Ooi, C. J., Zietman, A. L., Menon, V. , Goldberg, S., Sands, B. E., Podolsky, 
D. K. (2000). Acute and late toxicity of patients with inflammatory bowel disease 
undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol 
Phys. 46, 995-8. 
Woolf, C. M. (1958) A genetic study of carcinoma of the large intestine. Am J Hum 
Genet 10, 42-7 
Wu, Y., Antony, S., Juhasz, A., Lu, J., Ge, Y., Jiang, G., Roy, K., Doroshow, J. H. (2011). 
Up-regulation and sustained activation of Stat1 are essential for interferon-gamma 
(IFN-gamma)-induced dual oxidase 2 (Duox2) and dual oxidase A2 (DuoxA2) 
expression in human pancreatic cancer cell lines. J Biol Chem. 286, 12245-56. 
Xi, T., Jones, I. M., and Mohrenweiser, H. W., (2004). Many amino acid substitution 
variants identified in DNA repair genes during human population screenings are 
predicted to impact protein function. 83, 970-9 
Xu, L., Corcoran, R. B., Welsh, J. W., Pennica, D., and Levine, A. J. (2000). WISP-1 is a 
Wnt-1- and beta-catenin-responsive oncogene. Genes Dev. 14, 585-595. 
Yalcin, B. and Flint, F. (2012). Association studies in outbred mice in a new era of 
full-genome sequencing. Mamm Genome. 23, 719–726. 
Yang, C-K., Hsu, T-C., Wang, T-Y. (2008). Radiation-Induced Cancers of the Colon and 
Rectum-Analysis of Five Cases.  J Soc Colon Rectal Surgeon. 19, 41-46. 
 270 
Yeoh, E., Horowitz, M., Russo, A., Muecke, T., Robb, T., Chatterton, B. (1995). The 
effects of abdominal irradiation for seminoma of the testis on gastrointestinal 
function. J Gastroenterol Hepatol. 10, 125-30. 
Yi, N., and Xu, S. (2002). Mapping quantitative trait loci with epistatic effects. Genet 
Res. 79, 185-98. 
Yoon, H. Y., et al. (2006) ARAP2 effects on the actin cytoskeleton are dependent on 
Arf6-specific GTPase-activating-protein activity and binding to RhoA-GTP. J Cell Sci. 
119, 4650–66. 
Yu, K., Okayasu, R., Weil, M. M., Silver, A., McCarthy, M., Zabriskie, R., Long, S., Cox, R., 
Ullrich, RL. (2001). Elevated breast cancer in irradiated BALB/c associates with 
unique functional polymorphism of the Prkdc (DNA-dependent protein kinase 
catalytic subunit gene). Cancer Res. 61, 1820–1824. 
Zhang, H. T., Zhao, J., Zheng, S. Y., Chen, X. F. (2005). Is TGFBR1*6A Really Associated 
With Increased Risk of Cancer?  J Clin Oncol. 23, 7743-7744 
Zhao, J., Halfyard, B., Roebothan, B., West, R., Buehler, S., Sun, Z., Squires, .J., 
McLaughlin, J. R., Parfrey, P. S., Wang, P. P. (2010) Tobacco smoking and colorectal 
cancer, a population-based case-control study in Newfoundland and Labrador. Can J 
Public Health. 101, 281-9. 
Zhao, Z., Fu, Y.X., Hewett-Emmett, D., Boerwinkle, E. (2003). Investigating single 
nucleotide polymorphism (SNP) density in the human genome and its implications 
for molecular evolution. Gene. 17, 207–213. 
Zhao-Bang Zeng. (1994). Precision Mapping of Quantitative Trait Loci. Genetics 136, 
1457-68 
Zhong, S., Yang, J. H., Liu, K., Jiao, B. H., Chang, Z. J. (2012). Quantitative assessment of 
the association between MTHFR C677T polymorphism and colorectal cancer risk in 
East Asians. Tumour Biol. 33, 2041-51 
